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Abstract 
 
Amyotrophic Lateral Sclerosis (ALS) is a progressive motor neurodegenerative disorder 
with an average life expectancy of 2-5 years post-diagnosis. Common pathological features 
associated with ALS are the formation of cytoplasmic inclusions of intermediate filaments and 
RNA-binding proteins within motor neurons. The formation of intermediate filament 
cytoplasmic inclusions is believed to be driven by a loss of stochiometric expression between 
five neuronal intermediate filament proteins—NFL, NFM, NFH, INA and PRPH—where there is 
a selective suppression of the steady-state levels of NEFL, INA and PRPH mRNA. Further, three 
RNA-binding proteins—TDP-43, FUS and RGNEF—have been shown to co-aggregate with 
each other in ALS motor neurons indicating a possible common mechanism that leads to their 
dysregulation.  
In the last decade, microRNAs (miRNAs)—small RNA molecules generally responsible 
for post-transcriptional regulation of gene expression—were observed to be massively 
dysregulated in the spinal cord tissue of ALS patients, providing a possible explanation for the 
changes observed in intermediate filament steady-state mRNA levels and RNA-binding protein 
dysregulation in ALS. Further, TDP-43 and FUS regulate miRNA biogenesis, indicating there 
may be a regulatory network between RNA-binding proteins and miRNAs that is disrupted in 
ALS. I hypothesize that a regulatory network between specific RNA-binding proteins and 
miRNAs is disrupted in ALS leading to changes in miRNA processing which contributes to 
intermediate filament and RNA-binding protein pathology.  
In this dissertation, I have examined: 1) whether ALS-linked miRNA(s) contribute to the 
selective suppression of NEFL, PRPH, and INA; 2) whether ALS-linked miRNAs regulate the 
expression of NEFM and NEFH; 3) whether ALS-linked miRNAs regulate the expression of 
iii 
 
RNA-binding proteins whose metabolism is dysregulated in ALS (TDP-43, FUS, and RGNEF); 
and, 4) whether TDP-43 and FUS are in a regulatory network with ALS-linked miRNAs. 
Overall, 12 ALS-linked miRNAs were identified to regulate either intermediate filament or 
RNA-binding protein expression, and further, a novel negative feedback loop between TDP-43 
and two miRNAs (miR-27b-3p and miR-181c-5p) was identified. This dissertation highlights 
that changes to miRNA levels, as seen in ALS, would contribute to overall ALS pathology, 
making them viable avenues for potential therapeutics.   
 
 
Keywords: MicroRNA, ALS, RNA-binding proteins, TDP-43, intermediate filaments, 
neurofilaments, RNA, neurodegeneration, regulatory networks   
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Lay Abstract 
 Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disorder defined by the 
progressive loss of motor function such as walking, reaching grabbing, standing, etc., eventually 
confining individuals to a wheelchair. ALS is generally fatal within 2-5 years of diagnosis. This 
disease results from the dramatic loss of a specific cell-type within the brain and spinal cord 
tissue called motor neurons. Decades of research has tried to understand what causes the loss of 
motor neurons in ALS, and while much progress has been made, there remains a considerable 
amount that is not understood regarding the underlying cause(s) of ALS. Recent research has 
shown that small molecules known as microRNAs (miRNAs) are reduced in ALS motor 
neurons. MiRNAs regulate the levels of gene expression within our cells which is critical for 
cells to efficiently respond to environmental cues (i.e. stress) and maintain overall cell health. 
Lack of these small molecules, as seen in ALS motor neurons, has been shown to cause motor 
neuron death in mice, indicating the importance of miRNAs to motor neuron function. In this 
dissertation, I explored the potential consequence of reduced miRNA levels, as seen in ALS, and 
how this may relate to what we already know about ALS pathology. Further, I explored potential 
molecular pathways that may explain why miRNA reduction occurs in ALS. I have found that 
the loss of a specific pool of miRNAs in ALS may contribute to overall ALS pathogenesis.  In 
addition, I have identified a novel molecular network between miRNAs and TDP-43—a protein 
that is dysregulated in 97% of all ALS cases—which may explain the loss of miRNAs seen in 
ALS motor neurons. Overall, this thesis implicates miRNAs as major contributors to ALS 
pathogenesis and identifies a disrupted molecular network between miRNAs and TDP-43, 
providing new avenues to explore potential therapeutics for ALS.  
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Dedication 
 
To the individuals and families who have had to endure the extreme challenges of ALS. It 
is your continued bravery and relentless fight that inspires the research community to find a cure 
without surrender.    
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 Amyotrophic lateral sclerosis (ALS) is generally a late-onset neurodegenerative disease 
that results in motor neuron loss causing death within 2-5 years after diagnosis. Several genetic 
and pathological features of ALS have given us insights into the etiology of the disease (Strong, 
2017). However, despite these efforts, very few therapeutics have been successful in treating 
ALS. Therefore, we need to continue to explore the biological mechanisms underpinning ALS if 
we are to find novel drug targets that may slow or halt the progression. Recent work has shown 
that microRNAs (miRNAs) may be a major contributor to the disease pathogenesis.  
MicroRNAs (miRNAs) are endogenous small non-coding RNAs that regulate gene 
expression via formation of a ribonucleoprotein complex with Argonaute (AGO) proteins and 
complementary base pairing with their target mRNAs (Lee et al., 1993; Slack et al., 2000). 
Despite the apparent simplicity of miRNA function, their expression and mRNA targets are 
highly dependent on the stage of development, environmental cues, aging and cellular type. This 
highly dynamic process allows for the fine-tuning of gene expression depending not only on the 
global needs of the cell, but also somatotopically-specific needs such as the maintenance of the 
synaptic junction or the response to neuronal injury (van Rooij et al., 2007; Wilczynska and 
Bushell, 2015).  In this introduction, we will discuss motor neurons, ALS pathology, miRNA 
biology and their role in motor neuron disease, and finally, potential mechanisms that may 
contribute to the dysregulation of miRNAs seen in ALS.    
1.1 Motor Neurons   
 
Motor neurons are classified as either somatic or visceral. Visceral motor neurons are 
responsible for innervating smooth and cardiac muscle allowing for involuntary contractions. In 
contrast, somatic motor neurons innervate skeletal muscle to perform voluntary movement 
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(Goulding, 1998; Guthrie, 2007). This dissertation will focus on somatic motor neurons 
(henceforth referred to as “motor neurons”). 
In general, motor neurons can be further grouped into those whose projections remain 
within the central nervous system (CNS) and those that do not. Upper motor neurons (UMNs) 
are a group of descending supraspinal neurons, the majority of which arise from the primary 
motor cortex, premotor cortex and the supplementary motor area (Dum and Strick, 2005; Nachev 
et al., 2008). UMNs arising in these cortical regions course through the corticospinal tracts with 
the majority (75-90%) crossing at the level of the medulla to ultimately innervate contralateral 
spinal motor neurons. The remaining 10-25% innervate ipsilateral spinal motor neurons. UMNs 
send excitatory chemical signals via glutamate to activate spinal motor neurons (Fig. 1.1A). 
Spinal motor neurons belong to the category of lower motor neurons (LMNs) that, in concert 
with the muscle fibers that they innervate through their axonal terminals, constitute the motor 
unit (Lemon, 2008; Welniarz et al., 2016). The interaction between the axon terminals and 
skeletal muscle occurs at the neuromuscular junction (NMJ) where acetylcholine release across 
the synapse induces muscle contractions which allow us to perform basic motor functions such 
as standing, walking, reaching, grabbing, etc. (Fig 1.1B).  
1.1.1 Axonal Transport  
Axonal transport is necessary for motor neurons to send signals to other cells within the 
body. An individual motor neuron axon can extend for upwards of a meter, giving rise to a 
unique set of metabolic demands. Mitochondria, ribonucleoprotein (RNP) granules, and vesicles 
must be positioned at specific sites along the length of the axon depending on somatotopic needs 
and thus requiring a high degree of regulation (Fig. 1.1C) (Lin and Sheng, 2015; Vuppalanchi et 
al., 2009). Critical to the integrity of the axonal projection are key cytoskeletal proteins,   
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Figure 1.1. Motor neuron transmission. (A) The glutamatergic synaptic connection between 
lower motor neurons (LMNs) and upper motor neurons (UMNs). This synapse drives excitation 
of the LMN through a process that is dependent on the influx of Ca++ into the presynaptic 
terminus which in turn triggers release of glutamate into the synaptic cleft. There, glutamate 
stimulates the influx of Na+ and Ca++ into the post-synaptic LMN, which leads to its 
depolarization. (B) Transport across the long axon of motor neurons. Neurons must be constantly 
transferring mitochondria, vesicles and RNPs granules to localized spots in the axon depending 
on the need of the cell. Transport is bidirectional along the axon where the molecular motor 
kinesin drives anterograde transport, whereas dynein provides retrograde transport. This is 
crucial for the proper distribution of proteins, transcripts and organelles. (C) Neuromuscular 
junction. When the action potential has reached the neuromuscular junction, there is an influx of 
Ca++ into the axonal presynaptic bouton resulting in the synaptic release of acetylcholine. This 
causes the efflux of K+ and the influx of Na+ leading to the depolarization of the muscle fiber. 
The influx of Na+ causes the opening of sodium voltage-gated channels along the muscle fiber, 
allowing for the action potential to propagate through the muscle fiber (indicated by the golden 
arrows), generating the muscle contraction. 
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including microtubules which provide the highway that guides axonal transport, and 
neurofilaments which are key to maintaining the cytoskeletal architecture of the axon and thus 
indirectly, the degree of myelination (Hirokawa et al., 2010; Szaro and Strong, 2010). Further, 
axons and synapses are highly dynamic structures that are constantly changing in an activity-
dependent manner, and thus, there is a constant redistribution of mitochondria depending on 
localized energy demands (Miller and Sheetz, 2004). This is especially true for motor neurons as 
their axonal length requires precise movement of mitochondria to meet their high energy 
demands (Hinckelmann et al., 2013). 
Beyond mitochondrial trafficking, the transport of mRNA along the axon allows for 
somatotopically-specific protein synthesis. To accommodate this, mRNAs and translational 
machinery are incorporated into RNP granules and transported to distal regions along the axon 
for localized translation (Sutton and Schuman, 2006; Vuppalanchi et al., 2009).  It is widely 
accepted that during RNP transport that the mRNA within the granule is translationally silent, a 
state that is suggested to be largely mediated by various RNA-binding proteins (Bramham and 
Wells, 2007). However, it has also been shown that proteins essential for miRNA processing are 
found within these RNP transport granules (Barbee et al., 2006), suggesting that the post-
transcriptional regulation of mRNA within RNPs is likely an interaction between RNA-binding 
proteins and regulatory RNA molecules, allowing for localized protein synthesis and even 
mRNA degradation. 
1.1.2 Regeneration  
One of the fundamental differences between mature UMNs and LMNs is the ability for 
LMNs to regenerate. In general, the peripheral nervous system (PNS) in which LMNs reside  
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provides an environment where neurons can survive and regenerate subsequent to axonal 
damage. This is not the case in the CNS (Fitch and Silver, 1997; Fu and Gordon, 1997). This 
phenomenon has been attributed to the lack of neurotrophic factors and an abundance of 
inhibitory proteins present after a nerve injury in the CNS (Schwab, 1996). For example, the 
increased expression of neurotrophic factors brain-derived neurotrophic factor (BDNF) and 
fibroblast growth factor 2 (FGF-2) and their receptors – trkB and FGFR-1, respectively – 
promotes LMN regeneration in response to a nerve injury. However, within the CNS, the 
expression of these receptors and ligands are reduced after nerve injury, creating a less 
permissive environment for regeneration (Funakoshi et al., 1993; Kobayashi et al., 1996; Lewin 
and Barde, 1996).  Interestingly, ectopic expression of BDNF within the CNS after a neuronal 
injury enhances the regenerative capacity of the neurons, suggesting it is an essential protein for 
nerve recovery (Giehl and Tetzlaff, 1996; Kobayashi et al., 1997).  
Further, the upregulation of cytoskeleton proteins including actin, tubulin and peripherin also 
assist with the regeneration of LMNs by restructuring the axon as it recovers (Bisby and Tetzlaff, 
1992; Chadan et al., 1994; Jiang et al., 1994). However, there is a downregulation in 
neurofilament expression after a nerve injury, which has been shown to allow for efficient 
transport of actin, tubulin and peripherin to distal regions of the injured axon (Tetzlaff et al., 
1996; Zhu et al., 1998). This change in cytoskeleton proteins after an axonal injury is far less 
robust within the CNS, and thus, could be another reason why regeneration is not able to occur 
within UMNs (Kost and Oblinger, 1993; Tetzlaff et al., 1991). This tightly coordinated change in 
the expression of cytoskeleton genes within the PNS allows for efficient axonal repair, and thus, 
a transient network of regulatory elements, such as miRNAs, must play an essential role in this 
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regenerative process. Disruption of molecular pathways that are critical to motor neuron function 
like axonal transport and regeneration have been shown to be disrupted in patients with ALS. 
1.2 ALS  
 
ALS is a neurodegenerative disease which is defined by the loss of both upper and lower 
motor neurons within the brain and spinal cord tissue, respectively (Strong et al., 2005). This 
debilitating disease ultimately leads to a person being confined to a wheelchair with the inability 
to perform basic motor tasks including and not limited to reaching, grabbing, standing, walking, 
speech, swallowing and breathing (Strong et al., 2017). Currently, there are limited treatments 
for this disease which has an expected survival time of 2-5 years post-diagnosis.  
 
1.2.1 Demographics of ALS 
 
Generally, ALS is a late onset disease with an average age of diagnosis between 40-70 
years of age with an incidence rate of two out of 100,000 people (Zarei et al., 2015). Ninety 
percent of ALS cases have no familial history (sporadic ALS [sALS]), and within those cases, 
only about 12-13% carry a known genetic mutation to explain the etiology of their disease. The 
remaining 10% of ALS cases are familial (fALS), and in those cases, about two-thirds have a 
known genetic defect (Mathis et al., 2019; Taylor et al., 2016). By far, in both sporadic and 
familial ALS cases, the most common genetic alteration is a hexanucleotide (GGGGCC) repeat 
expansion in C9ORF72 making up about 25-40% of familial and 10% of sporadic genetic cases. 
This is followed by mutations in SOD1, TDP-43 and FUS, respectively, which total to about 
30% within familial cases and 2-3% within sporadic cases (Majounie et al., 2012; Taylor et al., 
2016). There have been several other genes that contain disease causative mutations which 
accumulate to ~12% of familial and <1% of sporadic ALS cases (Table 1.1). While it is clear 
that genetic alterations play a critical role within the disease etiology for some patients, the vast  
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Table 1.1. Known genes that carry disease causative variants of familial and sporadic ALS  
Gene ID 
Chromosome 
Location 
Mode of 
inheritance* 
Protein Function 
% of fALS 
cases** 
% of sALS 
cases** 
Reference 
C9ORF72 9p21.2 AD Nucleocytoplasmic transport 25-40% 10% 
(DeJesus-Hernandez et al., 
2011; Renton et al., 2011) 
SOD1 2q22.11 AD, AR Superoxide dimutase 20% 2% (Rosen et al., 1993) 
TARDBP 1p36.22 AD DNA/RNA-binding protein 5% <1% (Sreedharan et al., 2008) 
FUS 16p11.2 AD DNA/RNA-binding protein 5% <1% 
(Belzil et al., 2009; Vance 
et al., 2009) 
OPTN 10p13 AD, AR Autophagy 4% <1% (Maruyama et al., 2010) 
NEK1 4q33 Not determined Kinase and DNA repair 2-3% <1% (Kenna et al., 2016) 
VCP 9q13.3 AD Autophagy 2% <1% (Johnson et al., 2010) 
TIA-1 2p13.3 AD 
DNA/RNA-binding protein, 
stress granule formation 
2% <1% (Mackenzie et al., 2017) 
hnRNPA1 7p15.2 AD RNA-binding protein <1% <1% (Kim et al., 2013) 
hnRNPA2B1 12q13.3 AD RNA-binding protein <1% <1% (Kim et al., 2013) 
UBQLN2 Xp11.21 X-linked Autophagy <1% <1% (Deng et al., 2011) 
KIF5A 12q13.3 AD 
Anterograde transport of 
organelles and RNP granules 
<1% <1% 
(Brenner et al., 2018; 
Nicolas et al., 2018) 
TBK1 12q154.2 AD Autophagy and inflammation <1% <1% (Freischmidt et al., 2015b) 
PFN1 17p13.2 AD Actin polymerization <1% <1% (Wu et al., 2012) 
DNAJC7 17q21.2 Not determined Heat Shock 40 protein <1% <1% (Farhan et al., 2019) 
SQSTM1 5q35.3 AD Autophagy <1% - 
(Fecto et al., 2011; Le Ber 
et al., 2013) 
VAPB 20q13.33 AD Axonal transport <1% - (Nishimura et al., 2004) 
SEXT 9q34.13 AD DNA/RNA helicase ? ? (Chen et al., 2004) 
ALS2 2p33.2 AR Rho nucleotide exchange factor ? ? 
(Hadano et al., 2001; Yang 
et al., 2001) 
SPG11 15q21.1 AR Transmembrane protein ? ? 
(Hentati et al., 1998; 
Orlacchio et al., 2010) 
ALS7 20p13 AD Unknown ? - (Sapp et al., 2003) 
*Autosomal Dominate (AD); Autosomal Recessive (AR) 
**Percentages represent approximate values. May vary in different ALS cohorts studied.
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majority of cases have no known genetic cause, suggesting that environmental factors may also 
play a critical role in ALS. Thus, we must further explore changes to both RNA and protein if we 
are to understand the progression of the disease at the molecular level.  
1.2.2 ALS Pathology  
The formation of neuronal cytoplasmic inclusions (NCIs), consisting of aberrantly 
aggregated proteins, is a common pathological phenomenon is several neurodegenerative 
diseases, including ALS. The most common protein groups found to be aberrantly aggregated in 
ALS are intermediate filaments and RNA-binding proteins (Strong, 2017). The formation of 
intermediate filament inclusions is believed to be driven by changes to stochiometric expression 
between cytoskeleton proteins (Szaro and Strong, 2010), whereas RNA-binding protein 
inclusions are believed to be driven by changes to their low-complexity domain (LCD; i.e. post-
translational modifications, or mutations) that make the protein more prone to aggregate 
(Franzmann and Alberti, 2019; Molliex et al., 2015; Murakami et al., 2015; Murray et al., 2017; 
Patel et al., 2015). The formation of RNA-binding protein cytoplasmic aggregates is the most 
common pathology seen in ALS, indicating that RNA dysregulation may be a major driver of 
ALS (Keller et al., 2012; Strong, 2017).  
In 1981, Davidson et al. demonstrated using tinctorial stains that there was an 31% and 
42% reduction in total RNA content within ALS lumbar and cervical motor neurons, 
respectively, providing the first evidence of RNA dysregulation in ALS (Davidson and 
Hartmann, 1981; Davidson et al., 1981). It was subsequently demonstrated that an overall 
reduction in polyadenylated RNA in ALS motor neurons bearing neurofilament NCIs was 
present when assessed using in situ hybridization (Bergeron et al., 1994), suggesting a 
dysregulation of coding RNA. These works would kick-off decades of research that would later 
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show issues in mRNA expression, splicing, polyadenylation, transport, stability, and further, 
dysregulation of non-coding RNAs in ALS motor neurons. In this section, we will discuss the 
various RNA-binding protein pathologies followed by what we currently understand about RNA 
dysregulation in ALS as these two phenomena are highly connected.  
1.2.2.1 RNA-binding Protein Pathology  
 
1.2.2.1.1 TDP-43 
 
TAR DNA-binding protein 43 kDa (TDP-43) is a ubiquitously expressed nuclear protein 
that has a diverse set of functions which include: mRNA transcription, mRNA splicing, RNA 
export, mRNA translation, miRNA biogenesis, long non-coding RNA (lncRNA) processing, and 
stress granule formation (Ratti and Buratti, 2016). Re-localization of TDP-43 from the nucleus to 
the cytoplasm and the subsequent formation of NCIs in motor neurons is the most common 
pathological feature of ALS, being observed in 97% of all cases (Ling et al., 2013).  
Several of the ALS-linked mutations and phosphorylation sites associated with TDP-43 
pathology are harbored in the LCD (Buratti, 2015). LCD’s are intrinsically disordered domains 
which can form either alpha-helical or pleated beta-sheet structures regulating the solubility of 
the protein (Franzmann and Alberti, 2019). Both aberrant mutations and phosphorylation within 
the LCD of TDP-43 promotes beta-sheet structures which lead to the eventual accumulation and 
formation of insoluble protein aggregates (Barmada et al., 2010; Choksi et al., 2014; Liachko et 
al., 2010). The primary phosphorylation sites of TDP-43 associated with pathological aggregates 
in motor neurons of ALS patients are serine 409/410, amino acids that are found in the LCD 
(Neumann et al., 2009a; Neumann et al., 2006). This suggests that conformational changes 
within the LCD of TDP-43 contributes to its pathogenic role in ALS; however, the exact 
mechanism(s) that lead to these changes are still unclear.  
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Mixed results have been seen in whether or not overexpression of wild-type TDP-43 in 
mouse models can actually lead to the formation of pathological aggregates in motor neurons 
(Mitchell et al., 2015; Xu et al., 2010). However, in sporadic ALS cases with no known genetic 
background, increased expression of TDP-43 protein and mRNA levels within the spinal cord 
and motor neurons has been observed, and further, the overexpression of other proteins with 
LCD’s similar to TDP-43 have been shown to form insoluble aggregates in both in vitro and in 
vivo models (Koyama et al., 2016; Mitchell et al., 2013; Patel et al., 2015; Swarup et al., 2011; 
Xu et al., 2010).TDP-43 has been shown to co-aggregate with several other LCD-containing 
proteins including FUS, TIA-1 and MATR3 in ALS motor neurons (Keller et al., 2012; Liu-
Yesucevitz et al., 2010; Tada et al., 2018; Volkening et al., 2009). These observations suggest 
that the simple accumulation of TDP-43 alone may not sufficient to drive this protein into 
insoluble aggregates and that the presence of other LCD-containing proteins may be needed. 
Further investigation is needed.  
1.2.2.1.2 FUS, EWSR1 and TAF15 (FET) Proteins  
 
Fused in liposarcoma (FUS), Ewing sarcoma (EWSR1), and TATA-binding associated 
factor 15 (TAF15) make up the family of FET proteins that are mainly responsible for genomic 
maintenance, RNA transcription, mRNA splicing, mRNA metabolism and miRNA production. 
FET proteins are a highly conserved set of proteins that are primarily nuclear and expressed in 
every cell (Andersson et al., 2008; Ballarino et al., 2013; Morlando et al., 2012; Svetoni et al., 
2016). 
In ALS, all three of these proteins have been shown to re-localize from the nucleus to the 
cytoplasm and produce cytoplasmic aggregates, or contain mutations associated with the disease 
(Belzil et al., 2009; Couthouis et al., 2012; Couthouis et al., 2011; Kwiatkowski et al., 2009; 
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Neumann et al., 2009b; Ticozzi et al., 2011; Vance et al., 2009). Out of the three FET proteins, 
FUS immunoreactive NCIs are the most often observed in ALS, being present in about 1% of all 
ALS cases. EWSR1 and TAF15 inclusions have been seen in only a small number of ALS cases 
(>0.1%) (Ling et al., 2013). Similar to TDP-43, FET proteins contain an LCD that is believed to 
be the major driver of pathological aggregate formation in ALS.  
Causative FUS mutations for ALS tend to be concentrated within the nuclear localization 
sequence (NLS) and also in the LCD (Taylor et al., 2016). This suggests that the loss of nuclear 
localization of FUS is critical to the pathogenesis of ALS. Further, the accumulation of wild-type 
FUS leads to phase separation and insoluble protein aggregates in a process that can be 
accelerated by mutations in the LCD of FUS (Mitchell et al., 2013; Patel et al., 2015). Several 
rodent and in vitro models have shown that the overexpression of FUS is sufficient to drive 
cytoplasmic aggregation and that this aggregation is dependent on its’ LCD (Kato et al., 2012; 
Mitchell et al., 2013; Murakami et al., 2015). Increased levels of FUS protein have also been 
observed in sALS spinal cord with no known genetic history (Hawley et al., 2017). Thus, the 
pathological formation of aggregates by FUS may be concentration dependent, where mutations 
accelerate phase separation and the formation of cytoplasmic aggregates by promoting the 
accumulation of FUS through the LCD.      
 
1.2.2.1.3 HnRNPA1 and HnRNPA2B1 
Heterogeneous nuclear Ribonucleoprotein A1 and A2B1 (hnRNPA1 and hnRNPA2B1, 
respectively) are primarily nuclear proteins that are involved in mRNA splicing, stability, 
transport and miRNA processing (Zhao et al., 2018). Both these proteins contain mutations 
within their LCD in less than 1% of ALS cases (Kim et al., 2013; Molliex et al., 2015). 
Interestingly, muscle biopsies from ALS patients revealed that hnRNPA1 and hnRNPA2B1 
14 
 
mutations can lead to cytoplasmic aggregates within muscle tissue, although no aggregates were 
observed in motor neurons (Kim et al., 2013). While neither protein specifically has been shown 
to aggregate in motor neurons, loss of TDP-43 nuclear localization results in aberrant splicing of 
hnRNPA1, promoting an alternative isoform called hnRNPA1B that has an extended LCD. 
Interestingly, hnRNPA1B does form cytoplasmic aggregates in ALS motor neurons where there 
are also pathological aggregates of TDP-43 (Deshaies et al., 2018). These findings suggest that 
hnRNP’s may play multiple roles in the pathogenesis of ALS affecting both muscle and motor 
neuron cell populations.  
1.2.2.1.4 RGNEF 
 
Rho Guanine Nucleotide Exchange Factor (RGNEF) is both a guanine exchange factor 
involved in the RhoA signaling pathway and an RNA-binding protein. The mouse homologue, 
p190RhoGEF, was first described in murine tissues and was shown to activate RhoA and interact 
with microtubules (van Horck et al., 2001). Further, work showed that p190RhoGEF interacted 
with and destabilized mouse Nefl mRNA preventing neurofilament aggregation—a common 
feature seen in ALS (Lin et al., 2004). This provided the first clue that RGNEF may be involved 
in the pathogenesis of ALS. 
 Several guanine exchange factors and RNA-binding proteins are associated with 
neurodegenerative diseases, but RGNEF is the only protein that shares these two functions and is 
also associated with neurodegeneration (Droppelmann et al., 2014). Still, little is known about 
RGNEF’s role in RNA regulation although it has been shown to negatively regulate the mRNA 
stability of NEFL through interactions with the 3’UTR (Droppelmann et al., 2013a). Further, 
RGNEF has been shown to interact with NEFL mRNA only in ALS, but not control, spinal cord 
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homogenates (Volkening et al., 2010), and therefore, may play a major role in intermediate 
filament pathogenesis associated with ALS. 
In terms of pathology, RGNEF has been observed in ubiquitin-positive aggregates and to 
co-localize with TDP-43 and FUS cytoplasmic aggregates (Keller et al., 2012). Further, several 
mutations in ARHGEF28 (gene name of RGNEF) have been associated with ALS (Droppelmann 
et al., 2013b; Farhan et al., 2017; Ma et al., 2014; Song et al., 2020; Zhang et al., 2016). 
However, while there is a definite association between RGNEF and ALS, it is still unclear 
whether these mutations alone are causative of the disease.  
1.2.2.1.5 ATXN2 
Ataxin 2 (ATXN2) is an RNA-binding protein that is primarily expressed within the 
cytoplasm where it regulates mRNA stability, RNA polyadenylation and mRNA translation. In 
~5% of all ALS cases, ATXN2 contains a polyglutamine (polyQ) repeat element (CAG) that is 
greater than 37 repeats, while healthy individuals tend to have ~15-22 repeats (Ostrowski et al., 
2017; Zhao et al., 2018). Expanded repeats of this gene has been associated with other 
neurodegenerative diseases including Spinal Cerebellar Ataxia (SCA), frontotemporal dementia 
and Parkinson’s disease (Houlden and Singleton, 2012; Majounie et al., 2007; Rubino et al., 
2019). The exact role that these repeat expansions play in disease is relatively unclear. However, 
the repeat expansion of ATXN2 in ALS appears to enhance TDP-43 and FUS toxicity, while the 
suppression of ATXN2 expression using antisense oligos (ASOs) reduces TDP-43 toxicity in fly 
and rodent ALS models overexpressing TDP-43, making it a possible therapeutic target of ALS 
(Elden et al., 2010; Farg et al., 2013).    
1.2.2.1.6 MATR3 
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Matrin 3 (MATR3) is an DNA/RNA-binding protein that is involved with mRNA 
transcription, export and stability, and primarily found within the nuclear matrix. In less than 1% 
of ALS cases, there is a missense or splicing mutation in the MATR3 gene (Leblond et al., 2016; 
Taylor et al., 2016). Mutations in MATR3 still result in it being primarily nuclear within ALS 
motor neurons; however, some have reported either MATR3 diffusely localized to the 
cytoplasm, or in cytoplasmic inclusions with TDP-43 (Johnson et al., 2014; Tada et al., 2018). 
Transgenic mice overexpressing ALS-mutant MATR3 F115C showed muscle atrophy, but no 
effect on spinal motor neurons, indicating that MATR3 mutations may have a greater impact on 
muscle than motor neurons (Moloney et al., 2018). Others have observed in primary rat neuronal 
cell culture models that MATR3 mutations enhance neuronal death, where neurotoxicity is 
dependent on its nuclear localization, not cytosolic localization, as we have seen with other ALS-
associated RNA-binding proteins (Malik et al., 2018). Overall, a lot still needs to be understood 
about MATR3 mutations and its relation to the pathogenicity of ALS.  
1.2.2.1.7 TIA-1 
 
TIA1 cytotoxic granule associated RNA-binding protein (TIA-1) is a primarily nuclear 
protein involved in RNA processing and translation (Del Gatto-Konczak et al., 2000; Dixon et 
al., 2003; Forch et al., 2000; Piecyk et al., 2000). However, TIA-1 is better known for its role in 
stress granule assembly (Gilks et al., 2004; Kedersha et al., 2000; Kedersha et al., 1999). During 
periods of cellular stress, TIA-1 leaves the nucleus and enters the cytoplasm where it nucleates 
and initiates the formation of stress granules, which contain several ALS-related RNA-binding 
proteins including TDP-43, FUS, hnRNPA1, hnRNPA2B1, ATXN2 and MATR3 (Gilks et al., 
2004; Kedersha et al., 2000; Zhao et al., 2018). Stress has been suggested to be a seed to 
cytoplasmic aggregation of proteins associated with ALS as TIA-1 has been shown to form 
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pathological aggregates in ALS motor neurons that co-localize with TDP-43 (Liu-Yesucevitz et 
al., 2010; Volkening et al., 2009). More recently, several ALS-associated mutations have been 
observed within the LCD of TIA-1 (Mackenzie et al., 2017; Yuan et al., 2018; Zhang et al., 
2018b). While patients with these mutations did show TDP-43 cytoplasmic aggregates in motor 
neurons, no TIA-1 was observed in cytoplasmic aggregates. Despite this finding, mutations 
within the LCD of TIA-1 still promoted the phase separation of TDP-43 into insoluble 
aggregates in in vitro motor neuron models, indicating that TIA-1 mutations and its LCD likely 
contribute to TDP-43 pathology (Mackenzie et al., 2017).  
1.2.2.2 Other Major Protein Pathologies in ALS 
 
Several other proteins have been observed in ALS motor neurons to form cytoplasmic 
aggregates that are not categorized as RNA-binding proteins. However, here I will discuss two 
other major protein pathologies—SOD1 and C9ORF72—that have been also shown to contribute 
to RNA dysregulation in ALS.   
1.2.2.2.1 SOD1 
 
Cu/Zn-superoxide dimutase 1 (SOD1) cytoplasmic protein aggregation is seen in 2% of 
all ALS cases. Mutations in SOD1 (mtSOD1) leads to misfolding of the protein causing reduced 
activity and increased accumulation of free radicals that are toxic to cells (Kaur et al., 2016). 
Interestingly, mutant, but not wild-type, SOD1 binds to the 3’ untranslated region (UTR) of 
NEFL and VEGF mRNA, destabilizing these mRNA molecules and reducing their steady-state 
levels (Li et al., 2009; Lin et al., 2004; Lu et al., 2007; Menzies et al., 2002). Therefore, while 
not classically an RNA-binding protein, mtSOD1 appears to acquire a gain-of-function where it 
negatively regulates the levels of NEFL and VEGF through direct interactions with their 3’UTRs. 
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VEGF is a critical trophic factor known to promote motor neuron survival, while NEFL is critical 
for cytoskeleton formation (Oosthuyse et al., 2001; Szaro and Strong, 2010). This highlights that 
mtSOD1 toxicity not only disrupts cytoskeleton formation, which is critical for motor neuron 
structure and function, but as well reducing the expression of trophic factors critical for motor 
neuron survival. MtSOD1, due to protein misfolding, appears to have a high affinity for 
adenylate- and uridylate-rich elements (ARE’s) located in the 3’UTRs of NEFL and VEGF, and 
thus, while these are currently the only two RNA molecules known to be affected by mtSOD1, 
there could be other RNA molecules with ARE regions that mtSOD1 could target (Li et al., 
2009).  
1.2.2.2.2 C9ORF72 
 
Chromosome 9 open reading frame 72 (C9ORF72) GGGGCC intronic repeat expansions 
are the most common genetic variant associated with ALS where less than 24 repeats is 
considered a normal state, between 24-100 repeats represents an intermediate state (between 
normal and pathological), and over 100 repeats represents a pathological state (DeJesus-
Hernandez et al., 2011; Mathis et al., 2019; Renton et al., 2011). This expansion leads to aberrant 
translation—non-ATG or RAN-translation—of C9ORF72 creating dipeptide repeats (poly-GA, 
poly-GP, poly-GR, poly-PA and poly-PR dipeptides) that are known to form cytoplasmic 
aggregates that are linked to neurotoxicity (Mori et al., 2013a; Mori et al., 2013b; Wen et al., 
2014). Through a gain-of-function mechanism via the dipeptide repeats several RNA processing 
pathways are affected including RNA transcription, splicing and translation (Kwon et al., 2014; 
Suzuki et al., 2018; Zhang et al., 2018c). Further, in several in vitro and in vivo models, the 
dipeptide repeats have been shown to bind to multiple nucleoporin proteins which blocks nuclear 
export of RNA molecules (Freibaum et al., 2015; Shi et al., 2017; Zhang et al., 2015).  
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Overall, several proteins associated with ALS are in involved in the regulation of coding 
and non-coding RNA pathways making it clear that RNA dysfunction is likely a major 
contributor in the disease pathogenesis.  
1.2.2.3 RNA Dysregulation in ALS 
1.2.2.3.1 Cytoskeleton Pathology and RNA Dysregulation in ALS  
Intermediate filaments are a critical component that provide cellular structure, and in 
particular, provide axonal structure to neurons which allow for axonal transport and signaling 
which are necessary for neuronal survival (Szaro and Strong, 2010). In mature neurons, there are 
three intermediate filaments, generally called neurofilaments, that are critical for axonal 
structure; neurofilament light (NFL), medium (NFM) and heavy (NFH). Together they form a 
triplet protein structure where NFL either forms homopolymers or heteropolymers with NFM 
and NFH. Neither NFM or NFH alone can form homopolymers and are therefore dependent on 
NFL to form the cytoskeleton structure of an axon (Carpenter and Ip, 1996). Further, peripherin 
(PRPH) and α-internexin (INA) are two intermediate filaments responsible for forming the early 
cytoskeleton structure in developing neurons, but also interact with the neurofilament triplet 
protein structure in mature neurons (Athlan and Mushynski, 1997; Kaplan et al., 1990; Yuan et 
al., 2006; Yuan et al., 2012). These five intermediate filaments are under tight spatiotemporal 
control to maintain axonal structure and integrity (Szaro and Strong, 2010).  
In ALS, several of these intermediate filaments have been shown to form pathological 
aggregates within motor neurons, including NFH, NFM and PRPH (He and Hays, 2004; Keller 
et al., 2012; Mendonca et al., 2005; Migheli et al., 1993; Mizuno et al., 2011; Munoz et al., 1988; 
Strong et al., 2005). It is believed that loss of spatiotemporal control leads to an alteration in the 
stoichiometry between the intermediate filaments causing intermediate filament aggregation 
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(Szaro and Strong, 2010). This is because in several ALS mouse models where intermediate 
filaments have either been knocked-out, or knocked-in, intermediate filament aggregation was 
observed that was representative of what was seen in the disease, and in most cases, led to motor 
neuron death (Beaulieu and Julien, 2003; Beaulieu et al., 1999; Cote et al., 1993; Kriz et al., 
2000; Lee et al., 1994; Robertson et al., 2002; Zhu et al., 1997).  Further, in motor neurons of 
patients with sALS with no known genetic background, there is reduced expression of NEFL, 
PRPH and INA mRNA levels with no change to NEFM or NEFH levels (Wong et al., 2000). 
These changes in mRNA levels between intermediates filaments causes a change in 
stoichiometry that could result in intermediate filament aggregation.      
While intermediate filament mRNA dysregulation is a well-known phenomenon in ALS, 
it is unclear what causes this RNA dysregulation. Two ALS-related RNA-binding proteins—
TDP-43 and RGNEF—have been shown to interact with the 3’UTR and regulate NEFL mRNA 
by either increasing or reducing the mRNA levels, respectively (Droppelmann et al., 2013a; 
Volkening et al., 2009). Interestingly, NEFL mRNA in spinal cord homogenates was only bound 
to RGNEF when homogenates were derived from ALS patients and not from controls 
(Volkening et al., 2010). This suggests that dysregulation of TDP-43 and RGNEF, as seen in 
ALS motor neurons, may alter NEFL mRNA steady-state levels, contributing to changes in 
intermediate filament stoichiometry. 
Further, our group has shown several ALS-linked miRNAs interact with the NEFL 
3’UTR to regulate mRNA stability including: miR-146a*, miR-524-5p, miR-582-3p miR-b1336, 
and miR-b2403. Expression levels of miR-524-5p, miR-582-3p, miR-b1336 and miR-b2403 
have all been shown to be reduced in ALS spinal cord but increase mRNA stability when 
interacting with the NEFL 3’UTR.  In contrast, miR-146a* has been shown to be increased in 
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ALS spinal cord but decreases mRNA stability when interacting with the NEFL 3’UTR 
(Campos-Melo et al., 2013; Ishtiaq et al., 2014). These observations suggest that miRNA 
dysregulation may be a major contributor to reduced NEFL mRNA levels in ALS motor neurons, 
and to overall changes in intermediate filament stoichiometry. However, research still needs to 
be done to understand why there is a selective suppression of NEFL, PRPH and INA in ALS 
motor neurons while sparing the remaining intermediate filaments. 
1.2.2.3.2 Splicing Dysregulation in ALS  
Several ALS-related RNA-binding proteins are known to be involved in mRNA splicing 
including: TDP-43, FUS, TAF15, EWSR1, valosin-containing protein (VCP), hnRNPA1 and 
hnRNPA2B1 (Perrone et al., 2020). Thus, it is not surprising that mis-splicing of mRNA in 
motor neurons and spinal cord is a common phenomenon found in patients with ALS.  
TDP-43 dysregulation has been heavily associated with mis-splicing of several genes 
including, but not limited to CFTR, MAPT, SMN2, hnRNPA1 and STMN2 (Bose et al., 2008; 
Buratti and Baralle, 2001; Deshaies et al., 2018; Gu et al., 2017; Klim et al., 2019). In particular, 
mutations in the C-terminal end of TDP-43 have been associated with a gain-of-function where 
TDP-43 creates an alternative splicing event which skips exons that would normally be included 
(Fratta et al., 2018). These are known as “skiptic exons”. Further, loss of TDP-43 nuclear 
localization has been associated with loss-of-function splicing by which exons that would not 
normally be a part of the final transcript are placed in the transcript due to the absence of TDP-43 
(Fratta et al., 2018). These are known as “cryptic exons.” Both skiptic and cryptic exons have an 
increased prevalence in mouse models that contain gain or loss-of-function of TDP-43, 
respectively (Fratta et al., 2018). More recently, reduced TDP-43 levels within iPSC-derived 
motor neurons resulted in the production of a cryptic exon in the gene stathmin-2 (STMN2)—a 
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protein necessary for axonal regeneration—which leads to early termination of translation and 
loss of protein production. Further, this cryptic exon in STMN2 showed increased prevalence in 
ALS motor neurons where reduced STMN2 protein was also observed (Klim et al., 2019). 
TDP-43 also functions in the splicing of hnRNPA1. However, loss of TDP-43 nuclear 
localization promotes the production of the hnRNPA1B transcript, an alternative splice isoform 
which produces a protein that has an extended LCD and promotes the formation of hnRNPA1B 
cytoplasmic aggregates in ALS motor neurons (Deshaies et al., 2018).  
ALS-associated mutations in VCP have been shown to result in mis-splicing of Splicing 
Factor Proline and Glutamine rich (SFPQ) transcript causing the retention of intron 9 as shown 
in iPSC-derived motor neuron models (Luisier et al., 2018). The retention of this intron leads to 
increased binding of the SFPQ protein on the SFPQ transcript resulting in the protein exiting the 
nucleus and forming cytoplasmic aggregates. Clearance of SFPQ from the nucleus can be seen in 
motor neurons of mtVCP, mtSOD1, and sporadic ALS cases (Luisier et al., 2018). This provides 
an interesting mechanism by which mis-splicing, or intron retention, may directly contribute to 
the cytoplasmic aggregation of nuclear proteins as seen in ALS. 
Finally, FUS and other FET proteins (TAF15 and EWSR1) are known to interact with the 
spliceosome and regulate the splicing of several transcripts in the central nervous system (Kapeli 
et al., 2016; Orozco and Edbauer, 2013; Rogelj et al., 2012; Svetoni et al., 2016; Yu and Reed, 
2015; Zhou et al., 2002). FUS splicing events have been shown to be critical for neuronal 
function and survival (Lagier-Tourenne et al., 2012). Loss of FUS nuclear localization due to 
ALS-associated mutations has been known to cause massive changes in splicing within brain 
tissue of rodent models and in vitro neuronal models (Dormann et al., 2010; Kapeli et al., 2016; 
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Lagier-Tourenne et al., 2012; Reber et al., 2016; Zhou et al., 2013b). Overall, mis-splicing of 
transcripts appears to be a major contributor to the disease pathogenesis. 
1.2.2.3.3 Altered Polyadenylation in ALS  
Recent research has shown that altered poly(A) may be a contributing factor to the 
disease pathogenesis as a consequence of the loss of TDP-43 nuclear localization. In particular, 
TDP-43 regulates the poly(A) of STMN2 as shown in iPSC-derived motor neuron models, but 
loss of TDP-43 regulation promotes an early poly(A) termination site during transcription of 
STMN2 (Melamed et al., 2019). This leads to loss of STMN2 protein which, as mentioned 
previously, is a protein considered necessary for axonal regeneration (Klim et al., 2019). This 
early poly(A) termination of STMN2 has been observed in patients with ALS, indicating altered 
polyadenylation could be a factor contributing to motor neuron degeneration (Melamed et al., 
2019). While STMN2 is one example of altered polyadenylation in ALS, it would be worth 
exploring the extent of poly(A) dysregulation due to loss of TDP-43 nuclear function to 
understand the scope of this alteration across the transcriptome.  
1.2.2.3.4 Dysregulation of RNA Export in ALS 
Disruption in nucleocytoplasmic transport is a major phenomenon that occurs in ALS due 
to dysregulation of nuclear pore complexes (Chou et al., 2018; Freibaum et al., 2015; Taylor et 
al., 2016; Zhang et al., 2018a; Zhang et al., 2015). Nuclear pore complexes have been shown to 
interact with insoluble TDP-43. Mouse models and iPSC-derived motor neuron models 
containing disease-related mutations in TDP-43 showed impaired poly(A)-containing RNA 
export causing it to accumulate in the nucleus (Chou et al., 2018). Further, ALS-related 
mutations in MATR3 and C9ORF72 have also been shown to cause nuclear mRNA export 
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defects (Boehringer et al., 2017; Zhang et al., 2015). However, whether this is a global effect or 
if specific mRNA molecules are being retained is still in question.    
1.2.2.3.5 Non-coding RNA Dysregulation in ALS  
 
Non-coding RNA molecules that have been associated with the pathogenesis of ALS 
include miRNAs, long non-coding RNA’s (lncRNA’s) and small nucleolar RNA’s (snoRNA’s) 
(Campos-Melo et al., 2013; Chen and Chen, 2020; De Felice et al., 2014; Emde et al., 2015; 
Figueroa-Romero et al., 2016; Nishimoto et al., 2013; Riva et al., 2016). Although several 
snoRNA’s have been shown to be upregulated in ALS motor neurons, the significance of this 
finding and how it contributes to the pathogenesis of ALS is still unclear (Riva et al., 2016).  
 LncRNA NEAT1_2 has been observed to be increased in the motor neurons of sALS 
patients (Nishimoto et al., 2013). NEAT1_2 is an essential component for nuclear paraspeckle 
formation—RNP granules that regulate gene expression via nuclear retention of mRNA (Fox and 
Lamond, 2010). Increased NEAT1_2 levels coincide with an increase number of paraspeckles in 
sALS motor neurons where NEAT1_2 has been shown to interact with TDP-43 and FUS proteins 
(Nishimoto et al., 2013). Interestingly, ALS-linked mutations in FUS have been shown to cause 
paraspeckle dysfunction, but also lead to greater NEAT1_2 levels, indicating that FUS may be 
needed to form paraspeckles, and the loss of these structures could contribute to the pathology of 
the disease (An et al., 2019).  
As previously discussed, miRNAs have been the most extensively studied non-coding 
RNA molecules in ALS. The majority of miRNAs, but not all, have been shown to be reduced in 
the spinal cord and motor neurons of ALS patients (Campos-Melo et al., 2013; De Felice et al., 
2014; Emde et al., 2015; Figueroa-Romero et al., 2016; Reichenstein et al., 2019). It is tempting 
to hypothesize that this may be because several RNA-binding proteins that are dysregulated in 
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ALS are also involved in miRNA biogenesis. These include TDP-43, FUS, TAF15, EWSR1, 
hnRNPA1, and hnRNPA2B1 (Alarcon et al., 2015; Ballarino et al., 2013; Guil and Caceres, 
2007; Kawahara and Mieda-Sato, 2012; Kim et al., 2014; Morlando et al., 2012). However, very 
little is known about how miRNAs become dysregulated in the first place and whether this 
change in miRNA expression really has an impact on the disease pathogenesis. In this 
dissertation, my goal is to try and understand possible mechanisms for why miRNAs are reduced 
in ALS motor neurons and whether if any of the miRNAs affected result in altered expression of 
genes associated ALS. For example, does reduced miRNA expression alter intermediate filament 
stoichiometry, or lead to increased expression of LCD-containing proteins which may promote 
their aggregation? To understand miRNA dysregulation, we must first understand miRNA 
regulation. In the next section, I will discuss miRNA biogenesis, regulation and function, and 
then briefly discuss our current understanding of the role of miRNAs in motor neuron function 
and disease.   
1.3 MiRNAs 
 
MiRNAs are evolutionary conserved non-coding RNAs (ncRNAs) of 18-22 nucleotides 
that post-transcriptionally regulate the expression of most mammalian genes. First discovered in 
Caenorhabditis elegans over 25 years ago, miRNAs are the dominant class of small RNAs in 
somatic cells (Ha and Kim, 2014; Lee et al., 1993). The human genome harbours more than 
2,500 mature miRNAs that play major roles in a variety of biological pathways such as 
apoptosis, cell proliferation, development, differentiation and pathological processes (Bartel, 
2018). Each miRNA contains a unique nomenclature used to identify them (Table 1.2).  
1.3.1 MiRNA Biogenesis 
 
1.3.1.1 Canonical miRNA Biogenesis Pathway 
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Table 1.2. MiRNA nomenclature. 
Examples of miRNAs Symbol Meaning 
miR-218 “miR-“ Abbreviation for “miRNA” 
miR-218 “218” Unique identifier for specific miRNA 
miR-1 “miR-1” 
Name listed without asterisks 
represent predominant miRNA 
product that originates from 
precursor miRNA 
miR-1* “*” 
Asterisk refers to miRNA which is 
on the opposite arm from 
predominant product on the precursor 
miRNA 
miR-124-5p or miR-124-3p “-5p, -3p” 
Suffixes determine whether the 
miRNA originated from the 5’ end (-
5p) or 3’end (-3p) of precursor 
miRNA molecule 
miR-27a-3p or miR-27b-3p “a, b” 
Letters beside miRNAs with the 
same unique identifier refer to 
miRNAs that are a part of the same 
family. If miRNAs are in the same 
family, they contain the exact same 
seed sequence, but the full mature 
miRNA sequence is not the same 
miR-9-1-5p, miR-9-2-5p or miR-9-3-5p “-1, -2, -3” 
Numbers, written as such beside the 
unique identifiers, refer to duplicate 
miRNAs. These miRNAs have the 
exact same mature miRNA sequence 
but originate from different areas of 
the genome 
 
  
27 
 
In mammals, the majority of miRNAs are encoded within introns of either protein-coding 
or non-coding genes (Rodriguez et al., 2004). Several miRNA loci close in proximity are 
generally co-transcribed, thus constituting a miRNA cluster. Most miRNAs are transcribed by 
RNA polymerase II (Pol II); however RNA Pol III has been also shown to transcribe some viral 
and human miRNAs (Borchert et al., 2006; Pfeffer et al., 2005). MiRNA transcription is 
controlled by RNA Pol II-associated transcription factors such as MYC, ZEB1 and ZEB2 and 
epigenetic regulators (Cai et al., 2004; Davis-Dusenbery and Hata, 2010; Lee et al., 2004). 
Transcription products - primary miRNAs that are over 1 kb in length (pri-miRNAs) - contain a 
stem-loop structure in which mature miRNA sequences are embedded. Similar to mRNAs, pri-
miRNA transcripts contain a 7-methyl guanylate cap at the 5' end and a poly(A) tail at the 3' end 
(Davis and Hata, 2009). The nuclear RNAse III-type endonuclease DROSHA, and its essential 
cofactor DiGeorge syndrome chromosomal region 8 (DGCR8), form the microprocessor 
complex to target and cleave pri-miRNAs at the stem-loop to release the ~65 nt length precursor 
miRNA (pre-miRNA) (Denli et al., 2004; Gregory et al., 2004; Han et al., 2004; Lee et al., 
2003). The pre-miRNA is then exported to the cytoplasm by exportin-5 and Ras-related nuclear 
protein guanosine-5'-triphosphate (Ran-GTP) (Bohnsack et al., 2004; Lund et al., 2004; Yi et al., 
2003). It has been reported that exportin-5 is necessary but not critical for miRNA maturation, 
suggesting that other mechanisms complement its function (Kim et al., 2016).  
Pre-miRNA is cleaved by another RNAse III-type endonuclease called DICER, releasing 
the small miRNA duplex (Hutvagner et al., 2001; Ketting et al., 2001). DICER associates with 
the cofactors human immunodeficiency virus transactivating response RNA-binding protein 
(TRBP) and protein activator of the interferon-induced protein kinase (PACT), which do not 
seem to be essential for DICER-mediated pre-miRNA processing (Chendrimada et al., 2005; 
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Haase et al., 2005; Lee et al., 2013; Lee et al., 2006). However, it has been shown that TRBP is 
an integral cofactor for DICER processing in RNA-crowded environments, acting as a 
gatekeeper to preclude DICER from engaging with pre-miRNA-like substrates (Fareh et al., 
2016). After DICER processing, the miRNA duplex is loaded into AGO proteins (AGO 1-4 in 
humans) to form the RNA-induced silencing complex (RISC). Subsequently, the miRNA is 
unwound into two separate strands. The guide strand, which is determined during the AGO 
loading step based on relative thermodynamic stability, is usually much more prevalent and more 
biologically active than the passenger strand (miRNA*) (Ha and Kim, 2014; Kawamata and 
Tomari, 2010).  After AGO-mature miRNA binding, AGO seeks target mRNAs that are 
complementary to the miRNA seed sequence. Of note, miRNA silencing likely occurs by 
submicroscopic complexes in the cytoplasm that are constantly exchanging with cytoplasmic 
RNA granules called processing bodies (p-bodies) (Leung and Sharp, 2013). Finally, an 
interesting observation is that most mature miRNAs are also present in the nucleus, indicating 
that mature miRNAs can shuttle between the nucleus and cytoplasm. Exportin-1 (XPO1) and 
importin-8 (IPO8) have been shown to mediate the translocation to the nucleus of not only 
miRNAs, but also AGO proteins (Castanotto et al., 2009; Weinmann et al., 2009). Within the 
nucleus, miRNAs can function in gene activation or in an unconventional manner regulating the 
biogenesis and functions of miRNAs and long non-coding RNAs (lncRNAs) (Liang et al., 2013) 
(Fig. 1.2). 
1.3.1.2 Non-canonical miRNA Biogenesis Pathway  
 
Several alternative mechanisms of miRNA biogenesis have been described besides the 
canonical pathway, although only about 1% of conserved miRNAs are produced independently 
of DICER or DROSHA in vertebrates (Ha and Kim, 2014). The most common non-canonical 
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pathway is used for mirtron production: miRNAs encoded in introns at the exon junction site. 
Mirtron miRNAs bypass the DROSHA-DGCR8 complex. Pre-miRNAs are instead generated by 
mRNA splicing, lariat debranching and trimming (Berezikov et al., 2007; Ruby et al., 2007). 
DROSHA-mediated processing is also bypassed in the case of miRNAs derived from shRNAs, 
tRNAs or tRNA-like precursors, small nucleolar RNAs (snoRNAs) or snoRNA-like viral RNAs 
(Babiarz et al., 2008; Cazalla et al., 2011; Ender et al., 2008).  
In some cases, such as miR-451, miRNAs can also be generated by DICER-independent 
miRNA biogenesis. After DROSHA cleavage, pre-miR-451 is directly loaded and sliced by 
AGO2 (Cifuentes et al., 2010). Then, a poly(A)-specific ribonuclease (PARN) trims down the 3ʹ 
end of pre-miR-451 to produce the mature miR-451 (Yoda et al., 2013).  
Another class of miRNAs undergo DROSHA and DICER dependent biogenesis, but an 
additional processing step is included in between the two RNases. Precursors of these miRNAs 
carry a shorter (one-nucleotide long instead of two) 3ʹ overhang. Terminal uridylyl transferases 
(TUT2, TUT4 and TUT7) target these pre-miRNAs and extend their 3’end by 1 nucleotide  
through monouridylation for efficient DICER processing (Heo et al., 2012) (Fig. 1.3). Of 
interest, TUTs can also trigger pre-miRNA degradation through oligouridylation of 3' trimmed 
pre-miRNAs and pre-let-7 (see section “Regulation of miRNA expression”) (Kim et al., 2015).  
1.3.2 Regulation of miRNA Expression 
 
MiRNA expression can be regulated at multiple levels. Transcription is the first control 
point of the miRNA biogenesis. Of note, one-third of intronic miRNAs have transcription 
initiation regions independent of their host promoters. RNA Pol II-transcribed miRNA promoters 
are generally similar to mRNA promoters in terms of frequencies of CpG islands, TATA 
elements, TFIIB recognition elements, initiator elements (Inr), motif ten elements (MTE) and 
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Figure 1.2. MiRNA biogenesis of canonical miRNAs. The first part of miRNA processing 
occurs in the nucleus. Pri-miRNA is transcribed by RNA polymerase II or III (RNA pol II/III) 
and then cleaved by DROSHA/DGCR8 to form pre-miRNA. Pre-miRNA is exported to the 
cytoplasm by exportin-5 and then cleaved by DICER. MiRNA duplex is loaded into argonaute 
proteins (AGO 1–4) and subsequently unwound into two separated strands. For most miRNA 
targets, AGO is recruited to a complex that contains GW182 proteins (RNA-induced silencing 
complex, RISC) that induces translational repression and degradation of the mRNA targets. 
TDP-43 and FET family, RNA-binding proteins linked to amyotrophic lateral sclerosis (ALS), 
interact with DROSHA and/or DICER, regulating miRNA processing at both primary and 
precursor levels. 
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Figure 1.3. Non-canonical pathways of miRNA processing. For mirtron production, miRNAs 
encoded in introns at the exon junction site, miRNAs bypass DROSHA/DGCR8 and pre-
miRNAs are instead generated by mRNA splicing, lariat debranching and trimming. In other 
cases, miRNAs can also be generated by DICER independent miRNA biogenesis. After 
DROSHA cleavage miRNA is directly loaded and sliced by AGO2. PARN then trims down the 
3’ end of the pre-miRNA to produce the mature miRNA. A third class of miRNAs undergo 
DROSHA and DICER dependent biogenesis, but an additional processing step is included in 
between the two RNAases. Precursors of these miRNAs carry a shorter 3’ overhang. Terminal 
uridylyl transferases (TUT2, TUT4 and TUT7) target these pre-miRNAs and extend their 3’ end 
by 1 nucleotide through monouridylation for efficient DICER processing. 
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downstream promoter elements (DPE). Also, some transcription factors that control mRNA 
production regulate the transcription of miRNAs encoded in introns of protein coding genes 
(Davis and Hata, 2009; Ozsolak et al., 2008).  
Changes in the methylation of miRNA promoters or miRNA sequences can impact on the 
expression of miRNAs. The methylation status of some miRNA genes has been associated with 
cancer. For instance, hypermethylation of the CpG island upstream of the tumor suppressor miR-
33b, is responsible for its downregulation in gastric cancer (Yin et al., 2016). Also, methylation 
of promoters of the miR-200b cluster is associated with metastasis in advanced breast cancer 
(Wee et al., 2012). Interestingly, methylation of the 5’ monophosphate of pre-miR-23b and pre-
miR-145 inhibits the processing of these miRNAs by DICER (Xhemalce et al., 2012). This is 
because the interaction between DICER and the 5’ monophosphate is necessary for the efficient 
processing of pre-miRNAs (Park et al., 2011). MiRNA promoters are also regulated by histone 
modifications. Some miRNAs have been reported to be up- or down-regulated after the treatment  
with histone deacetylase (HDAC) inhibitors (Nasser et al., 2008; Saito and Jones, 2006; Scott et 
al., 2006). For instance, acetylation regulates the expression of miR-133a during chronic pressure 
overload-induced cardiac fibrosis (Renaud et al., 2015). Single nucleotide polymorphisms 
(SNPs) in miRNA genes can also affect miRNA biogenesis (Duan et al., 2007). For example, 
SNPs in miR-1206 and miR-612 genes within two cancer risk loci affect the expression of both 
mature miRNAs (Kim et al., 2012).  
RNA editing (adenosine to inosine catalyzed by adenosine deaminase that acts on RNA; 
(ADARs)) also impacts on miRNA processing. Let-7 pri-miRNA editing impairs the biogenesis 
of this miRNA and drives leukemia stem cell self-renewal (Zipeto et al., 2016). Another type of 
regulation of miRNA biogenesis is by RNA-tailing (nucleotidyl addition to the 3ʹ end of RNA). 
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For example, LIN28 proteins recruit terminal uridylyl transferases TUT4 and TUT7 C6 to induce 
oligouridylation of pre-let-7 (Hagan et al., 2009; Heo et al., 2008; Heo et al., 2009). This oligo-U 
tail blocks DICER processing, and facilitates miRNA decay by 3’-5’ exonuclease DIS3L2 
(Chang et al., 2013; Ustianenko et al., 2013). Some miRNA transcripts, like most mRNAs, are 
methylated at N6-adenosine (m6A). This modification acts as a mark for pri-miRNA processing. 
RNA-binding protein hnRNPA2B1 binds to m6A, interacts with DGCR8, and promotes pri-
miRNA cleavage to produce pre-miRNA (Alarcon et al., 2015).  Finally, levels of certain 
miRNAs are controlled by regulating miRNA stability. For instance, levels of miR-122 are 
stabilized by monoadenylation via the non-canonical cytoplasmic poly(A) polymerase GLD-2 
(TUT2) in mammals (D'Ambrogio et al., 2012; Katoh et al., 2009). Moreover, a highly 
complementary mRNA target can induce miRNA degradation through 3’ addition of a single 
non-templated uridine followed by 3’ to 5’ trimming of the miRNA with a 2′-O-methyl group 
added by Hen1 enzyme in Drosophila (Ameres et al., 2010; Baccarini et al., 2011). 
Recently, another layer of complexity has been added into miRNA regulation. Levels of 
mature forms of miR-122 are post-transcriptionally regulated by modulating its processing in 
a target-dependent manner during recovery from starvation-related stress (Bose and 
Bhattacharyya, 2016). 
1.3.3 Mechanisms of miRNA Function 
 
MiRNAs are able to regulate gene expression by several mechanisms (Fig. 1.4). In RNA 
silencing, miRNAs function as a guide to recognize target mRNAs, whereas AGO proteins 
function as effectors by recruiting factors that induce translational repression and/or mRNA 
decay (Ha and Kim, 2014). The 5’ region of the miRNA (seed, nucleotides 2 to 7) is crucial for 
target recognition through the complementary base pairing of miRNA recognition elements   
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Figure 1.4. Mechanisms of action of miRNAs. (A) MiRNAs promote mRNA degradation by 
recruiting deadenylases on the target mRNA via GW182 and also through the dissociation of 
PABP, increasing the accessibility of the poly(A) tail to deadenylases. (B) MiRNAs inhibit 
translation at the initiation step, however the exact mechanism is still unclear. Three mechanisms 
have been proposed; (i) PABP displacement mediated by GW182; (ii) recruitment of the 
translational repressors through GW182; and (iii) dissociation of eukaryotic initiation factor-4A 
(eIF4A) from the cap-binding complex eIF4F. (C) MiRNAs also induce upregulation of their 
targets. MiRNAs have been implicated in gene activation triggered by promoter-targeted small 
RNAs, known as RNA activation (RNAa). (D) Upregulation of certain transcripts can also be 
mediated by miRNA binding to mRNA 3’untranslated regions (3’UTRs), resulting in either 
translation activation or RNA stability enhancement. MiR-346-dependent upregulation of 
telomerase reverse transcriptase (TERT) occurs through the binding to TERT mRNA 3’UTR and 
is mediated by G-rich RNA sequence binding factor 1 (GRSF1). MiR-346 facilitates the 
recruitment of TERT mRNA to ribosomes to promote translation. In another example, miR-4661 
uses the binding sites of the tristetraprolin (TTP) in the IL-10 3’UTR preventing TTP-mediated 
IL-10 mRNA degradation in macrophages. 
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(MREs) that are mostly localized in the mRNA 3’untranslated region (UTR). Currently, MREs 
in 3’UTRs are determined using prediction algorithms and then validated with functional 
analysis. However, seedless 3’UTR MREs have been described, as well as MREs localized 
within 5’UTRs and coding regions (Forman et al., 2008; Lal et al., 2009; Moretti et al., 2010). To 
provide an alternative view of human miRNA targets, a protocol termed cross-linking, ligation 
and sequencing of hybrids (CLASH) was developed for high-throughput identification of 
miRNA-target RNA duplexes associated with AGO and is independent of bioinformatic 
predictors. Transcriptome-wide data set revealed that binding of most miRNAs to their targets 
includes the seed region, but around 60% of seed interactions are noncanonical. Of interest, seed 
interactions are generally accompanied by non-seed base pairing (Helwak et al., 2013). 
MiRNAs downregulate target mRNAs through translational repression and mRNA 
destabilization, with mRNA destabilization dominating most miRNA-mediated repression 
(Eichhorn et al., 2014; Guo et al., 2010; Hendrickson et al., 2009). Although miRNAs inhibit 
translation at the initiation step, the exact mechanism is still unclear. Three mechanisms have 
been proposed i) PABP displacement mediated by GW182 (Moretti et al., 2012; Zekri et al., 
2013), ii) recruitment of the translational repressors through GW182 (Kamenska et al., 2014; 
Meijer et al., 2013; Waghray et al., 2015) and iii) dissociation of eukaryotic initiation factor-4A 
(eIF4A) from the cap-binding complex eIF4F (Fukao et al., 2014; Fukaya et al., 2014).  
At the same time, mRNA destabilization is a consequence of miRNA-mediated deadenylation of 
target mRNAs which causes these mRNAs to undergo decapping and 5’ –3’decay (Behm-
Ansmant et al., 2006; Rehwinkel et al., 2005; Wu et al., 2006).  MiRNAs promote mRNA decay 
by recruiting the deadenylase complex CCR4–NOT or PAN2–PAN3 on the target mRNA via 
GW182 (Braun et al., 2011; Fabian et al., 2011). Also, miRNAs promote mRNA decay through 
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the dissociation of PABP, increasing the accessibility of the poly(A) tail to deadenylases (Moretti 
et al., 2012).  
Beside well-known downregulatory functions, there is increasing evidence that miRNAs 
can also induce upregulation of their targets (Campos-Melo et al., 2014; Valinezhad Orang et al., 
2014; Vasudevan et al., 2007). MiRNAs, similar to double stranded RNAs (dsRNAs), have been 
implicated in gene activation triggered by promoter-targeted small RNAs, known as RNA 
activation (RNAa). For instance, the expression of cyclin B1 (Ccnb1) depends on RNAa by 
miRNAs and components of miRNA biogenesis in mouse cells. Chromatin immunoprecipitation 
(ChIP) analysis had shown that AGO1 is selectively associated to the Ccnb1 promoter and miR-
744, which induces Ccnb1 expression, increases enrichment of RNA Pol II and trimethylation of 
histone 3 at lysine 4 (H3K4me3) at the Ccnb1 transcription start site. At a functional level, short-
term expression of miR-744 enhances cell proliferation, but prolonged overexpression causes 
tumor suppression (Huang et al., 2012). 
Finally, the upregulation of certain mRNA transcripts can also be mediated by miRNA 
binding to mRNA 3’UTRs, resulting in either translation activation or RNA stability 
enhancement. For example, miR-346-dependent upregulation of telomerase reverse transcriptase 
(TERT) occurs through the binding of miR-346 to TERT mRNA 3’UTR. When miR-346 is 
bound to the TERT mRNA 3′UTR, its middle sequence motif forms a “bulge loop”, facilitating 
the G-rich RNA sequence binding factor 1 (GRSF1)-mediated recruitment of TERT mRNA to 
polysomes to promote translation (Song et al., 2015). A similar mechanism of GRSF1 interaction 
with AGO2 in a miR-346-dependant manner, leading to upregulate the expression of AGO2, has 
been described for cervical cancer (Guo et al., 2015). It has also been reported that miR-4661 
uses the binding sites of the RNA-binding protein tristetraprolin (TTP) in the IL-10 3’UTR AU-
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rich elements, thus preventing TTP-mediated IL-10 mRNA degradation in macrophages (Ma et 
al., 2010).  
1.4 MiRNAs in Motor Neuron Function 
 
Transgenic mouse models containing loss of DICER function set the foundation for the 
importance of miRNA regulation within motor neurons. These experiments showed that in early 
development, loss of DICER function within motor neuron progenitor cells leads to aberrant 
motor neuron development in the lateral motor column, while in adult mice, loss of DICER 
expression in motor neurons resulted in progressive motor neurodegeneration (Chen and 
Wichterle, 2012; Haramati et al., 2010). With these two studies, it became apparent that the 
production of miRNAs is a critical factor to overall motor neuron function and survival. There is 
very little known about the miRNome (the full spectrum of miRNAs being expressed) of motor 
neurons. However, as we further discover miRNAs related to motor neuron development and 
degeneration, it becomes increasingly evident that there are specific miRNAs needed to regulate 
cytoskeleton integrity, neuronal development, signalling and function, synaptic plasticity, and 
overall survival of motor neurons which we have termed “MotomiR’s” (Table 1.3).   
1.4.1 MiRNAs in Motor Neuron Diseases  
 
Given the several roles of miRNAs in regulating motor neuron differentiation, structure, 
activity and cytoskeletal integrity, it is not surprising that alterations in the expression of 
miRNAs have been increasingly linked to human motor neuron degenerative disorders. These 
alterations can be in the miRNAs and/or MREs such as changes in the expression, editing and 
methylation, mutations and SNPs, and also alterations in competing endogenous RNAs 
(ceRNAs) involved in the regulation of the interaction of miRNAs and their targets. 
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Table 1.3. List of current MotomiRs and their function* 
 
MotomiR 
Genes shown 
to regulate 
Role within motor 
neurons 
Organism/Cell 
models used to 
describe function 
References 
miR-9 
OC1, FoxP1, 
NEFH, 
MAP1B, 
MCPIP1 
Development, 
cytoskeleton 
maintenance, cell 
survival 
Chick, mouse 
neuronal 
precursor cells, 
mouse 
(Dajas-Bailador et al., 2012; 
Haramati et al., 2010; 
Luxenhofer et al., 2014; 
Otaegi et al., 2011; Xu et al., 
2016) 
miR-124 
REST, Stat3, 
Kfl6 
Development, 
regeneration 
Mouse 
(Nagata et al., 2014; 
Visvanathan et al., 2007) 
miR-146*, 
miR-524, miR-
582, miR-
b1336, & 
miR-b2403 
NEFL 
Cytoskeleton 
maintenance 
In vitro 
interactions done 
in HEK293T cells 
 
(Campos-Melo et al., 2013; 
Ishtiaq et al., 2014) 
miR-218 
TEAD1, 
FOXP2, LHX1, 
SLC6A1, 
BCL11A, 
SLC1A1 
Development, 
membrane 
excitability, NMJ 
synaptic connections 
Mouse 
(Amin et al., 2015; Thiebes 
et al., 2015) 
miR-8 
FasIII, Nrg, 
wg, lar 
Synaptic plasticity Drosophila 
(Lu et al., 2014; Nesler et 
al., 2013) 
miR-958 & 
miR-289 
Lar Synaptic plasticity Drosophila (Nesler et al., 2013) 
miR-375 
PAX6, CCND2, 
p53 
Development, cell 
survival 
Human neural 
progenitor cell 
cultures 
(Bhinge et al., 2016) 
miR-310-313 Khc-43 
Synaptic vesicle 
release 
Drosophila (Tsurudome et al., 2010) 
miR-128 & 
miR-20a 
PDZ-RhoGEF 
Axonal growth, 
regeneration 
Rat cortical 
neuron cultures 
(Sun et al., 2013) 
miR-153 SNAP-25 
Axonal growth, 
synaptic vesicle 
release 
Zebrafish (Wei et al., 2013) 
miR-196 Hoxb8 Development Drosophila (Asli and Kessel, 2010) 
miR-183 mTOR Neurite growth 
Rat primary 
spinal motor 
neuron cultures 
(Kye et al., 2014) 
miR-206 BDNF, HDAC4 NMJ Regeneratoin Mouse 
 
(Miura et al., 2012; 
Williams et al., 2009) 
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miR-34 Nrx-IV,  Hts  
NMJ synaptic 
connections 
Drosophila (McNeill et al., 2020) 
miR-126 Sema3, NRP 
NMJ synaptic 
connections 
In vitro motor 
neuronal models 
(Maimon et al., 2018) 
miR-137 Calpain-2 
Regeneration, 
survival  
In vivo rat motor 
neurons 
(Tang et al., 2018) 
*Table adapted from Hawley et al., 2017a  
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1.4.1.1 MiRNA Dysregulation in Spinal Muscular Atrophy (SMA) 
SMA is an autosomal recessive disease characterized by progressive loss of lower motor 
neurons and atrophy of muscle (Burghes and Beattie, 2009). Proximal SMA has an incidence of 
∼1:10,000 newborns and is the most frequent SMA type (Wirth et al., 2006). SMA is caused by 
homozygous deletion or mutation of survival motor neuron 1 (SMN1) (Lefebvre et al., 1995). 
SMN has been found to play roles in RNA metabolism, specifically in snRNP (small nuclear 
ribonucleoproteins) biogenesis, alternative splicing, trafficking of RNA-binding proteins and 
translation of target mRNAs in neurites. SMN also binds to fragile X mental retardation protein 
(FMRP), KH-type splicing regulatory protein (KSRP) and FUS, which are important for miRNA 
biogenesis and function (Akten et al., 2011; Fallini et al., 2014; Fallini et al., 2011; Gubitz et al., 
2004; Hubers et al., 2011; Piazzon et al., 2008; Tadesse et al., 2008; Trabucchi et al., 2009; 
Yamazaki et al., 2012). In fact, several lines of evidence have involved miRNAs in SMA. It was 
reported that mice lacking the miRNA-processing enzyme DICER selectively in motor neurons 
display hallmarks of SMA (Haramati et al., 2010). Also, SMN protein has been shown to alter 
miRNA expression and distribution in neurons (Kye et al., 2014; Wang et al., 2014). 
Specifically, miR-183 is increased in neurites of SMN-deficient neurons. Inhibition of 
miR-183 expression in the spinal cord of an SMA mouse model prolongs survival and improves 
motor function of Smn-mutant mice (Kye et al., 2014). SMN protein also downregulates the 
expression of miR-9a. Interestingly, miR-9a levels have shown a positive correlation with SMA 
severity (Wang et al., 2014). A more recent study has shown that miR-431, involved in motor 
neuron neurite length, also plays a role in the SMA motor neuron phenotype. By integrating 
miRNA:mRNA profiles, it was observed that miR-431 expression is highly increased in spinal 
motor neurons, and a number of its putative mRNA targets are significantly downregulated in 
motor neurons after SMN loss (Wertz et al., 2016). Another miRNA involved in SMA motor 
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neuron phenotype is miR-375. Besides its role in neurogenesis, miR-375 protects neurons from 
apoptosis in response to DNA damage. Motor neurons derived from a SMA patient have shown 
reduced levels of miR-375, elevated p53 protein levels, and higher susceptibility to DNA 
damage induced apoptosis (Bhinge et al., 2016).  
Recently, the first vertebrate system allowing transgenic spatio-temporal control of the 
smn1 gene was developed using stable miR-mediated knockdown technology in zebrafish. The 
expression of anti-smn1 miRNAs in motor neurons reproduced most hallmarks observed 
previously in the ubiquitous knockdown model. In addition, smn1 knockdown in zebrafish motor 
neurons is sufficient to induce late-onset motor neuron degeneration (Laird et al., 2016). Finally, 
the potential use of miR-9, miR-206 and miR-132 as biomarkers in SMA has been proposed. It 
was shown that there is differential expression of all three miRNAs in spinal cord, skeletal 
muscle and serum samples in SMA mouse models, while only miR-9 and miR-132 were 
differentially expressed in serum samples of SMA patients (Catapano et al., 2016). 
 
1.4.1.2 MiRNA Dysregulation in ALS  
Numerous studies in ALS models and patient samples have demonstrated a mass 
disruption of miRNA expression in ALS (Butovsky et al., 2012; Dobrowolny et al., 2015; Koval 
et al., 2013; Marcuzzo et al., 2014; Parisi et al., 2013; Toivonen et al., 2014; Williams et al., 
2009; Zhou et al., 2013a).  The most consistent observation from the mtSOD1 mice is the 
upregulation of miR-9 and miR-206 (Dobrowolny et al., 2015; Toivonen et al., 2014; Williams et 
al., 2009; Zhou et al., 2013a). Specifically, miR-9 expression is upregulated in mtSOD1 mouse 
spinal cord (Dobrowolny et al., 2015; Shi et al., 2004; Tan et al., 2012; Zhao et al., 2009; Zhou et 
al., 2013a), while miR-206 expression is upregulated in muscle in both mtSOD1 and SMA 
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mouse models (Valsecchi et al., 2015). Of note, mtSOD1 disease progression is accelerated with 
downregulation of miR-206 expression (Williams et al., 2009).  
The first miRNA profile of human spinal cord tissue was obtained in 2013 and observed 
a massive downregulation of miRNAs in ALS (Campos-Melo et al., 2013). This disruption was 
subsequently shown to be specific to motor neurons (Emde et al., 2015). The reduction of 
miRNA levels has been previously indicated to be a consequence of the inhibition of DICER 
pre-miRNA processing activity (Emde et al., 2015). Of note, the downregulation of miRNAs  has 
also been observed in other ALS-derived tissues such as in motor cortex, fibroblasts, serum 
/plasma, and CSF (Benigni et al., 2016; Freischmidt et al., 2015a; Raman et al., 2015; Takahashi 
et al., 2015; Wakabayashi et al., 2014).  A consistent upregulation of miR-206 in muscle (de 
Andrade et al., 2016; Russell et al., 2013) and in serum samples of ALS patients has also been 
reported (de Andrade et al., 2016; Toivonen et al., 2014). The latter appears to correlate with the 
rate of clinical deterioration (de Andrade et al., 2016). Although studies in larger cohorts are 
necessary, these results suggest that miR-206 could be a potential biomarker for ALS. 
While miRNAs have clearly been shown to be reduced within the spinal cord and motor 
neurons of ALS patients (Campos-Melo et al., 2013; Emde et al., 2015), the exact cause of this 
mechanism is still unclear. However, a major contributor to reduced miRNA levels in ALS 
motor neurons is that several ALS-associated RNA-binding proteins have been shown to be 
involved in miRNA biogenesis as discussed earlier, including: TDP-43, FUS, TAF15, EWSR1, 
hnRNPA1 and hnRNPA2B1 (Alarcon et al., 2015; Ballarino et al., 2013; Kawahara and Mieda-
Sato, 2012; Kim et al., 2014; Kooshapur et al., 2018; Morlando et al., 2012). The common 
pathological feature among all these proteins in ALS is that they have been found to re-locate 
from the nucleus to the cytoplasm in motor neurons, and subsequently form cytoplasmic 
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aggregates. This indicates a loss of nuclear function of RNA-binding proteins in ALS may 
contribute to the changes in miRNA processing. Interestingly, cellular stress has been shown to 
transiently induce the re-localization of many ALS-related nuclear RNA-binding proteins to the 
cytoplasm providing a potential mechanism that could induce the pathology of these proteins in 
ALS and disrupt miRNA biogenesis.  
1.5 Stress Granules  
 
The compendium of genes that have been associated with ALS have shown a high 
enrichment for RNA-binding proteins, indicating that changes to RNA processing in motor 
neurons is a major factor to the disease progression (Andersen and Al-Chalabi, 2011; Chen et al., 
2013; Therrien et al., 2016). Further, many of the ALS-associated RNA-binding proteins are 
responsible for the formation, assembly, and disassembly of stress granules—transient 
ribonucleoprotein (RNP) granules that form during periods of cellular stress and contain 
translationally silent mRNA (Anderson and Kedersha, 2008; Aulas and Vande Velde, 2015; 
Buchan, 2014). ALS-linked RNA-binding proteins associated with stress granules include: TDP-
43, FUS, ATXN2, hnRNPA1, hnRNPA2B1, TAF15, EWSR1, RBM45, C9ORF72 and TIA1 
(Andersson et al., 2008; Colombrita et al., 2009; Kim et al., 2013; Li et al., 2015; Mackenzie et 
al., 2017; Maharjan et al., 2017; Nonhoff et al., 2007). This list contains many of the ALS-
related RNA-binding proteins that are involved in miRNA biogenesis mentioned in the previous 
section. Based on this information, it is widely believed that stress granules may be the seed to 
pathological aggregate formation of RNA-binding proteins ultimately leading to changes in 
miRNA processing in ALS.   
 
1.5.1 Stress Granule Assembly and Disassembly  
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When cells face adverse conditions within their environment (e.g. oxidative, osmotic, or 
proteasomal stress), cells start to produce structures called stress granules (Gilks et al., 2004; 
Kedersha et al., 2000; Kedersha et al., 1999). The purpose of these granules is to act as a triage 
for mRNA, where mRNA can be either stored within the stress granule, transferred to processing 
bodies (p-bodies) for degradation, or go back into polysomes to be translated (Anderson and 
Kedersha, 2008; Aulas and Vande Velde, 2015).  
Phosphorylation of eIF2α appears to be an early trigger that initiates stress granule 
assembly; however, there are cases of stress granule assembly that are independent of eIF2α 
phosphorylation (Kedersha et al., 2002; Kim et al., 2007; McEwen et al., 2005; Shenton et al., 
2006). The phosphorylation of eIF2α results in reduced formation and activity of translational 
machinery (Shenton et al., 2006). This is followed by an accumulation of RNA-binding proteins 
and RNA molecules into granules that lack a membrane structure (Anderson and Kedersha, 
2008; Baradaran-Heravi et al., 2020; Gilks et al., 2004). TIA-1 and G3BP1 are two RNA-binding 
proteins that early on were thought to be critical for proper stress granule formation. However, as 
we learn more about stress and stress granules, we are starting to understand how truly dynamic 
and diverse these structures are. Thus, while some proteins are critical for the formation of stress 
granules for certain stresses, they might not be critical for others (Aulas et al., 2015; Gilks et al., 
2004; Kedersha et al., 2016; Markmiller et al., 2018). For example, G3BP1 is critical for the 
formation of stress granules during oxidative stress, but it is not needed for stress granule 
assembly during periods of osmotic stress (Kedersha et al., 2016; Solomon et al., 2007). Further, 
proteomics of stress granules has shown different stresses and different cell types result in 
different protein profiles (Markmiller et al., 2018). This suggests that stress granule formation 
and proteomic profile are highly dynamic and context dependent. 
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After cellular stress disappears, stress granules start disassembling as the cell goes back 
to its homeostatic state allowing translation of previously silent mRNA to begin again (Molliex 
et al., 2015). Several mechanisms have been implicated in stress granule disassembly, including: 
reduced stress results in the formation and increased activity of translational machinery 
destabilizing the granule structure; inhibition of RNA helicases that promote assembly and 
maintenance of stress granules; heat shock proteins disassemble RNP complexes; and, 
ubiquitination of proteins via VCP allowing for stress granules to be targeted by autophagy 
pathways (Buchan et al., 2013; Cherkasov et al., 2013; Jain et al., 2016; Kroschwald et al., 2015; 
Meyer and Weihl, 2014; Protter and Parker, 2016; Wheeler et al., 2016). All these pathways 
likely work together to allow for efficient disassembly of stress granules. It is also clear that 
stress granule disassembly is an active process that requires ATP hydrolysis (Jain et al., 2016; 
Meyer and Weihl, 2014; Protter and Parker, 2016).  
In all of this, LCD-containing proteins appear to be critical for the formation of stress 
granules by allowing them to phase separate and form liquid droplets, which produces dynamic 
interactions with p-bodies, other stress granules and the cytosol of the cell (Aulas et al., 2015; 
Gilks et al., 2004; Kato et al., 2012; Mackenzie et al., 2017; Molliex et al., 2015; Murray et al., 
2017; Patel et al., 2015). Structurally, this is because the LCD participates in β-pleated sheet 
formation and forms amyloid-like interactions similar to what is seen in prion disease (Molliex et 
al., 2015; Murakami et al., 2015; Patel et al., 2015). These interactions are critical for the 
formation of RNA granules which lack a membrane to contain its components (Baradaran-
Heravi et al., 2020; Taylor et al., 2016). Therefore, phase transition into reversible liquid droplets 
is a critical mechanism for the formation of stress granules. While the LCD’s are necessary for 
quick assembly of stress granules, it can also be a detriment to the cells if proteins are left to 
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accumulate, risking the formation of hydrogels (Kato et al., 2012; Li et al., 2013; Molliex et al., 
2015).      
 
1.5.2 Hydrogels  
 
LCD-containing proteins in both cell-free and cell in vitro models have been shown to 
form hydrogels (Kato et al., 2012; Molliex et al., 2015; Murakami et al., 2015; Murray et al., 
2017). Hydrogels are defined by the aggregation of proteins leading to phase transition into 
liquid droplets and eventually irreversible gelatin structures (Murakami et al., 2015). The 
formation of these hydrogel structures is primarily driven by the LCD. (Kato et al., 2012; 
Molliex et al., 2015; Murakami et al., 2015; Murray et al., 2017).  
As discussed, several ALS-related proteins are LCD-containing proteins, including: TDP-
43, FUS, hnRNPA1, hnRNPA2B1, TAF15, EWSR1, RBM45 and TIA-1 (Baradaran-Heravi et 
al., 2020). ALS-linked mutations within the LCD of TDP-43, FUS and hnRNPA1 have been 
shown to increase the rate at which these proteins phase separate and form hydrogel-like 
structures (Conicella et al., 2016; Kim et al., 2013; Molliex et al., 2015; Murakami et al., 2015). 
Since LCD-containing ALS-related proteins tend to form insoluble aggregates, several 
researchers have focused on therapeutics that prevent the accumulation of these proteins. 
However, little research has been done on the dysregulation of miRNAs in ALS, and potential 
changes to their regulation on the expression of ALS-related genes that could be a major 
contributor to the accumulation of these proteins.     
 
1.6 Putting it all together: ALS, cell stress and miRNA dysfunction  
 
Based on the number of ALS-linked genes associated with stress granules, improper 
stress granule formation has been suggested to be a key precursor to the pathogenesis of ALS 
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(Aulas and Vande Velde, 2015; Li et al., 2013; Taylor et al., 2016). Intriguingly, out of the 190 
RNA-binding proteins identified by Treiber and colleagues to be involved in miRNA processing, 
33.2% were associated with stress granules (Treiber et al., 2017). This high enrichment of stress 
granule associated RNA-binding proteins found with pre-miRNA molecules provides some 
insight into how miRNAs are able to dynamically change their expression under different 
physiological conditions (Wilczynska and Bushell, 2015). Interestingly, cellular stressors like 
endoplasmic reticulum (ER) or oxidative stress have been known to impair miRNA biogenesis 
reducing overall miRNA expression (Emde et al., 2015). Many RNA-binding proteins during 
cellular stress are re-localized to stress granules, including TDP-43, FUS, TAF15, EWSR1, 
hnRNPA1, hnRNPA2B1 and ATXN2, which could explain the reduction in miRNA processing 
during cellular stress, as many of these proteins are involved with miRNA biogenesis (Alarcon et 
al., 2015; Andersson et al., 2008; Ballarino et al., 2013; Colombrita et al., 2009; Guil and 
Caceres, 2007; Kawahara and Mieda-Sato, 2012; Kim et al., 2013; Kim et al., 2014; Li et al., 
2015; Morlando et al., 2012; Nonhoff et al., 2007). Therefore, reduced miRNA levels, and by 
inference reduced activity, during periods of stress could result in accumulation of LCD-
containing proteins due to reduced miRNA-mediated silencing, indicating a potential negative 
feedback loop between miRNAs and RNA-binding proteins that is lost in ALS. Further, during 
periods of chronic or repeated stress, excessive protein accumulation due to low miRNA levels 
could result in the formation of insoluble aggregates.   
 Further, prolonged stress that alters the levels of miRNAs that target intermediate 
filaments would likely alter the stoichiometry of intermediate filament expression in a fashion 
that would promote their aggregation. Overall, changes to altered miRNA levels, as seen in ALS, 
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likely alters the regulation of RNA-binding protein and intermediate filament expression, thus 
contributing to the resulting pathology of these two protein groups in ALS.  
 
1.7 Hypothesis and Aims  
 
Taken together, the downregulation of miRNAs in ALS could be due to altered function 
and localization of RNA-binding proteins that would normally promote miRNA production, 
which in turn, leads to loss of miRNA regulation of ALS-associated RNA-binding proteins and 
intermediate filaments contributing to their pathogenesis. 
Hypothesis: A negative feedback loop between specific RNA-binding proteins and miRNAs is 
disrupted in ALS leading to changes in miRNA processing that contributes to RNA-binding 
protein and intermediate filament pathology.  
Aim 1: Determine if ALS-linked miRNAs contribute to the selective suppression of NEFL, 
PRPH, and INA intermediate filaments as seen in ALS motor neurons – Chapter 2. 
Aim 2: Determine if ALS-linked miRNAs regulate the expression of NEFM and NEFH, which 
may contribute to the loss of stoichiometry seen between intermediate filaments in ALS – 
Chapter 3.  
Aim 3: Determine if ALS-linked miRNAs regulate the expression of RNA-binding proteins 
(TARDBP, FUS, and RGNEF) associated with ALS – Chapter 4.  
Aim 4: Determine if TDP-43 and FUS are in a negative feedback network with ALS-linked 
miRNAs that is dependent on their nuclear localization – Chapter 5.   
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2.1 Abstract 
Intermediate filament aggregation within motor neurons is a hallmark of ALS 
pathogenesis. Changes to intermediate filament stoichiometry due to altered mRNA steady-state 
levels of NEFL, PRPH and INA is thought to drive protein aggregation, yet the exact cause of 
these changes is unknown. MicroRNAs (miRNAs)—master regulators of gene expression—are 
largely dysregulated within ALS motor neurons and are known to be major contributors to the 
disease. We show that miR-105 and miR-9 are downregulated within the spinal cord of ALS 
patients and target NEFL, PRPH and INA 3’UTRs to regulate gene expression. Further, both 
miR-105 and miR-9 were observed to regulate the mRNA stability of these three intermediate 
filaments endogenously within a neuronal-derived cell line. Our data demonstrates that miR-105 
and miR-9 can regulate the mRNA stability of these key intermediate filaments whose 
metabolism is dysregulated in ALS, and thus, these miRNAs likely contribute to their 
pathogenesis.  
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2.2 Introduction 
 
 Amyotrophic lateral sclerosis (ALS) is a fatal disease which is characterized by 
progressive degeneration of motor neurons (Strong, 2017). One major neuropathological 
hallmark of the disease is the formation of neuronal cytoplasmic inclusions (NCIs) containing 
intermediate filaments, which include neurofilament light, medium and heavy (NFL, NFM, and 
NFH, respectively), and peripherin (PRPH) (He and Hays, 2004; Hirano et al., 1984; Keller et 
al., 2012; Kondo et al., 1986; Xiao et al., 2006) 
 In general, intermediate filaments are essential proteins that make up the cytoskeleton 
and are needed for proper cellular structure and signaling within neurons. Neurofilament 
assembly requires NFL to form homopolymers, and as well as heteropolymers with NFM and 
NFH, to form a triplet protein structure (Carpenter and Ip, 1996; Szaro and Strong, 2010). 
Further, PRPH and α-internexin (INA) intermediate filaments are responsible for the formation 
of the early cytoskeleton within developing neurons, but both also interact with the 
neurofilament triplet protein structure within mature neurons (Yuan et al., 2006; Yuan et al., 
2012). Together these intermediate filaments maintain a specific stoichiometry that ensures 
appropriate cell structure, axonal transport, and overall neuronal health (Lariviere and Julien, 
2004; Szaro and Strong, 2010).  
Alterations to intermediate filament stoichiometry within motor neurons of mammalian 
ALS-models induces the formation of NCIs similar to those observed in ALS spinal motor 
neurons (Beaulieu et al., 1999; Kriz et al., 2000; Lee et al., 1994; Zhu et al., 1997). Further, in 
motor neurons of sporadic ALS (sALS) patients with no known genetic background, NEFL, 
PRPH and INA mRNA steady-state levels are selectively reduced with no effect on NEFM or 
NEFH (Wong et al., 2000), suggesting that the loss of intermediate filament stoichiometry results 
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from the loss of proper regulation of intermediate filament mRNA metabolism (Strong, 2010; 
Strong et al., 2004; Szaro and Strong, 2010; Thyagarajan et al., 2007).  
 While alterations in mRNA metabolism seem to be critical to the pathogenesis of ALS 
(Strong, 2010), it is still unclear the etiology of neuronal intermediate filament mRNA 
dysregulation. However, microRNAs (miRNAs)—critical regulators of gene expression 
generally through interactions with the 3’ untranslated region (UTR)—have been shown to be 
largely dysregulated within the spinal cord and motor neurons of sALS patients (Campos-Melo 
et al., 2013; Emde et al., 2015; Figueroa-Romero et al., 2016). Several of these ALS-linked 
miRNAs have been shown to regulate ALS-associated RNA-binding proteins (Dini Modigliani 
et al., 2014; Hawley et al., 2017b), suggesting that the loss of proper miRNA regulation is a 
contributing factor to the disease. Further, several miRNAs have been shown to regulate the 
mRNA levels of NEFL (Campos-Melo et al., 2013; Ishtiaq et al., 2014), which may explain the 
selective reduction of NEFL mRNA steady-state levels in sALS. However, the cause of PRPH 
and INA mRNA reduction, and whether the selective reduction of NEFL, PRPH and INA mRNA 
in sALS is caused by a common mechanism is still unknown. 
 In this study, we aim to identify a specific pool of ALS-linked miRNAs that may explain 
the selective reduction of NEFL, PRPH and INA mRNA steady-state levels. Our data revealed 
that within the pool of miRNAs that is dysregulated in sALS, miR-105 and miR-9 are critical 
regulators of neuronal intermediate filaments; however, only miR-105 directly interacts with the 
NEFL, PRPH and INA 3’UTRs to regulate mRNA levels, suggesting that its dysregulation is a 
key part to the etiology of altered intermediate filament mRNA expression in sALS.     
2.3 Methods and Materials  
 
2.3.1 Tissue Samples 
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ALS patient and neuropathologically healthy, age-matched control spinal cord tissue was 
collected and stored at -80oC, or formalin-fixed and paraffin-embedded (Table 2.1). All ALS 
cases used in this study were clinically and neuropathologically confirmed using the El Escorial 
Criteria (World Federation of Neurology Research Group on Neuromuscular Disease, 1994). The 
research was approved by “The University of Western Ontario Research Ethics Board for Health 
Sciences Research Involving Human Subjects (HSREB)”. Written consent for autopsy was either 
received from the patient antemortem, or the next of kin in accordance with the London Health 
Sciences Center consent for autopsy. All ALS patients were genetically screened and confirmed 
to have no mutations in SOD1, TARDBP, FUS, or expanded repeats in C9ORF72. 
2.3.2 MiRNA Selection 
 Candidate miRNAs were selected if they had predicted miRNA recognition elements 
(MREs) within the 3’UTRs identified in human spinal cord using miRanda software, and if they 
meant the criteria that we have previously reported (Hawley et al., 2017b).  
2.3.3 Real-time PCR 
 
 In order to determine miRNA changes in the spinal cord, total miRNA extraction was 
done on ventral lumbar human spinal cord using the mirVana miRNA extraction kit (Life 
Technologies Inc., Ambion, Carlsbad, CA, USA) in accordance with the manufactures protocol. 
Reverse transcription and real-time PCR was performed on miRNA extracts using miRCURY 
LNATM Universal RT microRNA PCR (Exiqon, Woburn, MA, USA) and ExiLENT SYBR 
Green master mix (Exiqon, Woburn, MA, USA) kits, respectively, in accordance with the 
manufacturer’s instructions. Candidate miRNA expression was normalized and examined 
between ALS patients and control subjects as previously described (Hawley et al., 2017b).  
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Table 2.1. Patient demographics. 
Cases Gender  Age of 
symptom 
onset 
Symptom 
onset 
Age of 
death 
Cause of Death 
Control  
F  - - 62 Heart Attack 
M  - - 74 Stroke 
F  - - 68 Unknown 
M  - - 68 Brain Tumor 
M  - - 75 Unknown  
F  - - 53 Pneumonia 
F  - - 74 Leukemia  
M  - - 67 Unknown  
ALS 
F  58 Unknown 60 Unknown 
M  69 
Upper/lower 
limbs 
72 Unknown 
F  40 Bulbar 41 Systemic Failure 
M  55 Unknown 61 Pneumonia 
M  64 
Upper/lower 
limbs 
67 
Respiratory 
Failure 
F  69 
Respiratory 
Symptoms 
71 
Respiratory 
Failure 
M  63 Unknown 64 Unknown 
F  47 Bulbar 49 
Respiratory 
Failure 
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Total RNA extraction from IMR-32 cells was done using TRIzol reagent (Life Technologies 
Inc., Ambion, Carlsbad, CA, USA) followed by cDNA synthesis using the SuperScript IV VILO 
reverse transcriptase according to the manufactures protocol (Invitrogen, Life Technologies Inc., 
Mississauga, ON, Canada). Changes to NEFL, PRPH, or INA mRNA levels were measured via 
real-time PCR using the TaqMan Fast Advanced Master Mix and TaqMan Gene Expression 
Assays (Applied Biosystems, Thermo Fisher Scientific). Intermediate filament expression levels 
were normalized to 18S, and then quantified using the 2-ΔΔCT method. 
2.3.4 Fluorescent In Situ Hybridization (FISH)  
 Neuropathologically intact human spinal cord was examined for candidate miRNA 
expression within motor neurons. Spinal cord tissue was formalin-fixed, paraffin embedded, and 
then cut into 7µm sections. Samples were UV treated overnight prior to experiment to reduce 
autofluorescent lipofuscin signaling. MiRNA FISH was performed as previously described (de 
Planell-Saguer et al., 2010).  MiRNA probes were double DIG tagged (Exiqon, Woburn, MA, 
USA), and were targeted using a DIG-HRP secondary antibody (1:100; Roche, Indianapolis, IN, 
USA) and Tyramide Signal Amplification tagged with a Cy3 fluorophore (PerkinElmer, 
Waltham, MA, USA). Spinal motor neurons were examined for positive expression of candidate 
miRNAs using the Olympus FV1000 confocal microscope.  
2.3.5 Cell Culture and Plasmid Construction 
 
HEK293T and IMR-32 cells were cultured in Dulbecco’s Modified Eagle’s Media 
(DMEM) and Eagle’s Minimum Essential Medium (EMEM), respectively, with 10% Fetal 
Bovine Serum (FBS) and incubated at 37oC with 5% CO2.  
NEFL, PRPH, and INA 3’UTRs identified in human spinal cord were individually cloned 
into the pmirGLO vector in between SalI and NheI restriction enzyme sites and downstream of 
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the firefly luciferase gene (Promega, Madison, WI, USA). Mutations made within the 3’UTRs 
were done as previously reported (Hawley et al., 2017b) using the Site-Directed Mutagenesis Kit 
II (Aligent Technologies Canada Inc., Missasauga, ON, Canada) in accordance with the 
manufacturer’s instructions. Cloned fragments and mutated sites were confirmed with Sanger 
sequencing.  
 
2.3.6 Luciferase Assay and Relative Quantitative RT-PCR  
 
 HEK293T cells were seeded 24 and 48 hours prior to transfection for luciferase and RT-
qPCR assays, respectively, as previously reported (Hawley et al., 2017b). PmirGLO vectors 
containing either the NEFL, PRPH, or INA 3’UTR were transfected into HEK293T cells either 
with or without miRNA mimics for luciferase and relative quantitative RT-PCR assays in 
accordance to what has been previously done (Campos-Melo et al., 2013; Hawley et al., 2017b) 
using the Lipofectamine 2000 protocol (Life Technologies Inc., Invitrogen, Burlington, ON, 
Canada). Luciferase activity was measured 24 hours post-transfection using the Dual-GLO 
Luciferase Assay System (Promega, Madison, WI, USA). For RT-PCRs firefly and renilla 
cDNAs were amplified and data was normalized in accordance to what has been previously 
described (Campos-Melo et al., 2013). Data for luciferase and RT-qPCR assays was quantified 
and plotted as relative difference of firefly expression from the control when in the presence of 
miR-105, miR-140-5p, miR-9, or let-7a (negative control) and is represented as mean ± SEM.   
 
2.3.7 Statistical Analysis 
  Student’s t-test was performed when comparing two conditions. One-way ANOVA 
followed by Tukey’s post-hoc was done when doing multiple comparisons between groups. Data 
was considered significant if p<0.05. 
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2.4 Results  
 
2.4.1 MiR-105 and miR-140-5p are downregulated in sALS and expressed in motor 
neurons.   
 
 Spinal cord obtained from neuropathologically intact subjects was used to identify NEFL, 
PRPH and INA 3’UTRs isoforms expressed within this tissue. We confirmed that already known 
3’UTRs of NEFL [1838 bases – GenBank NM_006158], PRPH [325 bases – GenBank 
NM_006262] and INA [1638 bases – GenBank NM_032727] were present in human spinal cord 
(data not shown).  
 Subsequently, using the miRanda prediction tool, 15 miRNAs were identified to have 
MREs within the NEFL, PRPH and INA 3’UTRs expressed in human spinal cord. However, we 
previously demonstrated that the expression of 6 of these miRNAs are not dysregulated in sALS 
(Campos-Melo et al., 2013). Thus, we focused on those 9 miRNAs that we previously reported 
to be dysregulated in sALS, or possessed MREs in the NEFL, PRPH or INA 3’UTR, but for 
which expression levels had not been characterized in sALS (Fig. 2.1). Of note, miR-9 has a 
non-canonical binding site within the PRPH 3’UTR (seed region is from +3 to +8, rather than +2 
to +7). Since miR-9 is predicted to regulate all intermediate filaments of interest, and several labs 
have shown its relationship to sALS (Campos-Melo et al., 2013; Campos-Melo et al., 2018; 
Emde et al., 2015; Haramati et al., 2010; Hawley et al., 2017a; Zhang et al., 2013), we decided 
miR-9 was critical to examine.    
 Our previous work has shown that miR-9 is expressed within motor neurons and 
significantly downregulated within the spinal cord of sALS patients (Campos-Melo et al., 2013; 
Campos-Melo et al., 2018), and others have shown this downregulation is specific to motor 
neurons (Emde et al., 2015). Thus, the remaining 8 miRNA candidates were further examined 
within the spinal cord tissue of sALS patients (n=8) and control subjects (n=5). Real-time PCR  
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Figure 2.1. MiRanda predicted 15 miRNAs to have MREs in NEFL, PRPH, and INA 
3’UTRs. A) Venn diagram showing 15 miRNAs that have MRE sites within the NEFL, PRPH 
and INA 3’UTRs according to miRanda software. However, we have shown previously that six 
miRNAs are not dysregulated in sALS (Campos-Melo et al., 2013). Thus, only those outlined in 
the black box were considered for further analysis. B) Schematic showing NEFL, PRPH and INA 
3’UTRs expressed in neuropathologically intact human spinal cord (n=3), and the location of the 
MREs of miRNA candidates within each 3’UTR.  
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confirmed our previous reports that miR-105 and miR-140-5p were significantly downregulated 
within the spinal cord tissue of sALS patients (Campos-Melo et al., 2013), while miR-185, miR-
1179, miR-1297, miR-3120, miR-4306 and miR-b4335 showed no significant change (Fig. 2.2).  
Since miR-105 and miR-140-5p were both downregulated in the spinal cord of sALS 
patients, we wanted to determine if these miRNAs were normally expressed within human motor 
neurons, as what has been seen with miR-9 (Campos-Melo et al., 2018; Emde et al., 2015). Both 
miR-105 and miR-140-5p are highly expressed within motor neurons (Fig. 2.3), suggesting that 
the observed downregulation of these two miRNAs is likely occurring in motor neurons. 
2.4.2 MiR-105 regulates a reporter linked to NEFL, PRPH and INA 3’UTRs. 
 
 NEFL, PRPH and INA 3’UTRs were individually linked to the firefly luciferase reporter 
gene to determine if candidate miRNAs altered the expression of the reporter gene. Both miR-
105 and miR-140-5p significantly increased luciferase activity when in the presence of the NEFL 
3’UTR strongly suggesting that miR-105 upregulates NEFL levels. Further, miR-105 
significantly increased or decreased luciferase activity when in the presence of either the PRPH 
or INA 3’UTRs, respectively, while miR-140-5p had no effect. Further, miR-9 significantly 
reduced luciferase activity when in the presence of either the NEFL, PRPH, or INA 3’UTR (Fig. 
2.4A). Let-7a was used as negative control and had no effect on luciferase activity when in the 
presence of any intermediate filament 3’UTR.  
Subsequently, we determined whether the changes observed in luciferase activity were 
due to changes at the mRNA level (Fig. 2.4B). Changes to luciferase mRNA levels when linked 
to either the NEFL, PRPH, or INA 3’UTR matched changes seen to luciferase activity when in 
the presence of miR-105. MiR-9 significantly reduced luciferase mRNA levels in the presence of 
either the NEFL or PRPH 3’UTR, but had no effect on the luciferase mRNA levels when in the 
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presence of the INA 3’UTR. MiR-140-5p had no effect on the mRNA levels of the luciferase 
gene when in the presence of either the NEFL, PRPH, or INA 3’UTR (Fig. 2.4B). Since miR-
140-5p had no effect on the mRNA levels when interacting with NEFL, PRPH or INA 3’UTRs, 
only miR-105 and miR-9 were further examined. 
 
2.4.3 MiR-105 directly interacts with the NEFL, PRPH and INA 3’UTRs to regulate 
reporter expression. 
 
 MREs of miR-105 and miR-9 were mutated at the +2 and +3 positions in the NEFL, 
PRPH and INA 3’UTRs to determine if these miRNAs needed to directly interact with the 
3’UTRs to regulate luciferase activity. Indeed, miR-105 had significantly reduced effects on 
increasing luciferase activity when the NEFL 3’UTR was lacking the miR-105 MRE; however, 
the effect was not completely abolished. This indicates miR-105 likely stabilizes NEFL by 
binding to the 3’UTR, but possibly also through an indirect mechanism by which miR-105 
regulates another target that stabilizes NEFL. Further, the PRPH 3’UTR lacking the miR-105 
MRE completely abolished the ability for miR-105 to upregulate luciferase activity (Fig. 2.5A). 
Interestingly, miR-105 has multiple MREs within the INA 3’UTR, and thus, we aimed to 
determine if miR-105 targeted a specific MRE to reduce luciferase activity. Indeed, mutations 
only in the MRE closest to the 5’end of the 3’UTR, or site 1 (S1), abolished the ability of miR-
105 to reduce luciferase activity. Mutations in the MREs closer to the 3’end, or sites 2 and 3 (S2 
and S3, respectively), had no effect on the ability of miR-105 to reduce luciferase activity, 
indicating the S1 MRE is critical for miR-105 function (Fig. 2.5A).   
MiR-9 has two MREs within the NEFL 3’UTR, but only one MRE in the PRPH and INA 
3’UTRs. Removal of the S1 MRE within the NEFL 3’UTR lead to a significant reversal in the 
reduction of luciferase activity via miR-9, but the effect was not completely abolished. It was   
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Figure 2.2. Differential expression of miRNA candidates within sALS spinal cord tissue. 
We examined the expression of candidate miRNAs in the spinal cord of sALS patients (n=8) 
compared to control subjects (n=5) using real-time PCR. MiR-105 and miR-140-5p are 
significantly downregulated in the spinal cord of sALS patients, while all other candidates 
showed no significant change in expression compared to the control population. Data was 
expressed miRNA fold-change (ALS/Control) ± SEM, and significance was determined using a 
Student’s t-test (* = p<0.05).  
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Figure 2.3. MiR-105 and miR-140-5p are expressed in human spinal motor neurons. FISH 
was used to examine the expression of both miR-105 and miR-140-5p within human ventral 
lumbar spinal cord. Both miRNAs showed strong expression within motor neurons of a control 
case (n=1). MiR-548c was used as a negative control. Motors neurons were identified based on 
size, as they are the only cells 50-70µm in size within the ventral spinal cord. Scale bar 
represents 10µm.  
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Figure 2.4. MiR-105 regulates luciferase activity and mRNA expression when it contains 
either the NEFL, PRPH, or INA 3’UTR.  HEK293T cells were transfected with the pmirGLO 
plasmid containing either the NEFL, PRPH, or INA 3’UTR, or cells were co-transfected with the 
pmirGLO plasmid containing the intermediate filament 3’UTRs and either miR-105, miR-140-
5p, or miR-9. A) Reporter gene assay showing changes in luciferase activity from control when 
either miR-105, miR-140-5p, or miR-9 interact with either the NEFL, PRPH or INA 3’UTR. B) 
Relative quantitative RT-qPCR showing changes in luciferase mRNA levels from control when 
either miR-105, miR-140-5p, or miR-9 interact with either the NEFL, PRPH or INA 3’UTR. 
Positive and negative values represent up- and downregulation, respectively. Let-7a was used as 
a negative control. Firefly luciferase expression was normalized to renilla luciferase expression, 
and then further normalized to account for the effect of the miRNA on the pmirGLO plasmid 
itself to determine the exact effect of the miRNA when it interacts with the respective 
intermediate filament 3’UTR. Data is represented as mean (n=3) ± SEM. Significance was 
determined using a Student’s t-test (*** = p<0.001; ** = p<0.01; * = p<0.05; NS = p>0.05).  
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only when the S2 MRE was removed that miR-9 no longer silenced luciferase activity (Fig. 
2.5B), indicating the S2 MRE within the NEFL 3’UTR is crucial for miR-9 mediated silencing. 
Mutations within the MRE of miR-9 in the PRPH 3’UTR lead to the eradication of the ability of 
miR-9 to reduce luciferase activity. However, elimination of the miR-9 MRE in the INA 3’UTR 
had no effect on its ability to reduce luciferase levels, indicating that miR-9 regulates INA 
expression through an indirect mechanism (Fig. 2.5B). Overall, these data indicate that miR-105 
directly binds to the 3’UTR of NEFL, PRPH and INA to regulate expression, while miR-9 only 
directly targets the NEFL and PRPH 3’UTRs.    
2.4.4 MiR-105 and miR-9 regulate the mRNA stability of endogenous NEFL, PRPH and 
INA. 
 The human neuron-derived cell line IMR-32, endogenously expresses NEFL, PRPH and 
INA, as well as miR-105 and miR-9 (Fig. 2.6). Therefore, we decided to determine whether miR-
105 and miR-9 regulated these intermediate filaments endogenously. Overexpression of miR-105 
lead to a significant increase in NEFL, while inhibition of miR-105 had a significant decrease on 
NEFL mRNA levels. Interestingly, overexpression of miR-105 was observed to have little effect 
on PRPH mRNA levels, yet its inhibition drastically reduced PRPH expression, which suggests 
that miR-105 is needed to stabilize the PRPH transcript. In contrast, miR-105 overexpression 
lead to a significant decrease, while miR-105 inhibition lead to a 2-fold increase (p = 0.08) in 
INA mRNA levels (Fig. 2.7A). This data indicates that miR-105 is a stabilizer of NEFL and 
PRPH, and a destabilizer of INA mRNA, consistent with what we observed in our luciferase 
assays.  
Further, overexpression of miR-9 within IMR-32 cells lead to a significant decrease in 
NEFL and PRPH mRNA levels which is consistent with alterations seen in the relative 
quantitative RT-PCR and the luciferase assay, while the inhibition of miR-9 lead to a significant 
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increase in NEFL and PRPH mRNA (Fig. 2.7B). As expected, based on our relative quantitative 
RT-PCR, overexpression of miR-9 had little effect on INA mRNA stability. However, inhibition 
of miR-9 within IMR-32 cells lead to a significant increase in INA mRNA. This could indicate 
that the indirect mechanism by which miR-9 suppresses INA expression, as suggested by our 
luciferase and site-directed mutagenesis assays, is lost upon inhibition of miR-9 (Fig. 2.7B).  
This data shows that both miR-105 and miR-9 regulate this network on intermediate filaments 
within a human neuronal-derived cell line, further emphasizing that alterations to these miRNAs 
is a major contributing factor to aberrant intermediate filament stoichiometry seen in sALS 
spinal cord.  
2.5 Discussion  
 
 In this study, we aimed to determine whether a specific pool of ALS-associated miRNAs 
contributes to changes in the mRNA metabolism of intermediate filaments that is observed in 
ALS spinal motor neurons. We identified two miRNAs—miR-105 and miR-9—to be central 
regulators of NFL, PRPH and INA, but only miR-105 binds directly to all intermediate filament 
3’UTRs. Further, we showed that miR-105 is highly expressed in motor neurons and has reduced 
levels within the spinal cord of sALS patients, suggesting that the regulation of these 
intermediate filaments in spinal motor neurons is disrupted in sALS via miR-105.  
Elucidating the mechanism that causes the selective reduction of NEFL, PRPH and INA 
has major significance in understanding ALS progression for several reasons. First, NFL is a 
necessary component of the neurofilament triplet protein structure, as NFM and NFH alone 
could not form a stable cytoskeleton (Szaro and Strong, 2010). Second, both INA and PRPH 
provide the early cytoskeleton for developing neurons, and thus, without the neurofilament triplet 
protein structure, INA and PRPH could potentially act as replacements for the neuronal 
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Figure 2.5. MiR-105 regulates firefly luciferase expression through direct interactions with 
the NEFL, PRPH, and INA 3’UTR.  HEK293T cells were co-transfected with either the 
pmirGLO plasmid containing the wild-type 3’UTR, or mutated form, and either with or without 
miR-105 or miR-9. A) Changes to luciferase activity from control when miR-105 either contains 
or lacks MREs within either the NEFL, PRPH, or INA 3’UTR. MiR-105 has three MREs within 
the INA 3’UTR, and thus each MRE was individually examined. B) Changes to luciferase 
activity from control when miR-9 either contains or lacks MREs within either the NEFL, PRPH, 
or INA 3’UTR. MiR-9 has two MREs within the NEFL 3’UTR, and thus each MRE was 
individually examined. Firefly luciferase expression was normalized to renilla luciferase 
expression, and then further normalized to account for the effect of the miRNA on the pmirGLO 
plasmid to determine the exact effect of the miRNA when it interacts with the respective 3’UTR. 
Data is represented as mean (n=3) ± SEM. Significance was determined using a one-way 
ANOVA followed by a Tukey’s post-hoc (*** = p<0.001; ** = p<0.01; * = p<0.05; NS = 
p>0.05).  
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Figure 2.6. Real-time PCR indicating expression of intermediate filaments and miRNAs of 
interest in IMR-32 cells. A) Expression of NEFL, PRPH and INA mRNA within IMR-32 cells. 
B) Expression of miR-105 and miR-9 in IMR-32 cells. Values represented as mean (n=3) CT ± 
SEM.  
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Figure 2.7. MiR-105 and miR-9 regulate the endogenous mRNA expression of NEFL, 
PRPH and INA. IMR-32 cells were transfected with either a miR-105 or miR-9, or let-7a 
(negative control) mimics, or inhibitors. Basal levels of intermediate filament mRNAs were 
measured in IMR-32 cells transfected with let-7a. Values above and below one represents either 
an increase or decrease in expression, respectively. Changes to the expression of intermediate 
filaments was measured using real-time PCR, and quantified using the 2-ΔΔCT method, where 
values were first normalized to 18S RNA levels prior to comparison. Data was represented as 
mean (n=5) ± SEM.  Significance was calculated using a one-way ANOVA followed by a 
Tukey’s post-hoc (*** = p<0.001; ** = p<0.01; * = p<0.05; NS = p>0.05). 
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cytoskeleton (Athlan and Mushynski, 1997; Kaplan et al., 1990; Yuan et al., 2006; Yuan et al., 
2012). In fact, there is an increase in INA and PRPH expression within injured neurons which 
allows for replacement of the cytoskeleton structure at the injured site (McGraw et al., 2002; 
Troy et al., 1990). However, since there is a selective reduction of NEFL, PRPH, and INA 
expression within spinal motor neurons of ALS patients (Wong et al., 2000), these motor 
neurons have no mechanism by which they can support and/or replace their cytoskeleton 
structure.  
 Reduction of miR-105 has generally been associated with tumor and cancer formation as 
it is responsible for regulating several tumor suppressor genes (Honeywell et al., 2013; Liu et al., 
2016; Lu et al., 2017; Zhang et al., 2017). However, this is the first time, to our knowledge, that 
miR-105 has been associated with the regulation of neuronal intermediate filaments. According 
to our results, reduced levels of miR-105 leads to decreased levels of NEFL and PRPH, and 
increased levels of INA mRNA. However, this does not match what is actually seen in sALS 
motor neurons, as all three intermediate filaments show decreased levels (Wong et al., 2000). 
Thus, while miR-105 appears to be a central regulator of ALS-linked intermediate filaments, the 
dysregulation of this miRNA in sALS is probably a contributing factor to the dysregulation of 
intermediate filaments, and not the sole cause.  
Beyond miR-105, we examined miR-9 given that it had previously been shown to be 
reduced in ALS spinal cord and motor neurons. We observed that miR-9 also was capable of  
reducing the expression of NEFL, PRPH and INA. Previous work has shown that miR-9 is a 
critical part of the intermediate filament pathway through the regulation of NEFH (Campos-Melo 
et al., 2018; Haramati et al., 2010). While Haramati et al. had also observed that miR-9 does not 
regulate mouse Nefl, it is noteworthy that miR-9 lacks MREs within the mouse Nefl 3’UTR. In 
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contrast, human NEFL 3’UTR has two sites for miR-9 binding. Further, our results suggest that 
loss of miR-9 expression in ALS would lead to an increase in all three of these intermediate 
filaments, which does not match what we have previously observed in sALS motor neurons 
(Wong et al., 2000). However, based on our data, loss of miR-9 expression would still alter the 
intermediate filament stoichiometry, which is the main factor that drives intermediate filament 
pathogenesis (Szaro and Strong, 2010). Overall, our findings indicate that miR-105 and miR-9 
are necessary components to maintain intermediate filament stoichiometry, and thus, loss of 
these miRNAs in sALS likely contribute to intermediate filament dysregulation.   
An intriguing finding in this study was the MRE site preference of miR-105 and miR-9 
within the INA and NEFL 3’UTRs, respectively. Despite having three MREs within the INA 
3’UTR, miR-105 only bound to one site (S1) to regulate mRNA stability, while miR-9 binds 
both MREs to reduce NEFL levels, with binding to the S2 MRE having a greater effect on NEFL 
downregulation than binding to the S1 MRE. It is a common phenomenon for a single miRNA to 
have multiple MREs within a transcript, where interactions with each MRE has either a 
synergistic or differential effect on transcript stability and translational output (Jangra et al., 
2010; Nasheri et al., 2011; Ott et al., 2011). For example, miR-122 has four MREs within the 
Hepatitis C Virus (HCV). When miR-122 binds to the S1 or S2 MRE it promotes viral 
translation (Jangra et al., 2010).  In contrast, interactions with the S4 MRE suppresses viral 
translation while binding to the S3 MRE has no effect on overall translational output of the virus 
(Henke et al., 2008; Nasheri et al., 2011). The exact reason why a miRNA binds to some MREs 
and not others or has differential effects on transcript stability at different MREs is unknown. 
Considering there are other trans-acting factors that regulate mRNA stability, how a miRNA 
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functions at a particular MRE is likely affected by the other trans-acting factors that are binding 
within that area.  
Further, while removing the miR-105 binding site from the NEFL 3’UTR reduced the 
stabilizing effect it had on the luciferase transcript, it did not completely abolish the effect. This 
could indicate that miR-105 regulates the expression of another target that is responsible for 
regulating NEFL stability. TDP-43 and RGNEF are two ALS-associated RNA-binding proteins 
known to regulate NEFL mRNA stability (Droppelmann et al., 2013; Volkening et al., 2009), 
and thus, it would be worth investigating whether the expression of these RNA-binding proteins 
are affected by changes to miR-105 levels.  
Both miR-9 and miR-105 downregulation in sALS likely contributes to the loss of 
intermediate filament stoichiometry, ultimately leading to intermediate filament aggregation and 
eventual neuronal death. MiRNAs are ideal therapeutic targets as they are known to regulate 
several genes within a network. For example, miR-506 and miR-146a are negative regulators of 
several genes involved in cancer metastasis and inflammation, respectively (Sun et al., 2015; Wu 
et al., 2015). Thus, rather than targeting individual genes that contribute to the disease, miRNAs 
offer an avenue in which we can target multiple genes involved in a disease process (Rupaimoole 
and Slack, 2017). Our data suggests that both miR-105 and miR-9 regulate a network of ALS-
associated neuronal intermediate filaments, and thus recovery of these miRNAs within sALS 
patients could slow disease progression by mitigating the alterations seen to intermediate 
filament stoichiometry. Further work within in vivo models is still needed to confirm this 
hypothesis.    
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3.1 Abstract  
 
Neurofilaments (NFs) are the most abundant cytoskeletal component of vertebrate 
myelinated axons. NFs function by determining axonal caliber, promoting axonal growth and 
forming a 3-dimensional lattice that supports the organization of cytoplasmic organelles. The 
stoichiometry of NF protein subunits (NFL, NFM and NFH) must be tightly controlled to 
avoid the formation of NF neuronal cytoplasmic inclusions (NCIs), axonal degeneration and 
neuronal death, all pathological hallmarks of amyotrophic lateral sclerosis (ALS). The post-
transcriptional control of NF transcripts is critical for regulating normal levels of NF proteins. 
Previously, we showed that miRNAs that are dysregulated in ALS spinal cord regulate the 
levels of NEFL mRNA. In order to complete the understanding of altered NF expression in 
ALS, in this study we have investigated the regulation of NEFM and NEFH mRNA levels by 
miRNAs. We observed that a small group of ALS-linked miRNAs that are expressed in 
human spinal motor neurons directly regulate NEFM and NEFH transcript levels in a manner 
that is associated with an increase in NFM and NFH protein levels in ALS spinal cord 
homogenates. In concert with previous observations demonstrating the suppression of NEFL 
mRNA steady state levels in ALS, these observations provide support for the hypothesis that 
the dysregulation of miRNAs in spinal motor neurons in ALS fundamentally alters the 
stoichiometry of NF expression, leading to the formation of pathological NCIs. 
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3.2 Introduction  
Neurofilaments (NFs) are unique neuron-specific intermediate filaments in 
vertebrates. They are highly dynamic structures that determine axonal caliber, promote 
axonal growth and organize the cytoplasm to form a stable 3-dimensional lattice that supports 
the organization of organelles and cytoplasmic proteins (Szaro and Strong, 2010; Walker et 
al., 2001).  
NF subunit proteins (low, medium and high molecular weight neurofilaments; NFL, 
NFM and NFH, respectively) form homo- and hetero-polymers following a specific 
stoichiometry and tight spatiotemporal regulation. Conserving NF stoichiometry by 
controlling the levels of expression of individual NF subunits is critical for the maintenance 
of healthy neurons. Alterations of NF mRNA steady stoichiometry and the associated 
formation of neuronal cytoplasmic inclusions (NCIs) composed of NF proteins are 
neuropathological markers of degenerating motor neurons in amyotrophic lateral sclerosis 
(ALS), a progressive neurodegenerative disease (Szaro and Strong, 2010; Thyagarajan et al., 
2007; Xiao et al., 2006). Although the exact mechanism by which NF NCIs exert toxicity is 
unknown, it has been suggested that they alter the internal structure of axons and disrupt 
axonal transport, in addition to impairing NMDA-mediated calcium influx, compromising the 
survival of neurons (Sanelli et al., 2004; Thyagarajan et al., 2007). 
Post-transcriptional control is crucial for preserving NF subunit expression in 
neuronal homeostasis and also during axonal outgrowth in development and regeneration 
(Ananthakrishnan et al., 2008; Ananthakrishnan and Szaro, 2009; Schwartz et al., 1994). 
MiRNAs are evolutionary conserved non-coding RNAs that control the expression of the 
majority of the mammalian transcriptome and have been increasingly linked to 
neurodegenerative disorders. We and others have described a profound dysregulation of 
miRNAs in spinal cord and motor cortex of ALS patients (Campos-Melo et al., 2013; Emde 
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et al., 2015; Figueroa-Romero et al., 2016; Wakabayashi et al., 2014). We previously 
demonstrated that a selective group of these miRNAs directly regulate NEFL mRNA stability 
(Campos-Melo et al., 2013), and postulated that this dysregulation of miRNA expression 
would contribute to the selective suppression of NEFL mRNA levels observed in ventral 
lateral spinal cord motor neurons in ALS (Bergeron et al., 1994; Wong et al., 2000). Proper 
control of the levels of the NF triplet is critical because the backbone of the NF is mainly 
formed by NFL (Leermakers and Zhulina, 2010) and the stoichiometry of NFL/NFM/NFH 
(4:2:1) has to be carefully maintained (Scott et al., 1985). The miRNAs responsible for 
regulating human NEFM and NEFH mRNA stability are however unknown. In this study we 
observed that a limited number of ALS-linked miRNAs that are expressed in spinal motor 
neurons directly regulate NEFM and NEFH mRNA levels, in a way that might explain the 
increase in NFM and NFH protein levels that we observed in ALS spinal cords and thus 
contribute directly to the formation of NF NCIs. 
3.3 Materials and Methods  
3.3.1 Tissue Collection  
Spinal cord samples from sALS patients and age-matched, neurologically intact 
control individuals were used. All ALS cases were both clinically and neuropathologically 
confirmed using the El Escorial Criteria (World Federation of Neurology Research Group on 
Neuromuscular Disease, 1994). Written consent for autopsy was obtained from the next of 
kin at the time of death or from the patient antemortem in accordance with the London Health 
Sciences Centre consent for autopsy. Cases were genotyped and confirmed to have no known 
mutations in SOD1, TARDBP, FUS or expanded repeats in C9ORF72 (Table 3.1). 
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Table 3.1. Patient demographics. 
Cases Gender  Age of 
symptom 
onset 
Symptom 
onset 
Age of 
death 
Cause of Death 
Control  
F  - - 62 Heart Attack 
M  - - 74 Stroke 
F  - - 68 Unknown 
M  - - 68 Brain Tumor 
M  - - 75 Unknown  
F  - - 53 Pneumonia 
F  - - 74 Leukemia  
M  - - 67 Unknown  
ALS 
F  58 Unknown 60 Unknown 
M  69 
Upper/lower 
limbs 
72 Unknown 
F  40 Bulbar 41 Systemic Failure 
M  55 Unknown 61 Pneumonia 
M  64 
Upper/lower 
limbs 
67 
Respiratory 
Failure 
F  69 
Respiratory 
Symptoms 
71 
Respiratory 
Failure 
M  63 Unknown 64 Unknown 
F  47 Bulbar 49 
Respiratory 
Failure 
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3.3.2 3’RACE PCR, cloning and miRNA target prediction  
NEFM and NEFH mRNA 3’UTRs were obtained using 3’RACE PCR. Briefly, 
TRIzol reagent (Thermo Fisher Scientific) was used for total RNA extraction from human 
spinal cord tissue. 3’RACE PCR was performed using SMARTer RACE 5’/3’ RACE Kit 
(Takara Bio. Inc., Clontech) and primers hNEFM_3RACE_F1D: 
5’CACTTCACACGCCATAGTAAAGGAAGTCACC3’ and hNEFH_3RACE_F2: 
5’GAGAAGGCCACAGAAGACAAGGCCGCCAAG3’ for NEFM and NEFH 3’UTRs, 
respectively. 3’UTR isoforms were cloned into pGEMT-Easy vector and sequenced. For 
luciferase assays, 3’UTRs were subcloned into pmirGLO vector between NheI and SalI sites 
and linked to the firefly luciferase coding region. Mutations in two nucleotides at the 3’end of 
each miRNA recognition element (MRE) within the NEFM and NEFH 3’UTRs were made 
using QuikChange Site-Directed Mutagenesis Kit II (Agilent) according to the 
manufacturer’s instructions. Mutations were carefully designed to ensure no changes were 
made in the secondary structures of the transcripts using the RNAFold WebServer 
(http://rna.tbi.univie.ac.at/cgi-bin/RNAfold.cgi). Both TargetScan 
(http://www.targetscan.org/) and miRanda 
(http://www.microrna.org/microrna/getGeneForm.do) software programs were used to 
determine miRNAs with predicted MREs in either NEFM or NEFH 3’UTRs.  
3.3.3 miRNA extraction and real-time PCR  
Total miRNA extraction using the mirVana miRNA isolation kit (Thermo Fisher 
Scientific) was performed from human ventral lumbar spinal cord using 5 controls and 8 ALS 
tissue samples according to the manufacturer’s instruction. Yield and purity of the miRNA 
solution was determined using spectrophotometry while RNA integrity was measured using a 
bioanalyzer instrument.   
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MiRNA extracts from the spinal cord of ALS patients or controls were reversed 
transcribed and then subjected to real-time PCR using the miRCURY LNATM Universal RT 
microRNA PCR (Exiqon) and ExiLENT SYBR Green master mix (Exiqon), according to the 
manufacturer’s instructions. PCRs were performed using the 7900 HT real-time PCR system. 
Relative expression of miRNAs was normalized to miR-16-5p, a miRNA previously 
demonstrated to have the same expression in sALS and controls (Campos-Melo et al., 2013). 
The analysis of the relative expression of candidate miRNAs between sALS and controls was 
done using the 2-ΔΔCT method. All experiments were run in triplicate and significance was 
determined using Student’s t-test. 
3.3.4 TaqMan real-time PCR 
To examine the expression levels of NEFM and NEFH mRNA, total RNA extraction 
was performed on ALS patient and control lumbar spinal cord tissue using TRIzol reagent 
(Ambion, Life Technologies). RNA samples were subjected to a cDNA synthesis reaction 
using the SuperScript IV VILO reverse transcriptase (Invitrogen, Thermo Fisher Scientific) in 
accordance to the manufacture’s instructions. Real-time PCR was done on the cDNA 
templates using the TaqMan Fast Advanced Master Mix and TaqMan Gene Expression 
Assays (Applied Biosystems, Thermo Fisher Scientific) targeting either NEFM or NEFH. 
Assays were performed in accordance to the manufacture’s instructions. TaqMan probes that 
targeted either NEFM or NEFH were designed with a FAM fluorophore. The expression of 
NEFM and NEFH was normalized to the expression of a reference gene (HPRT1), which was 
targeted by a TaqMan probe containing a VIC fluorophore. Changes in NEFM and NEFH 
mRNA expression between ALS patients and control subjects were determined using the 2-
ΔΔCT method. Experiments were run in triplicate and determined to be significantly different 
using a Student’s t-test. 
3.3.5 Fluorescent in situ hybridization (FISH)  
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To ensure that the miRNAs of interest are expressed in human motor neurons, 
neuropathologically normal lumbar spinal cord from control subjects was examined for 
miRNA expression. Tissue sections were formalin-fixed, paraffin embedded (FFPE) and cut 
into 7μm sections. Samples were UV treated overnight to reduce the lipofuscin-induced auto-
fluorescent signal. FISH was performed as described previously (Planell-Sauger et al 2010). 
LNA probes were designed with double DIG-labels that targeted the miRNA of interest 
(Exiqon). DIG-HRP secondary antibody, and Tyramide Signal Amplification (TSA) Systems 
tagged with a Cy3 fluorophore (PerkinElmer) were used to obtain a fluorescent signal of the 
miRNA target. Ventral horn of human lumbar spinal cord tissue was examined for positive 
staining within motor neurons using the Olympus FV1000 confocal microscope. 
3.3.6 Cell culture, luciferase assay and relative quantitative RT-PCR 
HEK293T cells were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) 
containing 10% fetal bovine serum (FBS), at 37oC with 5% CO2. HEK293T cells were plated 
on 96-well plates with a density of 10,000 cells/well 24 hours prior to transfection. 100 nM of 
miRNA mimics (Thermo Fisher Scientific) and 3.47 fmol of pmirGLO containing NEFM or 
NEFH 3’UTR were co-transfected into the cells using Lipofectamine 2000 reagent (Thermo 
Fisher Scientific).  
Luciferase assays and relative quantitative RT-PCR were performed 24 hours post-
transfection as was described previously (Campos-Melo et al., 2014). Data show positive 
values as upregulation and negative values as downregulation. All experiments were run in 
triplicate, and significance was determined using a Student’s t-test or one-way ANOVA 
followed by Turkey’s post hoc test.  
3.3.7 Western blot  
Total protein extraction from ventral lumbar spinal cord of 3 controls and 7 ALS 
patients was performed using NP40 lysis buffer containing proteinase inhibitors. Samples 
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were sonicated, resuspended in loading buffer, denatured at 90°C and run on an 8% SDS-gel. 
After transfer, the nitrocellulose membrane was probed with either mouse anti-NFM (1:1000; 
Boehringer Mannheim, 814-334), mouse anti-NFH (1:1000; Boehringer Mannheim, 814-
342), or rabbit anti-GAPDH (1:5000; Abcam, ab9485) and later with HRP-secondary 
antibody (goat anti-mouse 1:3000, or goat anti-rabbit 1:5000; BioRad and Invitrogen, 
respectively).  Relative protein expression of NFM and NFH were normalized to GAPDH 
expression levels. Student’s t-test was used to determine statistical differences in endogenous 
protein expression. 
3.4 Results 
 
3.4.1 Only one 3’UTR isoform of either NEFM are NEFH is expressed in human spinal 
cord 
 
Considering that 3’UTR polymorphisms have been increasingly reported in the 
literature, we determined if 3’UTR variants of NEFM and NEFH mRNAs are expressed in 
human spinal cord. A single variant form of NEFM and NEFH 3’UTRs (486 and 583 nt, 
respectively) was detected in lumbar spinal cord control tissue (Fig. 3.1). Analysis of ALS 
patients showed no difference in the 3’UTR variants of NEFM and NEFH expressed in spinal 
cord compared to control samples (data not shown). 
3.4.2 Several ALS-linked miRNAs have MREs within the NEFM and NEFH 3’UTRs 
Prediction algorithms showed that NEFM and NEFH 3’UTRs have multiple MREs for 
different pools of miRNAs. However, for this study we only considered those miRNAs that 
we previously observed to be differentially expressed in ALS tissue versus controls using the 
TaqMan assay (Campos-Melo et al., 2013). We performed real-time PCR using SYBR green 
of 40 miRNAs to validate differential expression of 6 miRNAs that have MREs in NEFM or 
NEFH 3’UTRs (Fig. 3.2A). Each miRNA, (miR-92a-3p, miR-125b-5p, miR-9-5p, miR-20b- 
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Figure 3.1. Single NEFM and NEFH mRNA 3’UTR variants are expressed in human 
spinal cord. 3’RACE-PCR was performed from spinal cord tissue samples of control 
individuals using specific primers to amplify NEFM and NEFH 3’UTRs. 3’UTRs were 
cloned and sequenced. One 3’UTR variant for each NEFM (486 nt) and NEFH (583 nt) 
transcript was observed in human spinal cord. NEFM specific primer anneals to a region 40 
nt upstream the stop codon.      
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5p and miR-223-3p and miR-519d-3p) showed significant downregulation of expression in 
ALS spinal cord versus controls (Fig. 3.2B).  
Next, we examined the neuronal expression of the group of miRNAs that potentially 
regulate NEFM and NEFH transcripts in human spinal cord motor neurons of control tissue 
through FISH. MiR-92a-3p is almost exclusively expressed in motor neurons of the spinal 
cord. MiR-125b-5p, miR-9-5p, miR-20b-5p and miR-519d-3p showed higher expression in 
motor neurons than in other cell types within the spinal cord. MiR-223-3p showed similar 
expression in motor neurons and surrounding cells. MiR-548c-3p was used as a negative 
control and miR-124-3p, which is highly expressed in neurons, was used as positive control. 
In summary, we observed that the 6 ALS-linked miRNAs that are predicted to regulate 
NEFM and NEFH mRNAs are expressed in motor neurons of human spinal cord (Fig. 3.3). 
3.4.3 MiRNA candidates interact with NEFM and NEFH 3’UTRs to regulate gene 
expression 
 
Functionality assays of these 6 miRNAs showed that miR-92a-3p and miR-125b-5p 
downregulate the levels of a luciferase reporter linked to NEFM 3’UTR (Fig. 3.4A). MiR-9-
5p, miR-20b-5p, miR-92a-3p and miR-223-3p downregulate the levels of the luciferase 
reporter coupled to NEFH 3’UTR (Fig. 3.4B). We observed that most of these miRNAs also 
significantly downregulate mRNA levels of the luciferase reporter bound to either NEFM or 
NEFH 3’UTR (Fig. 3.4C and D), which implies that miRNAs are dysregulating the stability 
of NEFM and NEFH transcripts. Reporter gene assay using NEFM or NEFH 3’UTR MRE 
mutants showed a decrease in the downregulatory effect of each miRNA compared with the 
wild type, indicating that miR-9-5p, miR-20b-5p, miR-92a-3p, miR-125b-5p and miR-223-3p 
directly regulate NEFM or NEFH 3’UTRs stability (Fig. 3.5).  
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3.4.4 NEFM and NEFH mRNA and protein are increased in ALS spinal cord 
Finally, considering the reduced expression of this group of 5 miRNAs in ALS spinal 
cords and the downregulatory function they showed on NEFM and NEFH, we should expect 
an increase of NEFM and NEFH transcript and protein levels in ALS spinal cord tissue 
compared to controls. Consistent with this, we observed an increase in both NEFM and 
NEFH transcript and protein levels in ALS ventral lumbar spinal cords (Fig. 3.6). 
3.5 Discussion 
In this study, we have shown that a small group of miRNAs that are dysregulated in 
the spinal cord of ALS patients directly regulate NEFM and NEFH mRNA stability and that 
this is associated with an increase in NFM and NFH protein levels in ALS spinal cord 
homogenates compared to neurological intact control spinal cord homogenates.  
The post-transcriptional control of NF transcripts is critical for establishing, 
consolidating and maintaining normal levels of NF proteins. The stoichiometry of NF 
subunits has to be tightly controlled to promote axonal outgrowth, control axon caliber and 
avoid the formation of NF aggregates, axonal degeneration and neuronal death (Julien, 1999; 
Thyagarajan et al., 2007). The regulation of NF transcripts expression occurs at multiple 
levels. It has been reported that splicing of the last intron of Xenopus NEFM increases 
nucleocytoplasmic export of the transcript which allows for robust gene expression (Wang 
and Szaro, 2016). Another level of regulation is at the mRNA transport. One study observed 
that the mRNAs of each NF subunit are present and translated within intact and regenerating 
rat sciatic nerve, demonstrating that NF transcripts are transported through axons (Sotelo-
Silveira et al., 2000). At the final stage of mRNA regulation, it has been shown that the RNA-
binding protein HuB increases the translation of NEFM transcript (Antic et al., 1999). 
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Figure 3.2. MiRNAs that have MREs in NEFM or NEFH 3’UTRs are downregulated in 
the spinal cord of ALS patients. (A) MREs within NEFM and NEFH 3’UTRs of ALS-
linked miRNAs. (B) Real-time PCR using SYBR green. Validation of differential expression 
in ALS versus control spinal cords of 6 miRNAs that have MREs in NEFM or NEFH mRNA 
3’UTRs is shown. Experiments were performed in triplicate. Values below 1 indicate 
downregulation. Results are shown as mean (n=3) ± SEM (Student t-test: **** p < 0.0001, 
*** p < 0.001, ** p < 0.01, * p < 0.05. MiR-9-5p, p = 0.0229; miR-20b-5p, p = 0.0230; miR-
92a-3p, p = 0.0234; miR-125b-5p, p = 0.0412; miR-223-3p, p = 0.0215 and miR-519d-3p, p 
= 0.0232). 
  
132 
 
 
  
133 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3. MiRNAs that have MREs within NEFM or NEFH 3’UTRs are expressed in 
motor neurons of human spinal cord control tissue. FISH was performed using FFPE 
control spinal cord tissue and LNATM-enhanced detection probes 5`-DIG and 3`-DIG labeled 
for miRNAs. Amplification was performed using anti-DIG-HRP and TSA Plus Cy3. MiR-
548c-3p, which is not expressed in human spinal cord, was used as negative control. MiR-
124-3p, which is known as highly expressed in neurons, was used as positive control. 
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Figure 3.4. A group of ALS-linked miRNAs regulate a luciferase reporter linked to 
NEFM or NEFH 3’UTRs. HEK293T cells were co-transfected with a reporter plasmid 
containing NEFM or NEFH 3’UTRs and miRNA mimics. (A, B) Reporter gene assays were 
performed 24 hours after transfection. Data are expressed as relative change and plotted in 
logarithmic scale. (C, D) Relative quantitative RT-PCRs were performed after RNA 
extraction, 24 hours post-transfection. Data are expressed as relative mRNA level change and 
plotted in logarithmic scale. All experiments were performed in triplicate. Results are shown 
as mean (n=3) ± SEM (Student t-test: **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 
0.05, relative to the pmirGLO vector control). Reporter gene assays: miR-92a-3p/NEFM, p < 
0.0001; miR-125b-5p/NEFM, p = 0.0005; miR-let-7a/NEFM, p = 0.6015; miR-9-5p/NEFH, 
miR-20b-5p/NEFH, miR-92a-3p/NEFH and miR-223-3p/NEFH, p < 0.0001; miR-519d-
3p/NEFH, p = 0.0723; miR-let-7a/NEFH, p = 0.0893. RT-PCRs:  miR-92a-3p/NEFM, p = 
0.0052; miR-125b-5p/NEFM, p = 0.0429; miR-9-5p/NEFH, p = 0.0431; miR-20b-5p/NEFH, 
p = 0.0518; miR-92a-3p/NEFH, p = 0.0003; miR-223-3p/NEFH, p < 0.001; miR-519d-
3p/NEFH, p = 0.0903). 
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Figure 3.5. MiRNAs directly regulate luciferase transcripts linked to NEFM or NEFH 
3’UTRs. HEK293T cells were co-transfected with a reporter plasmid containing mutant 
NEFM (A) or NEFH (B) 3’UTRs and miRNA mimics. Reporter gene assays were performed 
24h after transfection. Data are expressed as relative change and plotted in logarithmic scale. 
All experiments were performed in triplicate. Result are shown as mean (n=3) ± SEM (One-
way ANOVA followed by Tukey’s post hoc test: **** p <0.0001, *** p < 0.001, ** p < 0.01, 
* p < 0.05, relative to the pmirGLO vector control). MiR-92a-3p/NEFM, miR-125b-
5p/NEFM, miR-9-5p/NEFH, miR-20b-5p/NEFH, miR-92a-3p/NEFH and miR-223-
3p/NEFH, p < 0.0001). 
138 
 
  
A 
B 
C 
139 
 
 
 
 
 
 
 
 
 
Figure 3.6. NEFM and NEFH transcript and protein levels are increased in spinal cord 
of ALS patients. (A) Real-time PCR using TaqMan and (B) Western blots were performed 
using ventral lumbar spinal cord samples of 5 controls and 7 ALS patients. (C) Quantification 
by densitometry of Western blots in A. Protein levels were normalized to GAPDH. Data was 
expressed as the mean ± SEM (Student t-test: **** p < 0.0001, *** p < 0.001, ** p < 0.01, * 
p < 0.05. Real-time PCR: NEFM, p = 0.0027: NEFH, p = 0.0239. Western blot: NFM, p = 
0.0238; NFH, p = 0.4762).      
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mRNA stability is the regulatory process of NF transcripts most extensively studied in which 
multiple trans-acting factors participate. In mice, it has been shown that the RNA-binding 
protein p190RhoGEF stabilizes and that glycolytic isoenzymes aldolases A and C directly 
destabilize Nefl mRNA (Canete-Soler et al., 2005; Canete-Soler et al., 2001). Our previous 
studies have shown that the stability of NEFL is regulated by ALS-associated RNA-binding 
proteins. Mutant copper/zinc superoxide dismutase (mtSOD1) and Rho Guanine Nucleotide 
Exchange Factor (RGNEF; the human homologue of p190RhoGEF) mediate the 
destabilization and TAR DNA binding protein 43 kDa (TDP-43) the stabilization of NEFL 
mRNA (Droppelmann et al., 2013; Ge et al., 2005; Strong et al., 2007). In addition, fused in 
sarcoma/translocated in liposarcoma (FUS/TLS), another ALS-associated protein, has been 
shown to bind to murine Nefl, Nefm and Nefh transcripts (Lagier-Tourenne et al., 2012).  
The most prominent mechanism of RNA mediated gene silencing involves the 
interaction of miRNAs with their target mRNAs in which most, but not all, interactions 
between the miRNA and MREs leads to a degradation of the mRNA. Previously, we and 
others have observed a massive downregulation of miRNAs in ALS spinal cord (Campos-
Melo et al., 2014; Emde et al., 2015; Figueroa-Romero et al., 2016). We also showed that 
three miRNAs that are dysregulated in ALS, miR-146a*, miR-524-5p and miR-582-3p, 
regulate levels of NEFL mRNA (Campos-Melo et al., 2013). In this paper, we extended our 
study to miRNAs responsible for NEFM and NEFH post-transcriptional regulation. We 
created a list of miRNAs that are downregulated in ALS spinal cord and that also possess 
MREs within NEFM and NEFH 3’UTRs. From the published literature, we observed that two 
miRNAs of this group (miR-9 and miR-125b-5p) were confirmed to be reduced in ALS 
spinal cord (Emde et al., 2015; Figueroa-Romero et al., 2016). We established that a small 
group of ALS-linked miRNAs (miR-9-5p, miR-20b-5p, miR-92a-3p, miR-125b-5p and miR-
223-3p) directly downregulate human NEFM and NEFH mRNA levels, an effect that is 
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translated into a reduction of NFM and NFH protein levels within spinal cord homogenates. 
From this group of miRNAs that regulate NEFM and NEFH mRNA levels, only miR-9 has 
been reported to have a role in neuronal function. More specifically, by regulating several 
targets including OC1, FoxP1, MAP1B, and MCPIP1, miR-9 is critical for motor neuron 
development, function and survival (Hawley et al., 2017).  
As these group of miRNAs that regulate NEFM and NEFH are reduced in spinal cord 
of ALS tissue, we predicted that the net effect would be an increase of NFM and NFH protein 
levels in ALS-spinal cords. Several groups have shown that NFL, NFM and/or p-NFH levels 
are increased in biological fluids of ALS patients (Feneberg et al., 2018; Ganesalingam et al., 
2013; Haggmark et al., 2014; Rosengren et al., 1996; Xu et al., 2016), but there are no reports 
of NFs protein levels in spinal cord tissue. In this study we showed that both NFM and NFH 
levels are increased in ventral lumbar spinal cord of ALS patients compared to controls. This 
observation is in agreement with the increased in NEFM and NEFH transcripts in ALS 
ventral lumbar spinal cord homogenates that we observed here using real-time PCR and 
reported previously using RNase protection assay (Strong et al., 2004).  
A selective reduction of NEFL steady-state mRNA levels in spinal motor neurons of 
ALS patients has been well documented (Bergeron et al., 1994; Menzies et al., 2002; Wong 
et al., 2000) a finding that we have proposed is due to alterations in the expression of NEFL-
linked miRNAs (Campos-Melo et al., 2013). In concert with the observations of this study, 
we hypothesize that in ALS spinal cords the sustained dysregulation in time of the expression 
of groups of miRNAs that control NF levels fundamentally alters the expression of all three 
NF transcripts in a manner that induces an alteration in the stoichiometry of the individual NF 
proteins, favoring the formation of pathological NCIs.   
While this hypothesis supports the critical role of the alteration of miRNA expression 
in ALS, miRNAs alone are not the sole mediators of RNA stability. Indeed, understanding 
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the fundamental relationship between alterations in RNA-binding proteins and how this 
interacts with alterations in miRNAs expression will be critical to understanding the process 
of perturbed RNA-mediated gene silencing which appears to lie at the core of a majority of 
ALS cases.  
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4.1 Abstract 
Common pathological features of amyotrophic lateral sclerosis (ALS) include 
cytoplasmic aggregation of several RNA-binding proteins. Out of these RNA-binding proteins, 
TDP-43, FUS and RGNEF have been known to co-aggregate with one another within motor 
neurons of sporadic ALS (sALS) patients suggesting there may be a common regulatory network 
disrupted. MiRNAs have been a recent focus in ALS research, as they have been identified to be 
globally downregulated in the spinal cord of ALS patients. The objective of this study was to 
identify if there were miRNA(s) dysregulated in sALS that are responsible for regulating the 
TDP-43, FUS and RGNEF network. In this study, we identify miR-194 and miR-b2122 to be 
significantly downregulated in sALS patients, and were predicted to regulate TARDBP, FUS and 
RGNEF expression. Reporter gene assays and RT-qPCR revealed that miR-b2122 downregulates 
the reporter gene through direct interactions with either the TARDBP, FUS, or RGNEF 3’UTR, 
while miR-194 downregulates firefly expression when it contained either the TARDBP or FUS 
3’UTR. Further, we showed that miR-b2122 regulates endogenous expression of all three of 
these genes in a neuron-derived cell line. Also, an ALS-associated mutation in the FUS 3’UTR 
ablates the ability of miR-b2122 to regulate a reporter gene linked to the FUS 3’UTR, and sALS 
samples which showed a downregulation in miR-b2122 also showed an increase in FUS protein 
expression. Overall, we have identified a novel miRNA that is downregulated in sALS that 
appears to be a central regulator of disease-related RNA-binding proteins, and thus, its 
dysregulation likely contributes to TDP-43, FUS and RGNEF pathogenesis in sALS. 
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4.2 Introduction 
 
 Amyotrophic lateral sclerosis (ALS) is a progressive motor neurodegenerative disease 
resulting in paralysis and death within 2-5 years after diagnosis (Taylor et al., 2016; Zarei et al., 
2015). 5-10% of ALS cases are familial (fALS), while the remaining are sporadic (sALS) 
although ~10-12% of these latter cases also have a genetic basis (Al-Chalabi et al., 2017; Chen et 
al., 2013; Taylor et al., 2016). While our understanding of ALS pathogenesis has advanced 
significantly in recent years, this understanding, and in particular the relationship amongst the 
individual genetic defects and the associated formation of pathological intraneuronal inclusions 
which are a hallmark of the disease, remains in its early phases (Blokhuis et al., 2013; Keller et 
al., 2012; Xiao et al., 2006).  
Defects in mRNA metabolism have been suggested to be a major driver in the genesis of 
pathological inclusions in ALS (Cestra et al., 2017; Droppelmann et al., 2014; Freibaum et al., 
2010; Hideyama et al., 2012; Tsuiji et al., 2013).  Further, it has been shown that miRNAs, 
essential regulators of mRNA expression and protein synthesis, are globally downregulated 
within the spinal cord tissue of sALS patients (Campos-Melo et al., 2013; Figueroa-Romero et 
al., 2016). This downregulation of miRNA expression has been shown to be motor neuron 
specific (Emde et al., 2015), contributing to the concept that altered miRNA homeostasis is a 
major contributor to the pathogenesis of ALS (Hawley et al., 2017; Rinchetti et al., 2017). The 
finding of this global downregulation of miRNAs within sALS patients is intriguing, as TDP-43 
and FUS, two proteins often found to be dysregulated in sALS, are known to be essential 
components of miRNA biogenesis (Kawahara and Mieda-Sato, 2012; Morlando et al., 2012). 
Further, ALS mutations within the FUS 3’ untranslated region (UTR) have been shown to 
disrupt a negative feedback network between miR-141/200a and FUS, leading to an 
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accumulation of FUS within the cell (Dini Modigliani et al., 2014; Sabatelli et al., 2013). This 
suggests that there may be a disruption in the feedback networks between miRNAs and RNA-
binding proteins in ALS, including TDP-43 and FUS.  
Beyond TDP-43 and FUS, we have described RGNEF, another RNA-binding protein, 
that forms pathological aggregates within sALS spinal motor neurons and has mutations 
associated with ALS (Droppelmann et al., 2013a; Droppelmann et al., 2013b; Keller et al., 2012; 
Ma et al., 2014). Interestingly, we observed that TDP-43, FUS and RGNEF co-aggregate with 
each other within the motor neurons of sALS patients, suggesting a co-dysregulation of these 
three RNA-binding proteins (Keller et al., 2012). While miRNA biogenesis has been clearly 
shown to be affected in sALS, it is unclear the consequence of this mass downregulation, and 
how it may contribute to TDP-43, FUS and RGNEF pathogenesis.  
In the current study, we describe two miRNAs, miR-194 and miR-b2122, that are 
predicted to regulate TDP-43, FUS and RGNEF. The novel miR-b2122 is expressed in human 
spinal motor neurons, significantly downregulated in sALS patients, and regulates the expression 
of all three of these RNA-binding proteins. Further, an ALS-associated mutation within the FUS 
3’UTR located in the miRNA recognition element (MRE) of miR-b2122 disrupts its ability to 
suppress gene expression. Overall, our results suggest that the downregulation of miR-b2122 in 
sALS could result in altered levels of all three of these RNA-binding proteins, contributing to the 
pathological state of TDP-43, FUS and RGNEF observed within motor neurons of sALS 
patients.  
 
4.3 Materials and Methods  
 
4.3.1 Tissue samples 
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Spinal cord tissue was obtained from sALS patients and age-matched, neurologically 
intact individuals (Table 4.1). All ALS cases were both clinically and neuropathologically 
confirmed using the El Escorial Criteria (World Federation of Neurology Research Group on 
Neuromuscular Disease, 1994). All research was approved by “The University of Western 
Ontario Research Ethics Board for Health Sciences Research Involving Human Subjects 
(HSREB)”. Written consent for autopsy was obtained from the next of kin at the time of death or 
from the patient antemortem in accordance with the London Health Sciences Centre consent for 
autopsy. Cases were genotyped and confirmed to have no known mutations in SOD1, TARDBP, 
FUS, RGNEF or expanded repeats in C9orf72.  
 
4.3.2 3’ RACE  
 
 Total RNA extraction was performed on SH-SY5Y cells and spinal cord tissue from 
neurologically intact humans using TRIzol reagent (Life Technologies Inc., Ambion, Carlsbad, 
CA, USA). This was followed by cDNA synthesis and PCR with the SMARTer 5’/3’ RACE Kit 
(Takara Bio. Inc., Clontech, USA) to amplify the TARDBP, FUS and RGNEF 3’UTRs according 
to the manufactures instructions using the following forward primers: TARDBP 5’-TAG ACA 
GTG GGG TTG TGG TTG GTT GGT A-3’, FUS 5’- GCA GGG AGA GGC CGT ATT AAT 
TAG CCT-3’ and RGNEF 5’-GCC CCG AGG TAA TGG AAC TTA ATC G-3’. 3’UTRs were 
identified using a 1% agarose gel containing a SYBR Safe dye. 3’UTR bands were excised and 
extracted from the agarose gel, and then individually cloned into a pGEMT-easy vector 
according to manufactures instructions (Promega, Madison, WI, USA). All 3’UTRs were 
confirmed using Sanger sequencing.   
 
4.3.3 MiRNA selection  
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Table 4.1. Patient demographics. 
Cases Gender  Age of 
symptom 
onset 
Symptom 
onset 
Age of 
death 
Cause of Death 
Control  
F  - - 62 Heart Attack 
M  - - 74 Stroke 
F  - - 68 Unknown 
M  - - 68 Brain Tumor 
M  - - 75 Unknown  
F  - - 53 Pneumonia 
F  - - 74 Leukemia  
M  - - 67 Unknown  
ALS 
F  58 Unknown 60 Unknown 
M  69 
Upper/lower 
limbs 
72 Unknown 
F  40 Bulbar 41 Systemic Failure 
M  55 Unknown 61 Pneumonia 
M  64 
Upper/lower 
limbs 
67 
Respiratory 
Failure 
F  69 
Respiratory 
Symptoms 
71 
Respiratory 
Failure 
M  63 Unknown 64 Unknown 
F  47 Bulbar 49 
Respiratory 
Failure 
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MiRNAs predicted to target TARDBP, FUS and RGNEF 3’UTRs were selected using 
miRanda software. Further, the sequence of the miRNA had to be perfectly complementary to 
the miRNA recognition element (MRE) from +2 to +7. Novel miRNAs currently not found with 
the miRanda program were manually checked to see if their seed sequence had an MRE within 
the 3’UTR of TARDBP, FUS and RGNEF. We only considered those miRNAs for which we 
identified MREs within the 3’UTR isoforms of TARDBP, FUS and RGNEF in the spinal cord 
tissue.  
 
4.3.4 Real-time PCR 
 
Total miRNA extractions were performed on ventral lumbar spinal cord tissue using the 
mirVana miRNA extraction kit according to manufactures instructions (Life Technologies Inc., 
Ambion, Carlsbad, CA, USA). Yield and purity of the miRNA extracts were measured using 
spectrophotometry (Nanodrop, ThermoFisher Scientific, Burlington, ON, Canada), while 
integrity was measured using Bioanalyzer (Aligent Technologies Canada Inc., Missasauga, ON, 
Canada) analysis. MiRNA extracts were reversed transcribed and then subjected to real-time 
PCR using miRCURY LNATM Universal RT microRNA PCR (Exiqon, Woburn, MA, USA) and 
ExiLENT SYBR Green master mix (Exiqon, Woburn, MA, USA) kits, respectively, according to 
manufacturer’s instructions. To detect novel miRNAs, miRNAs extracts went under reverse 
transcription using the Taqman microRNA reverse transcriptase kit (Life Technologies Inc., 
Applied Biosystems, Forest City, CA, USA), and then were pre-amplified using the Taqman 
PreAmp Master Mix Kit (Life Technologies Inc., Applied Biosystems, Forest City, CA, USA) 
followed by real-time PCR with the TaqMan Universal PCR Master Mix (x2) no AmpErase 
UNG (Life Technologies Inc., Applied Biosystems, Roche, Branchburg, NJ, USA). The 7900 
HT Real Time PCR system was used to read PCR outputs. Relative expression of miRNAs was 
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normalized to an internal control (miR-16-5p), followed by comparison of the relative expression 
of candidate miRNAs between ALS cases and a control population using the 2-ΔΔCT method. 
Negative values show downregulation and positive values upregulation of the expression. 
Statistical significance was determined using Student’s t-test, and samples were considered 
significantly different if p<0.05. 
 
4.3.5 Fluorescent in situ hybridization (FISH) 
 
Neuropathologically normal human lumbar spinal cord tissue was formalin-fixed, 
paraffin-embedded and cut into 7µm sections. Samples were UV treated overnight prior to the 
experiment to reduce lipofuscin-induced autofluorescent signaling. FISH of miRNAs was 
performed as described before (de Planell-Saguer et al., 2010). Probes for miRNA detection were 
designed with double DIG labels (Exiqon, Woburn, MA, USA), and were targeted by a DIG-
HRP secondary antibody (1:100; Roche, Indianapolis, IN, USA) and Tyramide Signal 
Amplification tagged with a Cy3 fluorophore (PerkinElmer, Waltham, MA, USA). Olympus 
FV1000 confocal microscope was used to observe miRNA expression within spinal motor 
neurons. 
 
4.3.6 Cell culture and plasmid construction 
 
HEK293T and SH-SY5Y cells were cultured in Dulbecco’s Modified Eagle’s Media 
(DMEM) containing 10% Fetal Bovine Serum (FBS). Cells were incubated at 37oC with 5% 
CO2. 
3’UTR isoforms of RNA-binding proteins identified in the human spinal cord tissue were 
individually cloned into the pmirGLO vector in between SalI and NheI restriction enzyme sites 
and downstream from the firefly luciferase gene (Promega, Madison, WI, USA). Site-directed 
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mutagenesis assays were done by adding a two-nucleotide mutation within the +2 and +3 
positions of each miR-194 or miR-b2122 MRE using the Site-Directed Mutagenesis Kit II 
(Aligent Technologies Canada Inc., Missasauga, ON, Canada) according to the manufacturer’s 
instructions. Mutations were carefully designed to ensure no changes to mRNA secondary 
structure using RNAfold WebServer (http://rna.tbi.univie.ac.at/cgi-bin/RNAfold.cgi).    
 
4.3.7 Luciferase assay 
 
 HEK293T cells were seeded into 96 well plates (9,000 cells per well) 24 hours prior to 
transfection. Cells were co-transfected with 3.5 fmol of pmirGLO plasmid and 100 nM of 
miRNA mimics according to the Lipofectamine 2000 protocol (Life Technologies Inc., 
Invitrogen, Burlington, ON, Canada). Luciferase activity was measured 24 hours post-
transfection using the Dual-GLO Luciferase Assay System (Promega, Madison, WI, USA). 
Firefly activity was normalized to renilla activity. Experimental design and normalization of data 
was performed as previously described (Campos-Melo et al., 2014). Data was quantified as 
relative difference from the control and expressed as mean ± SEM. Statistical significance was 
determined by performing Student’s t-test, and was considered significantly different if p<0.05.  
 
4.3.8 Relative quantitative RT-PCR  
 
To determine the effects of miR-194 and miR-b2122 on the luciferase mRNA expression 
when it contained the 3’UTR of TARDBP, FUS or RGNEF, HEK293T cells were seeded into 24 
well plates (20,000 cells per well) 48 hours prior to transfection. Cells were co-transfected with 
20.6 fmol of pmirGLO plasmid and 100 nM of miRNA mimics according to the Lipofectamine 
2000 protocol (Life Technologies Inc., Invitrogen, Burlington, ON, Canada). 24 hours after 
transfection, total RNA extraction was performed using TRIzol reagent (Life Technologies Inc., 
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Ambion, Carlsbad, CA, USA) followed by first-strand cDNA synthesis (Life Technologies Inc., 
Invitrogen, Burlington, ON, Canada) and PCR amplification of firefly and renilla cDNA as 
previously described (Campos-Melo et al., 2013). Data was quantified as relative difference from 
the control and expressed as mean ± SEM. Statistical significance was determined by performing 
Student’s t-test and was considered significantly different if p<0.05.  
To identify whether miR-194 and miR-b2122 could regulate the endogenous mRNA 
expression of these three RNA-binding proteins within a neuronal-derived cell line, SH-SY5Y 
cells were seeded into 6-well plates (500,000 cells per well) 24 hours prior to the transfection. 
100 nM of miRNA mimics and anti-miRs were then either transfected individually or co-
transfected. 24 hours after transfection total RNA extraction was performed using TRIzol reagent 
(Life Technologies Inc., Ambion, Carlsbad, CA, USA) followed by cDNA synthesis (Life 
Technologies Inc., Invitrogen, Burlington, ON, Canada). Quantitative PCR (qPCR) to determine 
the relative change in endogenous mRNA expression of TARDBP, FUS and RGNEF was 
performed using following primers: TARDBP for: 5’-CAG GGT GGG TTT GGT AAC GT-3’ 
rev: 5’-AAA GCC CCC ATT AAA ACC AC-3’; FUS for: 5’-TCG GGA CCA AGG ATC ACG 
TC-3’ rev: 5’-ATC TGG TTT AGG GGC CTT ACA CTG-3’; RGNEF for: 5’-AGG AAC GCA 
ATA ACT GGA TGA GAC G-3’ rev: 5’-TTC CAC CTT CTC CCC TGC ATC AG-3’; 18S 
RNA for: 5’-AGT TGG TGG AGC GAT TTG TC-3’ rev: 5’-TTC CTC GTT CAT GGG GAA 
TA-3’. All expression profiles were normalized to 18S RNA levels prior to comparison. One-
way ANOVA followed by a Tukey’s post-hoc was used to determine statistical differences in 
endogenous mRNA expression, and samples were significantly different if p<0.05. 
 
4.3.9 Western blot analysis 
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SH-SY5Y cells were seeded into 6-well plates (500,000 cells per well) 24 hours prior to 
the experiment. 100 nM of miRNA mimics and inhibitors were then either transfected 
individually or co-transfected. 48 hours after transfection total protein extraction was performed 
using NP40 lysis buffer containing proteinase inhibitors (cOmplete, Roche, Indianapolis, IN, 
USA), followed by sonication. Samples were suspended in loading buffer and proteins were 
denatured at 90oC for 5 minutes. Samples ran on a 12% SDS-gel and transferred to a 
nitrocellulose membrane. To measure endogenous levels of TDP-43, FUS and RGNEF, the 
membrane was probed with either anti-TDP-43 (1:2500; Proteintech, 10782-2-AP), anti-FUS 
(1:3000; Proteintech, 11570-1-AP), or anti-RGNEF (1:1000; Abcam, ab157095) rabbit 
antibodies, respectively. Blots were then probed with an HRP-secondary antibody (goat anti-
rabbit; 1:5000; Life Technologies Inc., Invitrogen, Burlington, ON, Canada). Blots were stripped 
using stripping buffer (2% SDS, 62.5 mM Tris-HCl, 100 mM β-mercaptoethanol, pH 6.8) and re-
probed for GAPDH using anti-GAPDH rabbit antibody (1:2500; Abcam, ab9485). Relative 
protein expression of TDP-43, FUS and RGNEF were normalized to GAPDH expression levels. 
One-way ANOVA followed by a Tukey’s post-hoc was used to determine statistical differences 
in endogenous protein expression, and samples were significantly different if p<0.05. 
 
4.4 Results 
 
4.4.1 A small group of miRNAs contain MREs within the mRNA 3’UTR of TARDBP, FUS, 
and RGNEF. 
 
Spinal cord tissue from neurologically intact individuals was used to determine the 
3’UTR isoform(s) of TARDBP, FUS and RGNEF being expressed. TARDBP consistently 
showed one 3’UTR isoform across all human samples with a length of 1398bp (BC095435.1) 
(Fig. 4.1A) (Ayala et al., 2011). Subject two appeared to have a higher band, but we were unable 
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to confirm a longer 3’UTR through sequencing, and for that reason, we focused only on the 
transcript that was consistently expressed across all samples. 
FUS contained one 3’UTR isoform within three different control cases, which was 150bp 
in length (Fig. 4.1A) (NM_004960). While RGNEF appeared to have three 3’UTR isoforms in 
each control case, we were only able to confirm the top and bottom bands through sequencing. 
The two RGNEF 3’UTR isoforms that were confirmed had a length of 177bp and 981bp, which 
we termed RGNEF-short and RGNEF-long, respectively (Fig. 4.1A).  Both short and long 
3’UTRs of RGNEF have been previously described (NM_001244364.1 and NM_0010804079.2, 
respectively).  
Subsequently, we identified 5 miRNAs which had MREs within the 3’UTR of all three of 
these RNA-binding proteins. However, our previous work has indicated that miR-548d-3p was 
not dysregulated in sALS cases, and thus was eliminated from further analysis. We also 
previously observed that miR-194 is downregulated in sALS patients (Campos-Melo et al., 
2013), while miR-b2122, miR-sb659 and miR-548x have not been analyzed for dysregulation 
within sALS patients (Fig. 4.1B and C). The latter four miRNAs were thus of interest for further 
analysis.  
 
4.4.2 MiR-194 and miR-b2122 are downregulated in the spinal cord tissue of sALS 
patients.  
 
We characterized the relative expression of miR-194, miR-548x, miR-sb659 and miR-
b2122 within the spinal cord tissue of sALS patients compared to control subjects. Using real-
time PCR, we observed that miR-194 and miR-b2122 were significantly downregulated in sALS 
patients (Fig. 4.2). The downregulation of miR-194 is consistent with what we reported 
previously using TaqMan Array (Campos-Melo et al., 2013). Using FISH, we confirmed that  
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both miR-194 and miR-b2122 were strongly expressed within human spinal motor neurons of 
control samples with little to no non-motor neuronal expression, suggesting that the 
downregulation of these two miRNAs is likely motor neuron specific (Fig. 4.3).   
 
4.4.3 MiR-b2122 regulates a reporter linked to either TARDBP, FUS, or RGNEF 3’UTR. 
 
 A reporter gene assay was used to examine the effect of miR-194 and miR-b2122 on the 
regulation of firefly luciferase protein when it contained the 3’UTR of either TARDBP, FUS, or 
RGNEF that we identified within the human spinal cord. MiR-b2122 significantly reduced firefly 
protein activity when it contained either the TARDBP, FUS, RGNEF-short, or RGNEF-long 
3’UTR, whereas miR-194 downregulated firefly protein activity only when it contained either 
the TARDBP or FUS 3’UTR, and had no effect when it contained the RGNEF-long 3’UTR (Fig. 
4.4A). MiR-194 did not contain an MRE within the RGNEF-short 3’UTR and thus the 
interaction between these two components was not examined. Further, to determine if miR-194 
and miR-b2122 could also alter luciferase mRNA levels, we performed RT-PCR analysis. The 
results in the RT-PCR analysis matched the downregulation seen by these two mRNAs in the 
luciferase reporter gene assay, indicating that the effect of these miRNAs involves regulation of 
the levels of mRNA species (Fig. 4.4B).  
 To study if miR-194 and miR-b2122 were regulating firefly luciferase by directly 
interacting with the 3’UTR, we mutated two nucleotides within the MRE sites of miR-194 and 
miR-b2122. Mutating the miR-b2122 MRE sites within either the TARDBP, FUS, RGNEF-short, 
or RGNEF-long 3’UTR significantly abolished the ability of miR-b2122 to reduce firefly 
luciferase activity. Similarly, mutating the miR-194 MRE sites within either TARDBP or FUS 
ablated miR-194 downregulation of luciferase activity (Fig. 4.5). These findings indicate that 
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Figure 4.1. A small group of miRNAs have MREs within the 3’UTRs of TARDBP, FUS, 
and RGNEF. (A) 3’RACE PCR identified the 3’UTRs of TARDBP, FUS and RGNEF that are 
expressed in the human spinal cord tissue within three different control samples. One isoform of 
both TARDBP and FUS were identified with a length of 1,398 and 150 bases, respectively. Two 
isoforms of RGNEF, which we have termed RGNEF-short (RGNEF-S) and RGNEF-long 
(RGNEF-L) 3’UTRs, were identified in all three subjects running at 177 and 981 bases, 
respectively. Bands in figures appear higher than actual 3’UTR size, as primers were designed 
upstream from stop codon. (B) Five miRNAs were identified to have binding sites within the 
TARDBP, FUS and RGNEF mRNA 3’UTRs. MiR-548d-3p in previous work has shown to have 
no dysregulation in sALS, and thus, four miRNAs (outlined in the black box) went under further 
study. (C) Schematic of all TARDBP, FUS and RGNEF 3’UTRs identified within human spinal 
cord, and location of MREs for miRNA candidates. 
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Figure 4.2. Differential expression of candidate miRNAs within the spinal cord of sALS 
patients. Candidate miRNA expression was examined in ventral spinal cord tissue of sALS 
patients (n=8) and control subjects (n=5). MiR-194 and miR-b2122 were significantly 
downregulated in sALS patients, while miR-sb659 showed no difference and miR-548x was not 
expressed in the spinal cord tissue. Data was expressed as log10 (fold-change) ± SEM, and 
significance was determined using Students t-test (**=p<0.01, *p<0.05, NS=p>0.05).  
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Figure 4.3. MiR-194 and miR-b2122 are expressed in human spinal motor neurons. Ventral 
lumbar human spinal cord of control tissue (n=1) was analyzed using FISH to determine the 
expression of miR-194 and miR-b2122 within motor neurons. Both miRNAs showed strong 
positive staining within motor neurons. MiR-124 and miR-548c were used as positive and 
negative controls, respectively. Scale bar represents 10µm.   
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Figure 4.4. MiR-b2122 reduces firefly luciferase activity when it contains either the 
TARDBP, FUS or RGNEF 3’UTR. HEK293T cells were transfected with a pmirGLO plasmid 
containing the 3’UTR of one of the RNA-binding proteins of interest either with or without miR-
194 or miR-b2122. PmirGLO plasmid without any 3’UTRs were also transfected with or without 
miRNAs of interest to determine the miRNAs effect on the plasmid itself. (A) Reporter gene 
assay revealed miR-b2122 reduced firefly activity when it contained either the TARDBP, FUS, 
or RGNEF-short/long 3’UTR, whereas miR-194 downregulated firefly levels when it contained 
either TARDBP, FUS, but not RGNEF-long. MiR-194 has no MRE in RGNEF-short, and thus, 
the interaction between the two was not examined. (B) RT-qPCR results showed similar 
suppression of mRNA levels as observed in the reporter gene assay. Let-7a was used as a 
negative control for these experiments. Firefly was normalized to renilla luciferase, and then 
further normalized to account for the effect of each miRNA on the pmirGLO vector to determine 
the exact effect that each miRNA has on each 3’UTR. Each miRNA was compared to its own 
individual control based on the normalization of the data. Data is expressed as sample mean 
(n=3) ± SEM, and significance was determined using a Student’s t-test (***=p<0.001, 
**=p<0.01, *=p<0.05, NS=p>0.05). 
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Figure 4.5. MiR-b2122 and miR-194 directly interact with their 3’UTR targets.  HEK293T 
cells were co-transfected with either the pmirGLO plasmid containing the wild-type 3’UTR, or 
the 3’UTR mutant, and either with or without the miRNA of interest. Mutations within the MRE 
of miR-b2122 in the TARDBP, FUS, and RGNEF 3’UTRs, and the MRE of miR-194 in the 
TARDBP and FUS 3’UTRs abolished each miRNAs ability to reduce firefly activity. Firefly was 
normalized to renilla, and then further normalized to the effect of each miRNA on the pmirGLO 
vector to determine the miRNAs exact effect on the 3’UTR. Data is expressed as sample mean 
(n=3) ± SEM, and significance was determined using a student’s t-test (***=p<0.001, 
**=p<0.01, *=p<0.05).   
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both miR-194 and miR-b2122 directly interact with their 3’UTR targets to regulate gene 
expression.  
 
4.4.4 MiR-b2122 regulates endogenous TDP-43, FUS and RGNEF within a human 
neuronal cell line. 
 
 Next, we decided to determine if miR-b2122 and miR-194 regulate the endogenous 
mRNA expression of TARDBP, FUS and RGNEF within a human neuronal-derived cell line – 
SH-SY5Y cells. SH-SY5Y cells express the TARDBP, FUS and RGNEF 3’UTR isoforms we 
identified with in the spinal cord. SH-SY5Y cells showed multiple bands in the TARDBP lane, 
but we were not able to confirm the top two bands through sequencing, only the 1398 b 3’UTR 
isoform identified in spinal cord, which also appears to be dominantly expressed in SH-SY5Y 
cells (Fig. 4.6A).  Also, endogenous expression of miR-b2122 and miR-194 in SH-SY5Y cells 
was confirmed through real-time PCR (Fig. 4.6B).   
Transfection of miR-b2122 lead to a significant downregulation in TARBDP, FUS and 
RGNEF mRNA levels. Further, co-transfection of miR-b2122 with its anti-miR abrogates the 
downregulation of these transcripts via miR-b2122. Transfection of the anti-miR of miR-b2122 
alone lead to an upregulation in mRNA levels of all three genes (Fig. 4.7A). The upregulation 
observed with the addition of the anti-miR, suggests that miR-b2122 does regulate these RNA-
binding proteins endogenously within this neuronal cell line. Let-7a was used as negative 
control, as we showed it has no effect on the endogenous mRNA levels of these three genes (Fig. 
4.8).  
 Further, we also transfected miR-194 and/or its anti-miR into SH-SY5Y cells. Similar to 
the reporter gene assays, miR-194 only reduced TARDBP and FUS endogenous mRNA levels 
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with no effect on RGNEF mRNA levels, which was abolished when co-transfecting miR-194 
with its anti-miR (Fig. 4.7B). Also, only adding the anti-miR of miR-194 caused a strong trend 
towards upregulation of TARDBP mRNA expression, but no change in the FUS transcript levels, 
suggesting miR-194 might play a role in regulating TARDBP gene expression within SH-SY5Y 
cells. Overall, these results suggest that miR-b2122 is the central regulator of TARDBP, FUS and 
RGNEF mRNA expression. 
 To determine whether the alteration in mRNA levels was associated with alterations in 
protein expression, we examined protein levels of TDP-43, FUS and RGNEF post-transfection of 
miR-b2122 (Fig. 4.9A). MiR-b2122 alone had no significant effect on the protein levels of TDP-
43 within the cell, but when the anti-miR alone was added, there was a strong trend towards 
upregulation of TDP-43. This upregulation was significantly different from when miR-b2122 
was transfected alone, suggesting that endogenous miR-b2122 is likely participating keeping 
TDP-43 protein at steady-state levels, but loss of this miRNA leads to an increase in TDP-43 
protein output (Fig. 4.9B). Transfection of miR-b2122 alone showed a strong trend towards the 
downregulation in FUS protein levels, which was abrogated when the anti-miR was co-
transfected with miR-b2122. The transfection of the anti-miR of miR-b2122 alone did lead to a 
significant upregulation of FUS protein levels, indicating miR-b2122 regulates protein synthesis 
of FUS endogenously (Fig. 4.9B). 
Interestingly, miR-b2122 had the reverse effect on the protein levels of RGNEF as 
compared to the changes observed at the mRNA level (Fig. 4.9B). Transfection of miR-b2122 
alone lead to increased RGNEF protein levels, which was reduced to the control levels when   
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Figure 4.6. 3’UTR isoforms of RNA-binding proteins, and miR-194 and miR-b2122 are 
expressed in SH-SY5Y cells. (A) 3’RACE PCR showing TARDBP, FUS and RGNEF 3’UTR 
isoforms expressed in SH-SY5Y cells. FUS and RGNEF isoforms match those expressed in 
human spinal cord. TARDBP showed multiple isoforms, but only the 1398bp isoform identified 
in spinal cord could be confirmed by sequencing. (B) Real-time PCR indicating the expression of 
miR-194 and miR-b2122 in SH-SY5Y cells (n=3).   
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Figure 4.7. MiR-b2122 regulates mRNA expression of TARDBP, FUS and RGNEF in a 
human-derived neuronal cell line. SH-SY5Y cells were transfected individually with miR-194 
or miR-b2122, or co-transfected with miR-194 or miR-b2122, and their anti-miRs. Transfection 
of let-7a was used as a negative control. (A) Transfection of miR-b2122 significantly 
downregulates the mRNA levels of TARDBP, FUS and RGNEF, while co-transfection of miR-
b2122 with its anti-miR led to a recovery in the mRNA levels. Transfection of the anti-miR 
alone led to increased mRNA expression of all three RNA-binding proteins (B) Transfection of 
miR-194 alone resulted in reduction of TARDBP and FUS, which was abolished when it was co-
transfected with its anti-miR. No effect was observed on RGNEF when miR-194 and/or its anti-
miR were transfected. Data was expressed as the mean (n=3) ± SEM, and significance was 
determined using a one-way ANOVA followed by a Tukey’s post-hoc. 
(***=p<0.001, **=p<0.01 *=p<0.05).     
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Figure 4.8. Let-7a has no effect on mRNA levels of TARDBP, FUS, or RGNEF within SH-
SY5Y cells. Let-7a was transfected into SH-SY5Y cells to determine if it changed the basal 
mRNA levels of TARDBP, FUS or RGNEF, and was compared to a non-transfected control. The 
data indicated no significant change in the transcript levels of either TARDBP (p=0.64), FUS 
(p=0.51), or RGNEF (p=0.74) between the two conditions. Data is expressed as sample mean 
(n=3) ± SEM, and significance was determined using a Student’s t-test.  
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Figure 4.9. MiR-b2122 alters protein levels of TDP-43, FUS and RGNEF within a human-
derived neuronal cell line. Changes in protein levels of TDP-43, FUS and RGNEF were studied 
when SH-SY5Y cells were transfected with either miR-b2122, miR-b2122 plus its anti-miR, or 
the anti-miR alone. Transfection of let-7a was used as a negative control. (A) Western blot 
showing expression of TDP-43, FUS, RGNEF, and GAPDH (B) Quantification of Western blots 
for TDP-43, FUS and RGNEF protein levels. TDP-43 and FUS show small reductions in protein 
levels when transfected with miR-b2122 alone, while their protein levels increased when the 
anti-miR is added. Differences in protein levels when miR-b2122 or the anti-miR are added 
alone are significantly different for both TDP-43 and FUS. RGNEF has increased and decreased 
protein levels when either miR-b2122 or its anti-miR are added alone, respectively, and these 
differences are significantly different from one another. Protein levels were normalized to 
GAPDH. Data was expressed as the mean (n=3) ± SEM, and significance was determined using 
a one-way ANOVA followed by a Tukey’s post-hoc (**=p<0.01, *=p<0.05).      
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miR-b2122 was co-transfected with its anti-miR. Transfection of the anti-miR alone led to 
reduced levels of RGNEF compared with let-7a. While these results were not significantly 
different from the negative control, there was a significant difference in RGNEF protein levels 
between when either miR-b2122 or the anti-miR were transfected alone. All data was compared 
to let-7a (negative control), as we showed it, has no effect on the protein levels of these three 
genes (Fig. 4.10). Overall, these results indicate that miR-b2122 can regulate FUS protein 
expression, while having minor changes on TDP-43 and RGNEF protein levels. 
4.4.5 An ALS-associated mutation in FUS 3’UTR is located in miR-b2122 MRE. 
Previously, mutations within the FUS 3’UTR were found within ALS patients, all of 
which lead to the overexpression and increased cytoplasmic mislocalization of FUS protein 
(Sabatelli et al., 2013). Interestingly, one of these mutations (*c.108C>T) is located in the +2 
position of the MRE for miR-b2122 (Fig. 4.11A), suggesting this would critically affect the 
ability of miR-b2122 to bind and reduce FUS expression. We sought to investigate whether this 
mutation would affect the ability to regulate firefly expression when the firefly gene was linked 
to the FUS 3’UTR that contained the *c.108C>T mutation. Indeed, this mutation significantly 
abolished the ability for miR-b2122 to reduce the firefly expression, compared to when the 
firefly gene contained the wild-type FUS 3’UTR (Fig. 4.11B). This result implies that FUS 
would be overexpressed without proper regulation of miR-b2122 via direct interaction with the 
3’UTR. 
Based on the previous result, we decided to examine if sALS cases that showed a 
downregulation in miR-b2122 would have an increase in FUS expression. In sALS cases that 
showed a downregulation of miR-b2122 there was a 3-fold increase in FUS protein expression 
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(Fig. 4.11C and D), suggesting a relationship between reduced levels of miR-b2122 and increase 
FUS expression. 
4.5 Discussion  
 In this study, we identified miR-b2122 to be a central regulator of ALS-linked RNA-
binding proteins TDP-43, FUS and RGNEF. We showed that miR-b2122 was significantly 
downregulated within the spinal cord tissue of sALS patients, and specifically expressed within 
motor neurons. MiR-194, which was also found be downregulated in sALS patients, regulates 
the mRNA expression of TARDBP and FUS, but not RGNEF. Together, our data introduces a 
novel miRNA (miR-b2122) to sALS pathology and indicates that the downregulation of this 
miRNA in sALS could affect a regulatory network of RNA-binding proteins within motor 
neurons, contributing to the disease pathology.  
The 3’UTRs for TARDBP, FUS, and RGNEF identified in spinal cord match those that 
have been previously described; however, for TARDBP we were only able to describe one 
3’UTR isoform, while previous authors have described multiple. The TARDBP 3’UTR isoform 
we described matches the pA1 transcript isoform (Ayala et al., 2011). Whether this is the only 
isoform expressed in spinal cord, or a limitation of our technique, the pA1 isoform is known to 
be the dominant transcript expressed in steady-state conditions, and has been shown to be the 
main isoform for TDP-43 protein synthesis (Avendano-Vazquez et al., 2012; Bembich et al., 
2014; Koyama et al., 2016). Further, it has been hypothesized that the pA1 isoform is the one 
overexpressed in ALS (Koyama et al., 2016), providing another reason why we decided to focus 
on the pA1 isoform and its interactions with miR-194 and miR-b2122.  MiR-194 is a well-known 
tumor suppressor, and reduced levels of miR-194 has been linked to both cancer and diabetes 
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Figure 4.10. Let-7a has no effect on protein levels of TDP-43, FUS, or RGNEF within SH-
SY5Y cells. Let-7a was transfected into SH-SY5Y cells to determine if it changed the basal 
protein levels of TDP-43, FUS or RGNEF, and was compared to a non-transfected control. The 
data indicated no significant change in the protein levels of either TDP-43 (p=0.71), FUS 
(p=0.28), or RGNEF (p=0.87) between the two conditions. Data is expressed as sample mean 
(n=3) ± SEM, and significance was determined using a Student’s t-test.  
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Figure 4.11. ALS-associated mutation within FUS 3’UTR inhibits the ability for miR-b2122 
to reduce firefly activity. HEK293T cells were co-transfected with either the pmirGLO plasmid 
containing the wild-type FUS 3’UTR, or the mutated form, and either with or without miR-
b2122. (A) ALS-associated mutation (*c.108 C>T) affects the +2 binding site of the miR-b2122 
MRE. (B) ALS-associated mutation within the FUS 3’UTR inhibits miR-b2122 from reducing 
firefly activity. Firefly expression was normalized to renilla expression, and then further 
normalized to account for the effect miR-b2122 on the pmirGLO vector itself to determine the 
miRNAs exact effect on the 3’UTR (n=3). (C) Western blot of FUS protein expression in the 
spinal cord of 7 sALS cases versus 5 control subjects. (D) Quantification of western blot. Data is 
expressed as sample mean ± SEM, and significance was determined using a Student’s t-test 
(**=p<0.01; *=p<0.05).  
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(Bao et al., 2015; Dong et al., 2011; Latouche et al., 2016; Song et al., 2012; Zhang et al., 2016; 
Zhou et al., 2016). Interestingly, the dysfunctional pathways identified within both of these 
diseases relate to those described in ALS (Bao et al., 2015; Latouche et al., 2016). For example, 
miR-194 expression has been shown to be switched off by NF-kB - a proinflammatory 
transcription factor that has been associated with ALS progression via increase activation in 
astrocytes and microglia (Bao et al., 2015; Frakes et al., 2014; Swarup et al., 2011). Further, 
overexpression of TDP-43 has been related to an increase in NF-kB activation (Swarup et al., 
2011). In this study, reduction of miR-194 leads to increased levels of TARDBP mRNA, and 
thus, through its regulation of TDP-43, miR-194 may be part of an inflammatory regulatory 
network that contributes to ALS progression.   
Since miR-b2122 was a novel miRNA identified by our group previously [Ishtiaq et al., 
2014], this is the first pathway in which this miRNA has been implicated. Our data would 
suggest that the downregulation of miR-b2122 would lead to a significant increase in TARDBP, 
FUS and RGNEF mRNA levels in sALS patients. This is consistent with the increase of 
TARDBP mRNA and protein levels observed in sALS patients (Swarup et al., 2011). Further, 
rodent models overexpressing wild-type human FUS and TDP-43 do develop age-related motor 
deficiencies and cytoplasmic protein aggregation in motor neurons similar to that seen in ALS 
cases (Janssens et al., 2013; Mitchell et al., 2013; Wils et al., 2010; Xu et al., 2010). However, 
the latter models look at the overexpression of a single gene, when it is the dysregulation of both 
expression and localization of multiple RNA-binding proteins which contributes to the disease 
progression. This makes miR-b2122 an intriguing miRNA, as its downregulation in sALS would 
contribute to the overexpression and dysregulation of multiple RNA-binding proteins involved in 
the pathogenesis of ALS.  
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 While TDP-43, FUS and RGNEF protein levels showed discrete changes when compared 
to the negative control, there were significant changes between when miR-b2122 and its anti-
miR were transfected alone, suggesting that either overexpression, or reduced activity of miR-
b2122, does in fact alter protein levels. These noticeable changes to the TDP-43, FUS and 
RGNEF protein levels when miR-b2122 levels are increased or decreased, suggests that chronic 
changes to miR-b2122 activity might have more drastic effects on protein levels within the cell 
over-time.  
 Interestingly, RGNEF protein levels went in the opposite direction of the mRNA levels 
within our study. While rare to see inverse correlations between mRNA and protein levels of a 
single gene, it is not unprecedented (Marinova et al., 2015; Xiu et al., 2014). This could imply 
that when miR-b2122 binds to the RGNEF 3’UTR, its role is to maintain low levels of mRNA 
while keeping the transcript in a translationally stable state, and thus, loss of its binding stabilizes 
the mRNA molecule, but leaves the transcript in a translationally silent state. The latter 
phenomenon is a common one seen within stress and transport granules within neurons 
(Anderson and Kedersha, 2008; Buchan, 2014; Panas et al., 2016). However, this would suggest 
that there is competition between miR-b2122 and another miRNA, or RNA-binding protein at 
the RGNEF 3’UTR which would need further investigation.   
 We sought to determine whether an ALS mutation located in the MRE of miR-b2122 
within the FUS 3’UTR affected the ability of miR-b2122 to reduce gene expression. Clinically, 
the patient identified with this FUS 3’UTR mutation (*c.108C>T) had limb onset ALS with 
severe limb weakness and respiratory difficulties. Previously, fibroblast cells cultured from the 
ALS patient with this mutation showed an overexpression of FUS mRNA and protein and an 
increase in cytoplasmic localization – two factors believed to contribute to ALS development 
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(Sabatelli et al., 2013). Despite identifying these phenotypes there was no clear mechanism to 
why this may happen. In this study, we showed that loss of direct interaction between miR-
b2122 and the FUS 3’UTR may play a critical role in FUS overexpression. Further, we were able 
to show that reduce levels of miR-b2122 in sALS spinal cord seems to be related to an increase 
in FUS protein expression. In addition, reduction of the levels of miR-b2122 in a neuronal cell 
line (SH-SY5Y) using anti-b2122 hindered the ability for miR-b2122 to reduce endogenous FUS 
leading to an overall increase in both mRNA and protein levels.  
In this study, we have not only provided an explanation of the significance for reduced 
levels of miR-b2122 in sALS, but provide a molecular link showing the importance of the 
interaction between miR-b2122 and the FUS 3’UTR. Thus, dysregulation of miR-b2122 either 
through reduce levels or mutations within the MRE could be a major contributing factor to FUS 
dysregulation and pathogenesis in ALS. In a different study, a group examined another ALS-
related mutation within the FUS 3’UTR, which lead to an overexpression of FUS. This aberrant 
expression of FUS was attributed to the loss of its interaction with miR-141/200a due to the 
3’UTR mutation (Dini Modigliani et al., 2014). These findings emphasize the importance of 
examining mutations outside of the coding regions, as alterations within the 3’UTR can have 
drastic effects on both protein expression and localization (Berkovits and Mayr, 2015; Mayr, 
2016).  
 While it is interesting to note the relationship between the dysregulation of RNA-binding 
proteins and miRNAs, it is still unclear how miRNAs, like miR-b2122 and miR-194, become 
reduced in sALS. However, there is strong evidence suggesting that the miRNA biogenesis 
pathway is disrupted in sALS, as both TDP-43 and FUS are crucial parts of miRNA production 
(Kawahara and Mieda-Sato, 2012; Morlando et al., 2012).  More specifically, it appears that the 
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dysregulation in miRNA biogenesis happens at the level of DICER, as it is the mature miRNA 
form and not the pre-miRNA form showing a global downregulation in sALS (Emde et al., 
2015). Also, ALS-linked mutations in TDP-43 and FUS affects miRNA biogenesis specifically 
at the level DICER (Emde et al., 2015). Thus, it is plausible that TDP-43 and/or FUS could 
regulate the biogenesis of miR-b2122 and miR-194, suggesting a negative feedback loop 
between RNA-binding proteins and miRNAs exists and it is the loss of this negative feedback 
loop that drives, at least in part, sALS disease progression.  
 It has been previously shown that the pathogenesis of sALS patients likely does not rely 
on the dysregulation of a single RNA-binding protein, but a combination of TDP-43, FUS and 
RGNEF, as they co-aggregate with each other in motor neurons of sALS patients (Keller et al., 
2012).  In the current study, we have identified a single miRNA that regulates all three of these 
RNA-binding proteins. The observation that miR-b2122 is downregulated in sALS suggests that 
this miRNA may play an essential role in the pathogenic mechanism of sALS. As we further 
look at those miRNAs related to ALS, we start developing an understanding of a miRNA 
network critical for motor neuron function which we have previously termed MotomiRs (Hawley 
et al., 2017). Further, it would be intriguing to know whether these miRNAs play a role in 
closely related neurodegenerative diseases, including primary lateral sclerosis (PLS), spinal 
muscular atrophy (SMA), or frontotemporal dementia (FTD). Based on the current study, miR-
b2122 should be added to the already established list of MotomiRs, as it regulates a network of 
RNA-binding proteins essential for motor neuron function, and its regulation could potentially 
contribute to motor neuron degeneration in ALS. 
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5.1 Abstract  
 
 TAR DNA-binding protein 43 (TDP-43) and Fused in sarcoma (FUS) are DNA/RNA-
binding proteins that are integral to RNA processing. Among these functions, both play a critical 
role in microRNA (miRNA) biogenesis through interactions with either the DROSHA and/or 
DICER complexes. It has been previously shown that there is a global reduction in miRNA 
levels within the spinal cord and spinal motor neurons of amyotrophic lateral sclerosis (ALS) 
patients. The most common pathological feature of TDP-43 and FUS in ALS is a re-distribution 
from the nucleus to the cytoplasm in motor neurons where they form cytoplasmic inclusions. 
Among miRNAs dysregulated in ALS, several are known to regulate TDP-43 and FUS 
expression. In this study, we demonstrate that TDP-43 is in a regulatory negative feedback 
network with two miRNAs—miR-27b-3p and miR-181c-5p—that is dependent on its nuclear 
localization within HEK293T cells; however, we are unable to show FUS is in an similar 
network with the miRNAs it regulates. Further, we show that cellular stress which induces a 
redistribution of TDP-43 from the nucleus to the cytoplasm correlates with the reduced 
production of miR-27b-3p and miR-181c-5p. This suggests that reduced nuclear TDP-43 disrupts 
a negative feedback network between itself and miRNAs. These findings provide a further 
understanding of altered miRNA biogenesis as a key pathogenic process in ALS.   
 
  
197 
 
5.2 Introduction 
 
 TAR DNA-binding protein 43 (TDP-43) and Fused in Sarcoma (FUS) are primarily 
nuclear DNA/RNA-binding proteins that are ubiquitously expressed in every cell, and both share 
a diverse set of functions which include: mRNA transcription, mRNA splicing, mRNA transport, 
microRNA (miRNA) and long non-coding RNA (lncRNA) processing, mRNA translation, and 
stress granule formation (Ratti and Buratti, 2016; Svetoni et al., 2016). Several of these functions 
have been identified as dysregulated within motor neurons of patients with amyotrophic lateral 
sclerosis (ALS) where both TDP-43 and FUS have been shown to re-locate from the nucleus to 
the cytoplasm resulting in the subsequent formation of pathological aggregates. In particular, 
TDP-43 pathology occurs in 97% of all ALS cases, while FUS pathology is only observed in 1% 
of cases (Campos-Melo et al., 2013; Fratta et al., 2018; Ling et al., 2013; Weskamp and 
Barmada, 2018).   
 Cellular stress can induce the re-localization of TDP-43 and FUS from the nucleus to the 
cytoplasm, where they can partition into stress granule structures (Baradaran-Heravi et al., 2020; 
Khalfallah et al., 2018; McDonald et al., 2011; Moisse et al., 2009). Accumulation of proteins 
with low-complexity domains (LCD’s), like TDP-43 and FUS, have been shown to phase 
separate into liquid droplets. However, if left to accumulate, LCD-containing proteins can form 
irreversible insoluble fibrils which is believed to cause the pathology of these proteins in ALS 
motor neurons (Kato et al., 2012; Molliex et al., 2015; Murakami et al., 2015). Evidence that 
stress granules may act as a seed for pathological cytoplasmic aggregates in ALS is that TIA-1—
an essential stress granule component—co-localizes with TDP-43 aggregates in ALS motor 
neurons (Liu-Yesucevitz et al., 2010; Volkening et al., 2009). Further, increased mRNA and 
protein levels of TDP-43 have been observed within both the spinal cord and motor neurons of 
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patients with ALS (Koyama et al., 2016; Swarup et al., 2011), suggesting that TDP-43 levels are 
being aberrantly regulated which may contribute to its accumulation into cytoplasmic aggregates. 
Further, overexpression of FUS in in vitro or in vivo models is associated with cytoplasmic 
inclusion formation similar to what is observed in ALS motor neurons (Mitchell et al., 2013; 
Patel et al., 2015). Interestingly, both TDP-43 and FUS have been observed to co-aggregate with 
each other in ALS motor neurons (Keller et al., 2012).   
 Our lab, and others, have shown that a large pool of miRNAs—small RNA molecules 
(20-22 nucleotides) that are generally responsible for post-transcriptional gene suppression 
(Bartel, 2018)—have reduced levels within ALS spinal cord and motor neurons (Campos-Melo 
et al., 2013; Emde et al., 2015). Further, we have shown that ALS-linked miRNAs suppress 
TDP-43 and FUS expression suggesting that loss of miRNA function could result in increased 
levels of TDP-43 and FUS in ALS motor neurons (Hawley et al., 2017). Given the observation 
that TDP-43 and FUS are involved in the miRNA biogenesis pathway through interactions with 
either DROSHA and/or DICER complexes (Kawahara and Mieda-Sato, 2012; Morlando et al., 
2012),  we postulated that TDP-43 and FUS regulates the production of miRNAs that in turn will 
suppress their expression. We further hypothesize that TDP-43 and FUS are in a negative 
feedback loop with a specific group of miRNAs and that this function is dependent on their 
nuclear localization. FUS has been shown to be in a negative feedback loop with ALS-linked 
miRNAs (miR-141/200a) previously (Dini Modigliani et al., 2014), and therefore, we sought to 
determine whether there are other miRNAs involved with this negative feedback loop.        
In this chapter, we explore the negative feedback network between TDP-43 and two 
ALS-related miRNAs, miR-27b-3p and miR-181c-5p, in HEK293T cells, and we show that this 
regulation is dependent on TDP-43 nuclear localization. Further, we show that TDP-43 regulates 
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the processing of these two miRNAs at different levels within the miRNA biogenesis pathway. 
In contrast, while we were able to determine two miRNAs (miR-2110 and miR-6804-5p) with 
MREs in the FUS 3’UTR whose expression was promoted by FUS, we were unable to show 
these miRNAs were in a negative feedback loop. 
5.3 Methods and Materials 
 
5.3.1 Plasmid Constructs  
 
SiRNA resistant plasmids (siRES) were either pC32-FLAG-TDP-43 wild-type or pC32-
FLAG-TDP-43 ∆NLS and were resistant to an siRNA that targets endogenous TARDBP (siTDP 
#2) (Deshaies et al., 2018).  
TARDBP and FUS  3’UTRs that are expressed in human spinal cord were linked to the 
firefly luciferase gene within the pmirGLO plasmid (Promega Cat. # E1330) as described 
previously (Hawley et al., 2017). Mutations were put into the +2 and +3 position of the miRNA 
recognition element (MRE) of either miR-27b-3p or miR-181c-5p of the TARDBP 3’UTR using 
the QuikChange Site-Directed Mutagenesis Kit (Agilent Cat. # 210219). Cloned sequences and 
mutants were confirmed using Sanger sequencing.  
5.3.2 Cell culture and transfection 
 
 HEK293T cells were maintained in Dulbecco’s Modified Eagles Media (DMEM; Gibco 
Cat. # 11965084) which contained 10% fetal bovine serum (FBS) at 37oC with 5% CO2. Sorbitol 
was added to cell media at a concentration of 400 mM to induce an osmotic stress. Media with 
sorbitol was then added to HEK293T cells with an 80% confluency. The osmotic stress was 
maintained for five hours prior to experimentation. 
HEK293T cells were seeded into a 6-well plate (150,000 cells/well) and incubated for 48 
hours. Cells were then either transfected with 100 nM of SCR (Sigma-Aldrich Cat. # SIC001) or 
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a custom siRNA targeting endogenous TARDBP (siTDP #2; Dharmacon) but not exogenous 
TARDBP cloned into siRNA resistant (siRES) plasmids as previously described (Deshaies et al., 
2018). 24 hours post-transfection of siTDP #2, cells were transfected again with 2.5μg of either 
pcDNA 3.1 (negative control), pC32-FLAG-TDP-43 wild-type or pC32-FLAG-TDP-43 ∆NLS 
siRES plasmids. Mature miRNA levels were examined 24 hours post-transfection of plasmids. 
Transfections were done using the Lipofectamine 2000 Reagent (Invitrogen Cat. # 11668019) 
protocol following the manufacturer’s instructions. 
 
5.3.3 Microarray analysis  
 
 HEK293T cells were seeded into a 6-well plate (150,000 cells/well) and incubated for 48 
hours. Cells were either transfected with an 100nM of siRNA SMARTpool targeting TARDBP 
(siTDP #1; Dharmacon Cat. # L-012394-00-0005), siRNA SMARTpool targeting FUS (siFUS; 
Dharmacon Cat. # L-009497-00-0005), or a scramble negative control (SCR; Sigma-Aldrich Cat. 
# SIC001) at a 60% confluency using the Lipofectamine 2000 Reagent (Invitrogen Cat. # 
11668019) protocol. Total RNA extraction was then performed 48 hours post-transfection using 
the RNeasy Mini Kit (Qiagen Cat. # 74106). RNA samples were tested for integrity using 
bioanalyzer analysis. Total RNA extracts were sent to the Center of Applied Genomics – TCAG 
Facilities at the University of Toronto for microarray analysis using the GeneChip miRNA 4.0 
Array (Applied Biosystems Cat. # 902412). Quality control and experimental data from the 
microarray was analyzed using the Transcriptome Analysis Console Software (ThermoFisher 
Scientific). 
 
5.3.4 Real-time PCR 
 
201 
 
 Samples from HEK293T cells underwent a small RNA extraction using the mirVana 
miRNA Isolation Kit (Invitrogen Cat. # AM1560) to obtain RNA molecules <200nts which 
allowed us to separate pri-miRNAs (>200nts) from pre-miRNAs (<200nts). Yield and purity of 
small RNAs was determined using spectrophotometry. When measuring mature miRNA levels, 
small RNA extracts went under cDNA synthesis using the TaqMan Advanced cDNA Synthesis 
Kit (Applied Biosystems Cat. # A28007), but when measuring the levels of pre-miRNAs, small 
RNA extracts went under cDNA synthesis using the SuperScript IV VILO Master Mix with 
DNease Enzyme (Invitrogen Cat. # 11766050) protocol. All cDNA synthesis protocols were 
done according to the manufacturers’ instructions. Real-time PCR for mature miRNAs and pre-
miRNAs was done either using the TaqMan Advanced miRNA Assay (Applied Biosystems Cat. 
# A25576) or the TaqMan Pre-miRNA Assay (Applied Biosystems Cat. # 4331182), 
respectively, and the Fast TaqMan Advanced Master Mix (Applied Biosystems Cat. # 4444965) 
in accordance to the manufactures protocol. Since microarray was normalized to an exogenous 
control, confirmation of changes to miRNA levels was done using an endogenous control (miR-
1296-5p) which showed no change in expression following TDP-43 knockdown. Candidate 
miRNA expression for the rest of the experiments was normalized to an RNA spike-in (cel-miR-
39b-5p). All real-time PCR data was quantified according to the 2^-∆∆CT method.    
 
5.3.5 Reverse transcriptase relative quantitative PCR (RT-qPCR) 
 
 HEK293T cells were either transfected with a SCR (Sigma-Aldrich Cat. # SIC001), miR-
27b-3p, miR-181c-5p, miR-2110 or miR-6804-5p human miRNA mimics (Invitrogen Cat. # 
4464066) to measure changes to either endogenous TARDBP or FUS mRNA levels, or cells were 
transfected with either SCR (Sigma-Aldrich Cat. # SIC001) or siTDP #1 (Dharmacon Cat. # L-
012394-00-0005) to measure changes in pri-miRNA levels using the Lipofectamine 2000 
202 
 
Reagent (Invitrogen Cat. # 11668019) protocol. Total RNA extraction using the RNeasy Mini 
Kit (Qiagen Cat. # 74106) was performed 48 hours post-transfection. Yield and purity of RNA 
was determined using spectrophotometry. RNA extracts went under cDNA synthesis using the 
SuperScript II Reverse Transcriptase (Invitrogen Cat. # 18064014) in accordance with the 
manufactures instructions which was followed by quantitative PCR using the Platinum Taq DNA 
Polymerase (Invitrogen Cat. # 10966018) protocol for amplification via primers outlined in 
Table 5.1. Expression levels were normalized to 18S rRNA levels prior to comparison.    
 
5.3.6 Luciferase assay 
 
 HEK293T cells were co-transfected with either SCR (Sigma-Aldrich Cat. # SIC001), or 
human miRNA mimics (miR-27b-3p or miR-181c-5p; Invitrogen Cat. # 4464066) and either an 
empty pmirGLO plasmid or a pmirGLO plasmid containing the 3’UTR of TARDBP using the 
Lipofectamine 2000 Reagent (Invitrogen Cat. # 11668019) protocol. Luciferase activity was 
measured 24 hours post-transfection using the Dual-GLO Luciferase Assay System (Promega 
Cat. # E2920). Firefly luciferase levels were normalized to renilla luciferase levels, and data was 
further normalized to account for the effect the miRNAs have on the plasmid itself prior to 
comparison as previously described (Campos-Melo et al., 2014).  
 
5.3.7 Western blot 
 
 All protein extractions were done from HEK293T cells using the NP40 lysis buffer with 
proteinase inhibitors followed by sonication. Protein lysates were resuspended in loading buffer 
containing 5% β-mercaptoethanol and denatured at 90oC for 5 minutes. Samples ran on an 10% 
SDS-page gel and then were transferred onto a nitrocellulose membrane. Blots were probed with 
either rabbit anti-TDP-43 (1:5000; Proteintech Cat. # 10782-2-AP), rabbit anti-FUS (1:5000;  
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Table 5.1. Primer Design for RT-qPCR and site-directed mutagenesis assays. 
Primer Name Sequence 
pri-miR-27b 
forward 
5’ AGGGATTACCACGCAACCACGACCTTG 3’ 
pri-miR-27b 
reverse 
5’ CCTTCTCTTCAGGTGCAGAACTTAG 3’ 
pri-miR-181c 
forward 
5’ GGTTTGGGGGAACATTCAACCTGTCG 3’ 
pri-miR-181c 
reverse 
5’ GAATGTTGATTGTGACCTCGGCTGTGG 3’ 
miR-27b 
mutant forward 
5’ CCCTTTGTCAACTGCTGTGTTTGCTGTATGGTGTGTGTTC 3’ 
miR-27b 
mutant reverse 
5’ GAACACACACCATACAGCAAACACAGCAGTTGACAAAGGG 3’ 
miR-181c 
mutant forward 
5’ GATAACCCACATTAGATGAATCCGTTAAGTGAAATGATACTTG 3’ 
miR-181c 
mutant reverse 
5’CAAGTATCATTTCACTTAACGGATTCATCTAATGTGGGTTATC 3’ 
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Proteintech Cat. # 11570-1-AP), mouse anti-FLAG (1:2500; Cedarlane Cat. # CLANT146-2), 
rabbit anti-DROSHA (1:1000; abcam Cat. # ab12286), rabbit anti-DCGR8 (1:1000; abcam Cat. 
# ab191875), mouse anti-XPO5 (1:1000; abcam Cat. # ab57491), mouse anti-DICER (1:1000; 
abcam Cat. # ab14601), mouse anti-AGO2 (1:1000; abcam Cat. # ab57113), rabbit anti-TRBP 
(1:1000; Proteintech Cat. # 15753-1-AP), or rabbit anti-GAPDH (1:5000; abcam Cat. # ab9485) 
and later with an HRP secondary antibody (goat anti-mouse 1:3000; Biorad Cat. # STAR207P, 
or goat anti-rabbit 1:5000; Invitrogen Cat. #  65-6120). Data was quantified using densitometry 
measured by ImageJ software. Relative protein levels were normalized to GAPDH expression 
prior to comparison.  
 
5.3.8 Fluorescent in situ hybridization (FISH) 
  
 Neuropathologically intact human spinal cord tissue was used to examine whether 
candidate miRNAs were expressed in human spinal motor neurons. Tissue was cut into 7μm 
sections. FISH was done as previously described (Hawley et al., 2019). MiRCURY LNA 
miRNA Detection Probes that targeted miRNA candidates contained 5’ and 3’ DIG labels 
(Qiagen Cat. # 339111), which were further targeted by an HRP secondary antibody (Sigma-
Aldrich Ca. # 11633716001) and a Tyramide Signal Amplification tagged with a Cy3 
fluorophore (PerkinElmer Cat. # NEL744001KT). Spinal cord samples were examined for 
positive expression of candidate miRNAs using the Leica TSC SP8 confocal microscope. 
 
5.3.9 Immunocytochemistry  
 
 Cells were fixed using 4% paraformaldehyde (PFA) and blocked with 8% Bovine Serum 
Albumin (BSA). Proteins of interest were targeted by either rabbit anti-TDP-43 (1:250; 
Proteintech Cat. # 10782-2-AP), goat anti-TIA-1 (1:100; Santa Cruz Cat. # sc-166247), or rabbit 
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anti-FLAG (1:100; abcam Cat. # ab49763) primary antibodies, which were targeted by Alexa 
488 goat anti-rabbit, Alexa 555 donkey anti-goat, and Alexa 488 goat anti-mouse, respectively, 
secondary antibodies (1:200; Life Technologies Cat. # A32721, A21432, and A32721, 
respectively). Samples were imaged using the Leica TSC SP8 confocal microscope.   
 
5.3.10 Fractionation 
 
 Nuclear and cytosolic protein and RNA fractionations was performed using the PARIS 
kit (Invitrogen Cat. # AM1921) in accordance to the manufacturer’s instructions. 100 U/ml of 
SUPERase IN RNase Inhibitor (Invitrogen Cat. # AM2694) was added to the cell fractionation 
buffer and cell disruption buffer within the PARIS kit to prevent RNA degradation.  
 
5.3.11 Statistics  
 
 Significance was determined either using a Students t-test when comparing two 
conditions, or one-way ANOVA followed by a Tukey’s post-hoc when comparing multiple 
conditions. Data was considered significant if p<0.05. 
5.4 Results  
 
5.4.1 Knockdown of either TDP-43 or FUS alters small RNA profile in HEK293T cells 
 
 Knockdown of either TDP-43 or FUS in HEK293T cells was accomplished using siRNA 
pools targeting either TARDBP (siTDP #1) or FUS (siFUS) mRNA, respectively (Fig. 5.1A & 
5.1E). MiRNA expression was then analyzed by microarray. The results showed that more than 
370 and 300 small RNAs (scaRNAs, snoRNAs, and miRNAs) were significantly dysregulated 
following knockdown of either TDP-43 or FUS, respectively, most of which were miRNAs (Fig. 
5.1B & 5.1F; list of small RNAs can be found in Appendix A). Interestingly, several miRNAs 
that were downregulated following knockdown of TDP-43 also contained a miRNA recognition 
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element (MRE) within the 3’untranslated region (UTR) of TARDBP (Fig. 5.1C) according to 
miRanda software. Further, we confirm reduction of miR-141-3p and miR-200a-3p following 
knockdown of FUS, but also identified two other miRNAs (miR-2110 and miR-6804-5p) 
downregulated with MREs in the FUS 3’UTR (Fig. 5.1G) according to miRanda software. 
However, we could not identify any upregulated miRNAs that had MREs in the TARDBP or 
FUS 3’UTRs. We selected five miRNA candidates with MREs in the TARDBP 3’UTR that had 
the greatest reduced fold-change following knockdown of TDP-43, and confirmed with real-time 
PCR that four of the five selected miRNAs (miR-27b-3p, miR-30a-5p, miR-181c-5p and miR-
425-3p) were significantly downregulated after knockdown of TDP-43, while miR-1260b 
showed a non-significant reduction (Fig. 5.1D).   
Since miR-141-3p and miR-200a-3p have already been shown to be in a negative 
feedback loop with FUS which is dependent on FUS nuclear localization (Dini Modigliani et al., 
2014), we decided to look at miR-2110 and miR-6804-5p to see if we could expand on this 
network. We confirmed reduced levels of miR-2110 and miR-6804-5p following knockdown of 
FUS via real-time PCR (Fig. 5.1H).  
In previous work, we had shown that out of the 4 miRNA candidates that we identified 
for TDP-43, miR-27b-3p, miR-181c-5p and miR-425-3p, but not miR-30a-5p, were significantly 
reduced in ALS spinal cord (Campos-Melo et al., 2013). Further, TargetScan 7.2 showed that 
only miR-27b-3p and miR-181c-5p had conserved MREs in the TARDBP 3’UTR giving them a 
high probability that they would affect TDP-43 expression, and therefore, we further examined 
these two miRNAs. However, miR-2110 and miR-6804-5p are not known to be affected in ALS 
and they do not have conserved MREs in the FUS 3’UTR. Despite this information we decided 
to further explore miR-2110 and miR-6804-5p to determine if there was a potential negative 
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feedback loop between these miRNAs and FUS. All four miRNA candidates (miR-27b-3p, miR-
181c-5p, miR-2110 and miR-6804-5p) were found to be expressed in human spinal motor 
neurons according to fluorescent in situ hybridization analysis (Fig. 5.2), and therefore, we 
decided to explore these miRNAs and their relation to either TDP-43 or FUS expression.   
5.4.2 MiR-27b-3p and miR-181c-5p reduce TDP-43 expression 
 
 To determine whether miRNA candidates regulated either TDP-43 or FUS expression, 
miRNA mimics of miR-27b-3p, miR-181c-5p, miR-2110 and miR-6804-5p were individually 
transfected into HEK293T cells. Transfection of either miR-27b-3p or miR-181c-5p led to a 
reduction of both endogenous TDP-43 protein and mRNA levels 48 hours after transfection (Fig. 
5.3A-C). However, transfection of either miR-2110 or miR-6804-5p had no effect on FUS 
protein/mRNA levels (Fig. 5.3E-G), indicating these two miRNAs were not in a negative 
feedback loop with FUS.  
Since miRNAs regulate gene expression generally by interacting with the 3’UTR of 
mRNA, we wanted to determine whether miR-27b-3p and miR-181c-5p regulated TARDBP 
expression via the 3’UTR. Reporter gene assays indicated that when TARDBP 3’UTR is linked 
to a firefly luciferase gene that this leads to a reduction in luciferase activity when in the 
presence of either exogenous miR-27b-3p or miR-181c-5p (Fig. 5.3D). Using the same assay, we 
examined whether miR-2110 or miR-6804-5p could regulate luciferase expression in the 
presence of the FUS 3’UTR. They had no effect (Fig.5.3H). Therefore, we decided to only 
continue to explore the relationship between TDP-43 and miR-27b-3p/miR-181c-5p.  
 Next, we determined whether miR-27b-3p and miR-181c-5p regulated TARDBP 
expression through direct interactions with its 3’UTR. Wild-type TARDBP 3’UTR, or TARDBP 
3’UTR containing mutations in the +2 and +3 position of either the miR-27b-3p or miR-181c-5p  
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Figure 5.1. Global change in miRNA expression following knockdown of either TDP-43 or 
FUS in HEK293T cells using siRNAs. (A)Western blot showing knockdown of TDP-43 via 
siRNA (siTDP #1). (B) Volcano plot indicating change in small RNA expression following 
knockdown of TDP-43 (n=3). Green and red represent downregulated and upregulated RNAs, 
respectively. (C) List of miRNAs that are downregulated following knockdown of TDP-43 and 
have binding sites within the TARDBP 3’UTR. (D) Real-time PCR was used to confirm the 
change in candidate miRNA expression following TDP-43 knockdown (n=3). (E) Western blot 
showing knockdown of FUS via siRNA (siFUS). (F) Volcano plot indicating change in global 
small RNA expression following knockdown of FUS (n=3). Green and red represent 
downregulated and upregulated RNAs, respectively. (G) List of miRNAs downregulated 
following FUS knockdown and have binding sites within the FUS 3’UTR. (H) Real-time PCR 
was used to confirm the change in candidate miRNA expression following FUS knockdown 
(n=3). Real-time PCR data was normalized to an endogenous control (miR-1296-5p).  Bars 
represent mean (n=3) fold-change (2^-∆∆CT) ± SEM in real-time PCR analyses. Student’s t-test 
was used to determine significance in microarray and real-time analyses (*p<0.05, **p<0.01, 
***p<0.001).   
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Figure 5.2. MiR-27b-3p, miR-181c-5p, miR-2110 and miR-6804-5p are expressed in human 
spinal motor neurons. A lumbar spinal cord from a neuropathologically intact individual (n=1) 
was used for fluorescent in situ hybridization (FISH) analysis in order to determine whether 
miRNA candidates were expressed in human spinal motor neurons. Red puncta indicate positive 
staining for miRNAs. MiR-548c was used as a negative control. Scale bar represents 25μm.
10μm 25μm 
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MREs were linked to a firefly luciferase gene (Fig. 5.4A). Reporter gene assays revealed that 
when the firefly gene contains the TARDBP 3’UTR with mutations in either the miR-27b-3p or  
or miR-181c-5p MREs, miR-27b-3p and miR-181c-5p are no longer able to effect luciferase 
activity, respectively (Fig. 5.4B). This indicates that both miR-27b-3p and miR-181c-5p must 
interact with the 3’UTR of TARDBP in order to reduce gene expression.       
 
5.4.3 Nuclear localization of TDP-43 is required to regulate miR-27b-3p and miR-181c-5p 
expression 
 
 Since cellular stress is known to alter TDP-43 localization from the nucleus to the 
cytoplasm, we wanted to determine whether stress would lead to a reduction in the levels of 
miR-27b-3p and miR-181c-5p similar to that observed following knockdown of TDP-43. After 
an induced cellular stress, levels of both miR-27b-3p and miR-181c-5p were significantly 
reduced concomitant with the expected reduction of nuclear localization of TDP-43 (Fig. 5.5). 
Based on this information, we next determined if the nuclear localization of TDP-43 is a 
requirement for the regulation of miR-27b-3p and miR-181c-5p expression. To do this, we used 
siRNA plasmids (siRES) resistant to a specific siRNA (siTDP #2) which contained either FLAG-
tagged wild-type TDP-43 (siRES pC32-FLAG-TDP-43 WT) or FLAG-tagged TDP-43 without 
its nuclear localization signal (siRES pC32-FLAG-TDP-43 ∆NLS), as previously described 
(Deshaies et al., 2018). Both plasmids had a transfection efficiency of ~70% (Fig. 5.6A-B). 
SiTDP #2 was able to knockdown endogenous TDP-43 (Fig. 5.7A) without affecting the 
expression of the siRES plasmids (Fig. 5.6C-E). The siRES pC32-FLAG-TDP-43 WT plasmid 
was primarily nuclear, while siRES pC32-FLAG-TDP-43 ∆NLS was primarily cytoplasmic (Fig. 
5.7B) as expected. 24 hours after transfection of either SCR (negative control) or siTDP #2, 
either pcDNA 3.1 (negative control), siRES pC32-FLAG-TDP-43 WT, or siRES pC32-FLAG-
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TDP-43 ∆NLS were transfected into HEK293T cells. Recovery of both miR-27b-3p and miR-
181c-5p to normal levels 48 hours post-knockdown of TDP-43 was seen only when cells were 
transfected with siRES pC32-FLAG-TDP-43 WT and not when either pcDNA 3.1 or siRES 
pC32-FLAG-TDP-43 ∆NLS plasmids were transfected (Fig. 5.7C), indicating that TDP-43 
nuclear localization is necessary for the expression of miR-27b-3p and miR-181c-5p.  
5.4.4 Knockdown of TDP-43 or cellular stress affect primary miRNA processing 
 Based on the reduction of mature miRNA levels of miR-27b-3p and miR-181c-5p 
following knockdown of TDP-43, we wanted to determine at what level in the biogenesis 
pathway of these two miRNAs TDP-43 was acting. When examining primary miRNA (pri-
miRNA) levels following knockdown of TDP-43, we observed that there was a significant 
increase in the amount of pri-miR-181c, while there was no change pri-miR-27b levels (Fig. 
5.8A) indicating that TDP-43 only regulates the levels of pri-miR-181c.  
 We next examined whether cellular stress would have a similar effect on the pri-miRNAs 
as observed with knockdown of TDP-43. We observed that there was a significant increase in 
pri-miR-27b and pri-miR-181c following a cellular stress (Fig. 5.8B). Taken together, the data 
suggest that reduced levels of mature miRNA levels either by knockdown of TDP-43 or cellular 
stress is not due to reduced pri-miRNA levels, but rather, later reduced processing of miRNAs. 
Given this, we next further investigated precursor structures of miR-27b and miR-181c. 
5.4.5 Knockdown of TDP-43 and cellular stress affects precursor miRNA processing  
 
 Knockdown of TDP-43 showed no change in the overall levels of pre-miR-27b or pre-
miR-181c (Fig. 5.9A), while cellular stress led to a significant increase in pre-miR-27b but had 
no effect on pre-miR-181c levels (Fig. 5.9B). Since precursor miRNA molecules are present in  
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Figure 5.3. Transfection of miR-27b-3p and miR-181c-5p decreased protein and mRNA 
expression of TDP-43, while transfection of miR-2110 and miR-6804-5p had no effect on 
FUS expression within HEK293T cells. (A) Western blot showing TDP-43 and GAPDH 
protein levels following transfection of either scramble control (SCR), miR-27b-3p and miR-
181c-5p. (B) Quantification of relative TDP-43 protein expression when normalized to GAPDH 
(n=3). (C) Change in mRNA expression of TARDBP when normalized to 18S rRNA following 
transfection of either SCR, miR-27b-3p, or miR-181c-5p (n=3). (D) Plasmids containing a 
reporter gene linked to the TARDBP 3’UTR were co-transfected in HEK293T cells with either 
SCR (control), miR-27b-3p, or miR-181c-5p to determine changes in reporter gene expression in 
the presence of either miR-27b-3p or miR-181c-5p. Data was normalized to renilla expression 
prior to comparison (n=3). (E) Western blot showing FUS and GAPDH protein levels following 
transfection of either scramble control (SCR), miR-2110 and miR-6804-5p. (F) Quantification of 
relative FUS protein expression when normalized to GAPDH (n=3). (G) Change in mRNA 
expression of FUS when normalized to 18S rRNA following transfection of either SCR, miR-
2110, or miR-6804-5p (n=3). (H) Plasmids containing a reporter gene linked to the FUS 3’UTR 
were co-transfected in HEK293T cells with either SCR (control), miR-2110, or miR-6804-5p to 
determine changes in reporter gene expression in the presence of either miR-2110 or miR-6804-
5p. Data was normalized to renilla expression prior to comparison (n=3). Bars represent mean ± 
SEM. Significance was determined using a one-way ANOVA followed by a Tukey’s post-hoc 
for multiple comparisons (B, C, F, and G) and a Student’s t-test was used to determine 
significance between two groups (D and H) (NSp>0.05, *p<0.05, **p<0.01, ***p<0.001). 
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Figure 5.4 MiR-27b-3p and miR-181c-5p interact with the TARDBP 3’UTR to regulate 
gene expression. (A) Mutations were put in the +2 and +3 position of the miR-27b-3p or miR-
181c-5p MRE within the TARDBP 3’UTR. (B) Reporter gene assays showing the change in 
expression of the reporter gene when its linked to the either the wild-type (TDP WT) or mutated 
(TDP Mut.) TARDBP 3’UTR when in the presence of either miR-27b-3p or miR-181c-5p. Data 
was normalized to renilla prior to comparison. Bars represent mean (n=3) ± SEM. Significance 
was determined using a one-way ANOVA followed by a Tukey’s post-hoc for multiple 
comparisons (NSp>0.05, ***p<0.001) 
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Figure 5.5. Reduced expression of miR-27b-3p and miR-181c-5p that is concomitant with 
reduced nuclear TDP-43 levels five hours post osmotic stress. (A) HEK293T cells were either 
not treated (control) or treated with 400 mM of sorbitol to induce an osmotic stress. Cells were 
fixed and stained for TDP-43 (red) and TIA-1 (green) immunofluorescence. (B) MiR-27b-3p and 
miR-181c-5p expression between non-stressed and stressed cells was measured via real-time 
PCR. Expression levels were normalized to an exogenous control (cel-miR-39b-5p) prior to 
comparison. Bar represents mean (n=5) fold-change (2^-∆∆CT) ± SEM. Student’s t-test was 
used to determine significance (*p<0.05, **p<0.01).  
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Figure 5.6. SiRES plasmids have an ~70% transfection efficiency and are resistant to a 
specific TDP-43 siRNA (siTDP #2). (A) Immunofluorescence showing the expression of either 
pC32-FLAG-TDP-43 wild-type (TDP WT) or pC32-FLAG-TDP-43 ∆NLS (TDP ∆NLS) siRES 
plasmids following transfection within HEK293T cells. (B) Quantification of percentage of cells 
positive for either siRES TDP WT or TDP ∆NLS plasmids following transfection within 
HEK293T cells (n=3). (C) Western blot showing expression of endogenous GAPDH, TDP-43 
and siRES TDP WT after cells were transfected with either SCR (control) or siTDP #2. (D-E) 
Quantification of (D) siRES TDP WT or (E) endogenous TDP-43 expression when cells were 
transfected with either SCR or siTDP #2 (n=3). Expression levels were normalized to GAPDH 
prior to comparison. Bar represents mean ± SEM. Significance was determined using a Student’s 
t-test (NSp>0.05, ***p<0.001). 
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Figure 5.7. Nuclear localization signal of TDP-43 is required for the regulation of miR-27b-
3p and miR-181c-5p expression. (A) Western blot showing knockdown of TDP-43 following 
transfection of siRNA (siTDP #2). (B) Immunofluorescence showing localization of either pC32-
FLAG-TDP-43 wild-type (TDP WT) or pC32-FLAG-TDP-43 ∆NLS (TDP ∆NLS) siRES 
plasmids. (C) HEK293T cells were transfected with either SCR (control) or siTDP #2, and then 
transfected again 24 hours later with either pcDNA (control), TDP WT or TDP ∆NLS plasmids. 
MiR-27b-3p and miR-181c-5p levels were measured 24 hours after transfection of plasmids. 
Expression levels were normalized to an exogenous control (cel-miR-39b-5p) prior to 
comparison. Bar represents mean (n=3) fold-change (2^-∆∆CT) ± SEM. SCR+pcDNA samples 
were negative controls in which the bar representing their expression levels was set at one for 
comparison purposes. Significance was determined using a one-way ANOVA followed by a 
Tukey’s post-hoc for multiple comparisons (NSp>0.05, **p<0.01). 
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Figure 5.8. Knockdown of TDP-43 increases levels of pri-miR-181c, while cellular stress 
increases levels of the pri-miR-27b and pri-miR-181c. RT-qPCR of pri-miR-27b and pri-miR-
181c following (A) knockdown of TDP-43, or (B) an osmotic stress. Expression levels were 
measured using densitometry and were normalized to 18S rRNA prior to comparison. Bars 
represent mean (n=4) ± SEM. Significance was determined using a Student’s t-test (NSp>0.05, 
*p<0.05, **p<0.01). 
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the nucleus and cytoplasm, we wanted to determine the levels of pre-miR-27b and pre-miR-181c 
within both cellular compartments.  
We successfully fractionated samples into nuclear and cytosolic fractions (Fig. 5.10). 
Both knockdown of TDP-43 and an induced cellular stress caused a significant reduction in 
cytosolic pre-miR-181c, but no significant change in its nuclear levels, whereas there was no 
significant change in nuclear or cytosolic levels of pre-miR-27b in both conditions (Fig. 5.11). 
This suggests that the knockdown of TDP-43 and cellular stress can affect the levels of certain 
pre-miRNA molecules within the cytosolic compartment, specifically pre-miR-181c, while 
having no effect on other pre-miRNA molecules, such as pre-miR-27b.  
Despite showing that knocking down TDP-43 causes deficits at several levels of miRNA 
processing, there was no effect on the expression of the major proteins involved in the miRNA 
biogenesis pathway at the time we see changes to miRNA levels (Fig. 5.12). This suggests that, 
in this time frame, TDP-43 plays a critical role in the function of proteins within the miRNA 
biogenesis pathway when processing miR-27b-3p and miR-181c-5p.  
 
5.5 Discussion 
 
 We have provided evidence of a negative feedback regulatory loop in which TDP-43, 
miR-27b-3p and miR-181c-5p interact in a manner that is dependent on the nuclear localization 
of TDP-43. We show that TDP-43 regulates these two miRNAs differently within the miRNA 
biogenesis pathway, and that cellular stress that reduces TDP-43 nuclear localization had similar, 
but not the exact same effects on the processing of these two miRNAs as reduced TDP-43 levels.  
 In our experiments, we were unable to identify miRNAs in a negative feedback network 
with FUS. Although miR-2110 and miR-6804-5p contained MREs in the FUS 3’UTR, there was 
no evidence to suggest that these two miRNAs regulated FUS expression. Interestingly, two 
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miRNAs (miR-141-3p and miR-200a-3p) that had been previously shown to be in a negative 
feedback loop with FUS (Dini Modigliani et al., 2014), were significantly downregulated in our 
microarray analysis. Thus, while we were unable to expand on the potential miRNAs involved in 
a negative feedback network with FUS, we still believe that loss of the negative feedback loop 
between FUS and miR-141/200a could be a major driver of the disease pathogenesis, as both 
miR-141/200a have been shown to be reduced in ALS spinal cord (Campos-Melo et al., 2013).       
 TDP-43 has previously been shown to be involved in pri-miRNA and pre-miRNA 
processing within the DROSHA and DICER complex, respectively (Kawahara and Mieda-Sato, 
2012).  Interestingly, TDP-43 regulates miRNAs in different ways, including selectively 
promoting the processing of certain pri-miRNAs, or promoting or preventing the processing of 
certain pre-miRNAs (Kawahara and Mieda-Sato, 2012; King et al., 2014). However, the 
molecular reason for this selectivity is still unclear. In line with previous work, our data showed 
this diverse role of TDP-43 within miRNA biogenesis, where knockdown of TDP-43 led to 
reduced levels of cytoplasmic pre-miR-181c and mature miR-181c-5p levels but increases in pri-
miR-181c levels. Low levels of TDP-43 function likely reduce DROSHA processing, which 
could explain the accumulation of pri-miR-181c. The reduction of cytoplasmic pre-miR-181c 
either means that reduced TDP-43 levels impede pre-miR-181c transport or that it promotes the 
degradation of this pre-miRNA molecule in the cytoplasm. Regardless, it is clear that TDP-43 
promotes the production of miR-181c-5p at several levels within the miRNA biogenesis 
pathway. Further, knockdown of TDP-43 only caused a reduction of mature miR-27b-3p with no 
effect on the pri and pre-miRNAs, indicating that TDP-43 likely promotes DICER processing of 
pre-miR-27b. Since TDP-43 interacts with DROSHA and DICER in both an RNA-dependent 
and independent manner (Kawahara and Mieda-Sato, 2012), it is difficult to know   
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Figure 5.9. Knockdown of TDP-43 has no effect on overall pre-miR-27b or pre-miR-181c 
levels, while cellular stress increases levels of pre-miR-27b. Real time PCR of pre-miR-27b 
and pre-miR-181c following (A) knockdown of TDP-43, or (B) an osmotic stress. Expression 
levels were normalized to an exogenous control (cel-miR-39b-5p) prior to comparison. Bar 
represents mean (n=3) fold-change (2^-∆∆CT) ± SEM. Significance was determined using a 
Student’s t-test (NSp>0.05, *p<0.05, **p<0.01). 
  
230 
 
  
A 
B 
231 
 
 
 
 
 
 
 
Figure 5.10. Fractionation protocol successfully separates protein and RNA nuclear and 
cytosolic fractions. (A) Western blot showing protein expression of Lamin A/C (nuclear 
protein) and GAPDH (primarily cytosolic protein) from nuclear and cytosolic protein extracts 
(n=3). (B) Agarose gel showing PCR amplicons of pri-miR-27b (a nuclear RNA species) 
expression in nucleus, but not cytosolic RNA extracts (n=3). Total RNA from whole cell extracts 
was used as a positive control.    
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Figure 5.11. Nuclear/cytosolic fractionation indicated reduced cytoplasmic levels of pre-
miR-181c following knockdown of TDP-43 or cellular stress. Real-time PCR showing levels 
of nuclear and cytosolic pre-miRNA levels of either miR-27b or miR-181c following (A) 
knockdown of TDP-43, or (B) osmotic stress. Expression levels were normalized to an 
exogenous control (cel-miR-39b-5p) prior to comparison. Bar represents mean (n=3) fold-change 
(2^-∆∆CT) ± SEM. Significance was determined using a Student’s t-test (NSp>0.05, *p<0.05). 
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Figure 5.12. Knockdown of TDP-43 has no effect on the levels of proteins associated with 
the miRNA biogenesis pathway. (A) Western blots showing the protein expression of TDP-43, 
DROSHA, DCGR8, XPO5, DICER, AGO2, TRBP and GAPDH within HEK293T cells when 
either transfected with SCR (control) or siTDP #1. (B) Quantification of DROSHA, DCGR8, 
XPO5, DICER, AGO2 and TRBP protein levels when cells were either transfected with SCR or 
siTDP #1. Expression levels were normalized to GAPDH prior to comparison. Bar represents 
mean (n=3) ± SEM. Significance was determined using a Student’s t-test (NSp>0.05). 
  
236 
 
whether TDP-43 needs to bind directly to either pri- and/or pre-miRNAs, DROSHA and/or 
DICER complexes, or both to assist in the processing of these two miRNAs, and therefore, 
warrants further investigation. 
  While TDP-43 has been shown to regulate several different miRNAs in multiple cell 
lines, this is the first study, to our knowledge, that shows TDP-43 in a negative feedback network 
with miRNAs. Similar networks have been identified between other RNA-binding proteins and 
miRNAs, such as FUS and miR-141/200a, and hnRNPA1 and miR-18a (Dini Modigliani et al., 
2014; Fujiya et al., 2014; Guil and Caceres, 2007). These negative feedback networks are likely 
critical biological mechanisms that regulate homeostatic levels of RNA-binding proteins and 
miRNAs.  
Our data suggests that the regulation of miR-27b-3p and miR-181c-5p, and hence the 
negative feedback network, are dependent on the nuclear localization of TDP-43 providing 
relevance for several neurodegenerative diseases that show accumulation of TDP-43 in neuronal 
cytoplasmic inclusions including ALS, FTD and Alzheimer’s Disease (Amador-Ortiz et al., 
2007; Arai et al., 2006; Tan et al., 2007).  In some cases, TDP-43 has been known to form 
intranuclear inclusions in FTD-ALS, FTD and Alzheimer’s Disease (Amador-Ortiz et al., 2007; 
Neumann et al., 2006), and in this case, it still likely that TDP-43 cannot perform its function in 
the miRNA biogenesis pathway due to it being trapped in these inclusions. Thus, both the loss of 
nuclear localization and the formation of TDP-43 inclusions likely results in miRNA 
dysregulation. 
 Both miR-27b-3p and miR-181c-5p have been shown to be reduced in the spinal cord of 
patients with ALS (Campos-Melo et al., 2013). We show here that these miRNAs are expressed 
in motor neurons (Fig. 5.2), providing a correlation between TDP-43 cytoplasmic re-localization 
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and the dysregulation of these two miRNAs within ALS. MiR-181c-5p has been shown to be 
reduced within the anterior temporal cortex and parietal lobe cortex of patients with Alzheimer’s 
Disease, and in cultures of primary hippocampal neurons from Alzheimer mouse models, 
indicating that miR-181c-5p may be critical for overall central nervous system and neuronal 
function (Schonrock et al., 2012; Schonrock et al., 2010). Previous work has already shown that 
TDP-43 regulates the mature levels of miR-27b-3p and miR-181c-5p, and other members of the 
miR-181 family (miR-181a-d) in several cell lines (Chen et al., 2018; Di Carlo et al., 2013; 
Kawahara and Mieda-Sato, 2012). Thus, TDP-43 regulation on the biogenesis of miR-27b-3p 
and the miR-181a-d family likely represents a broad phenomenon rather than a cell-specific one. 
 Further, we showed that an induced cellular stress which causes reduced TDP-43 nuclear 
localization alters miRNA processing leading to a reduction in miR-27b-3p and miR-181c-5p, 
similar to what was seen after knockdown of TDP-43. This is a critical finding as cellular stress 
has been shown to drive TDP-43 from the nucleus to the cytoplasm in both in vitro and in vivo 
neuronal models (Khalfallah et al., 2018; McDonald et al., 2011; Moisse et al., 2009), indicating 
that cellular stress, while not the only effect, results in the reduction of nuclear TDP-43 levels to 
regulate miRNA biogenesis. This may be a major component to the pathogenesis of ALS where 
an extensive reduction in miRNA levels in spinal cord and motor neurons is observed (Campos-
Melo et al., 2013; Emde et al., 2015).  
In conclusion, we propose a biological mechanism by which under normal conditions 
TDP-43 is in a negative feedback network with miRNAs (i.e. miR-27b-3p and miR-181c-5p), 
and that this is perturbed during cell stress due to reduced TDP-43 nuclear localization. Thus, 
reduction of nuclear TDP-43 reduces miRNAs levels resulting in a de-repression of the TARDBP 
transcript, and ultimately, increased TDP-43 cytoplasmic levels. This biological mechanism 
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could have important implications for the pathogenesis of neurodegenerative diseases, such as 
ALS, where the reduction of miRNA levels coincides with the upregulation and mis-localization 
of TDP-43 (Campos-Melo et al., 2013; Emde et al., 2015; Koyama et al., 2016; Swarup et al., 
2011; Tan et al., 2007). Further, enhancement of miRNA processing at the level of DICER has 
been shown to improve motor function of rodent models who carry ALS-related mutations in 
TDP-43 (Emde et al., 2015). Since we and others have shown that TDP-43 affects miRNA 
processing at multiple levels within the miRNA biogenesis pathway (Kawahara and Mieda-Sato, 
2012), an enhancement of both the DROSHA and DICER complexes may be necessary to have 
the greatest impact to slow ALS disease progression.  
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Chapter 6 
 
 Discussion and Conclusion 
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6.1 Summary of Results  
 
 In this dissertation, I aimed to elucidate the potential consequences of reduced miRNA 
levels as seen in ALS, and to understand the mechanism by which miRNAs may become 
dysregulated in the first place. Data presented showed that reduced miRNA expression may 
contribute to both RNA-binding protein and intermediate filament pathogenesis as many ALS-
linked miRNAs regulate these two protein groups as shown within in vitro cell models. Further, I 
identified a novel negative feedback network between TDP-43 and miRNAs in HEK293T cells 
which may provide insight into how miRNA levels become reduced in ALS motor neurons.  
 Chapters 2-3 highlighted several ALS-associated miRNAs that may contribute to the loss 
of intermediate filament stoichiometry in ALS. Previous work had shown that ALS-associated 
miRNAs could contribute to the suppression of NEFL mRNA—a common phenomenon 
observed in motor neurons of patients with ALS (Bergeron et al., 1994; Campos-Melo et al., 
2013; Wong et al., 2000). However, in mature motor neurons there are 5 main intermediate 
filaments expressed (NFL, NFM, NFH, PRPH and INA), and it is the overall loss of 
stoichiometry between these 5 intermediate filaments that drives intermediate filament pathology 
(Szaro and Strong, 2010). Therefore, I sought to determine the ALS-linked miRNAs that are 
involved in regulating overall intermediate filament stoichiometry. I identified two miRNAs 
(miR-105-5p and miR-9-5p) that showed reduced expression in ALS, that are expressed in motor 
neurons and that regulate the mRNA levels of NEFL, PRPH and INA. MiR-105-5p enhanced the 
expression of NEFL and PRPH but suppressed INA expression while miR-9-5p suppressed the 
expression of all three intermediate filaments of interest in the human neuronal-derived cell line 
IMR-32 (Hawley et al., 2019).  
245 
 
In chapter 3, a series of motor neuron expressing miRNAs that are reduced in ALS were 
identified to suppress the levels of a reporter gene when interacting with the 3’UTR of either 
NEFM (miR-92a-3p and miR-125b-5p) or NEFH (miR-9-5p, miR-20b-5p, miR-92a-3p, miR-
223-3p) providing more examples of miRNAs responsible for regulating intermediate filament 
stoichiometry (Campos-Melo et al., 2018). All this suggests that several miRNAs are responsible 
for the tight regulation of intermediate filament stoichiometry, and loss of these miRNAs, as seen 
in ALS, could contribute to intermediate filament pathogenesis.    
 Chapter 4 focused on ALS-linked miRNAs that are responsible for the regulation of three 
RNA-binding proteins—TDP-43, FUS and RGNEF—that are known to co-aggregate together in 
ALS motor neurons (Keller et al., 2012). I identified miR-b2122 to be a central regulator of 
TDP-43, FUS and RGNEF expression in SH-SY5Y cells—a human neuronal-derived cell line—
and further, provided evidence that miR-194-5p may be responsible for TDP-43 and FUS gene 
silencing. Further, I described an ALS-associated mutation in the FUS 3’UTR that was located in 
the MRE of miR-b2122. This mutation disrupted the ability of miR-b2122 to bind to the 3’UTR 
of FUS to regulate gene expression, providing a genetic link between miRNA regulation and 
ALS (Hawley et al., 2017b). Since TDP-43 has been shown to be overexpressed in ALS spinal 
cord and motor neurons and FUS overexpression has been known to cause ALS-like phenotypes 
within in vitro and in vivo models, it is clear that the loss of homeostatic levels of these proteins 
contributes to the disease pathogenesis (Koyama et al., 2016; Mitchell et al., 2013; Sabatelli et 
al., 2013; Swarup et al., 2011). Thus, the loss of miR-194-5p and miR-b2122 in ALS motor 
neurons could be a major contributor to the disease progression.      
 Finally, in Chapter 5, a negative feedback loop between TDP-43 and two ALS-linked 
miRNAs (miR-27b-3p and miR-181c-5p) that is dependent on TDP-43 nuclear localization was 
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identified in HEK293T cells, thus providing a biological mechanism that may be disrupted in 
ALS (Hawley et al., 2020). While I looked at both TDP-43 and FUS, I did not identify a negative 
feedback loop between FUS and miRNAs. However, previous work has shown that FUS is in a 
negative feedback loop with two other ALS-linked miRNAs (miR-141-3p and miR-200a-3p; 
Dini Modigliani et al., 2014), indicating that this biological mechanism does exist for FUS. 
Further, TDP-43 regulated the expression of miR-27b-3p and miR-181c-5p at different levels in 
the miRNA biogenesis pathway, as reduced TDP-43 levels led to increased pri-miR-181c and 
reduced cytoplasmic pre-miR-181c, while lowering mature miR-27b-3p levels with no changes 
to either miR-27b primary or precursor levels. This suggested that TDP-43 regulates miRNAs at 
several levels in the biogenesis pathway, consistent with what has been seen previously 
(Kawahara and Mieda-Sato, 2012).   
 Overall, the data presented in this dissertation demonstrates that reduced miRNA levels 
in motor neurons of patients with ALS likely contributes to both intermediate filament and RNA-
binding protein pathogenesis in ALS. Further, I have provided a biological mechanism that 
provides evidence that loss of TDP-43 nuclear localization, as seen in ALS, may contribute to 
the reduction of miRNAs seen in ALS motor neurons.  
 
6.2 Implications 
 
6.2.1 MiRNA network that regulates intermediate filament stoichiometry 
 
 Proper intermediate filament stoichiometry is considered necessary for the formation and 
maintenance of cytoskeleton structures in neuronal cells (Szaro and Strong, 2010). Alterations to 
this stoichiometry have been associated with the formation of intermediate filament aggregates 
that are observed in ALS motor neurons (Beaulieu and Julien, 2003; Beaulieu et al., 1999; Kriz 
et al., 2000; Lee et al., 1994; Wong et al., 2000; Zhu et al., 1997). Previous work has indicated 
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two ALS-related RNA-binding proteins (TDP-43 and RGNEF) and miRNAs play essential roles 
in regulating the levels of NEFL mRNA (Campos-Melo et al., 2013; Volkening et al., 2010; 
Volkening et al., 2009). The work presented here identified 8 miRNAs, in addition to the five 
miRNAs previously shown to regulate NEFL (Campos-Melo et al., 2013; Ishtiaq et al., 2014), 
that are responsible for regulating the transcript levels of the five main intermediate filaments 
(NEFL, NEFM, NEFH, PRPH and INA) expressed in mature neurons (Campos-Melo et al., 2018; 
Hawley et al., 2019).     
Identification of these interactions between miRNAs and intermediate filaments 
highlights the complex network of trans-acting regulatory elements that are required to maintain 
the appropriate spatiotemporal stoichiometry of these proteins. This fact paired with the evidence 
that these miRNAs are reduced in ALS shows that a highly sophisticated regulatory network 
between miRNAs and intermediate filaments is likely to be disrupted in ALS, thus contributing 
to the formation of intermediate filament cytoplasmic aggregates. Beyond miRNAs, we know 
that RNA-binding proteins play an integral role in post-transcriptionally regulating neurofilament 
stoichiometry, including TDP-43, RGNEF, hnRNPK, ALDOA, ALDOC, HuB, 14-3-3 and 
hnRNPE1/E2 (Antic et al., 1999; Canete-Soler et al., 2005; Droppelmann et al., 2013; Ge et al., 
2007; Stefanizzi and Canete-Soler, 2007; Thyagarajan and Szaro, 2004, 2008; Volkening et al., 
2010; Volkening et al., 2009). Amongst these proteins, TDP-43, RGNEF and 14-3-3 have been 
associated with ALS pathology, indicating that the dysregulation of these proteins could also 
contribute to loss of intermediate filament stoichiometry (Keller et al., 2012). It is still unclear 
how miRNAs and RNA-binding proteins work together to finely regulate intermediate 
stoichiometry and how their co-dysregulation in ALS contributes to overall intermediate filament 
pathology.   
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Further, there is evidence that long non-coding RNAs (lncRNAs), small nucleolar RNAs 
(snoRNAs), and circular RNAs (circRNAs) are increasingly associated with ALS (Dolinar et al., 
2019; Errichelli et al., 2017; Nishimoto et al., 2013; Riva et al., 2016; Salvatori et al., 2020). This 
provides even further complexity, as miRNAs, lncRNAs, snoRNAs, circRNAs and RNA-binding 
proteins work together to tightly regulate gene expression both transcriptionally and post-
transcriptionally (Salvatori et al., 2020). While it is still unclear how lncRNAs, snoRNAs and 
circRNAs contribute to ALS pathogenesis, it will be interesting to determine if these non-coding 
RNA molecules play an essential role in regulating neuronal intermediate stoichiometry and how 
that may be affected in ALS.  However, the understanding of the role of ALS-linked miRNAs in 
neuronal intermediate filament post-transcriptional regulation has allowed us to develop a deeper 
knowledge of the potential pathogenesis of these proteins in ALS. This has provided a 
foundation to further explore these networks in neuron models to determine how these miRNAs 
work with RNA-binding proteins, and potentially other non-coding RNA species, to regulate 
neuronal intermediate filament stoichiometry, and how this system may be manipulated to 
prevent the loss of intermediate filament stoichiometry in ALS motor neurons (Wong et al., 
2000).   
 
6.2.2 Potential contributions of miRNAs in RNA-binding protein pathogenesis 
 
 An overwhelming amount of evidence has shown that the simple accumulation of LCD-
containing proteins, like the RNA-binding proteins observed in ALS, can cause them to phase 
separate into irreversible insoluble aggregates (Conicella et al., 2016; Kato et al., 2012; 
Murakami et al., 2015; Murray et al., 2017). Thus, several research groups have searched for 
ways to prevent the toxic cytoplasmic accumulation of these proteins as potential therapeutics 
(Barmada et al., 2010; Tamaki et al., 2018; Tradewell et al., 2012). The work presented in this 
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dissertation provides a unique perspective in the potential use of miRNAs as a therapeutic target 
to prevent the accumulation of these proteins into cytoplasmic aggregates.  
  The data provided in this dissertation indicates that reduced miRNA levels, as seen in 
ALS, could contribute to the overexpression, and potentially the formation of cytoplasmic 
aggregates by RNA-binding proteins. MiR-b2122 was identified to silence the mRNA expression 
of three RNA-binding proteins (TDP-43, FUS and RGNEF) that co-aggregate with each other in 
ALS motor neurons (Hawley et al., 2017b; Keller et al., 2012). Overexpression of TDP-43 and 
FUS have both been shown to result in the formation of cytoplasmic aggregates in both in vitro 
and in vivo models, and further, both have been shown to have increased levels in the spinal cord 
of ALS patients (Dini Modigliani et al., 2014; Hawley et al., 2017b; Koyama et al., 2016; 
Mitchell et al., 2013; Swarup et al., 2011; Xu et al., 2010). In our work, we had identified a 
relationship between reduced levels of miR-b2122 and increased levels of FUS in the spinal cord 
of sALS patients, and an ALS-associated genetic variant in the FUS mRNA 3’UTR that prevents 
miR-b2122 from binding to the FUS 3’UTR to regulate gene expression (Hawley et al., 2017b). 
All this put together, suggests miR-b2122 may be a potential therapeutic target to reduce the 
RNA-binding protein expression via gene silencing and prevent the aggregation of all three of 
these proteins.  
 
6.2.3 Identification of novel negative feedback network 
  
A novel negative feedback network between TDP-43 and miRNAs was identified 
providing further insight biological mechanisms that may be affected in ALS motor neurons. The 
identification of this network not only has major implications for our understanding ALS disease 
progression, but as well our understanding of basic biological networks.   
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 Negative feedback networks are classic self-regulating biological systems designed to 
maintain homeostasis (Tsang et al., 2007). Since miRNAs have been described as the “master 
regulators”, it is not surprising that miRNAs are involved in several negative and positive 
feedback networks. Further, in a panel of over 70 pre-miRNA baits, researchers were able to 
pulldown over 180 RNA-binding proteins that preferentially bound to specific miRNA groups 
which demonstrated the vast network of RNA-binding proteins that participate in the biogenesis 
of a small subset of miRNAs (Treiber et al., 2017). Several RNA-binding proteins have been 
shown to be in negative, positive and double negative feedback networks with miRNAs 
indicating the importance of these two groups to work together to maintain homeostasis (Tsang 
et al., 2007).  
 Under physiological stress conditions, several RNA-binding proteins leave the nucleus 
and enter the cytoplasm to form stress granule structures, including TDP-43 (Protter and Parker, 
2016). Further, cellular stress has generally shown to cause a reduction in miRNA processing 
(Emde et al., 2015), as I showed with miR-27b-3p and miR-181c-5p. Therefore, one hypothesis 
may be that reduced miRNA processing during stress allows for de-repression of RNA-binding 
proteins needed for stress granule formation, but overaccumulation of LCD-containing RNA-
binding proteins—which are prone to aggregate—either through chronic or repeated stresses 
may induce the formation of insoluble cytoplasmic aggregates. Thus, while reduced miRNA 
processing may be beneficial for a rapid stress response, repeated or chronic stresses increase the 
risk of developing cytoplasmic aggregates that are toxic to the cell. 
 The identification of a negative feedback network between TDP-43 and miRNAs is the 
second negative feedback network that has been identified between ALS-related miRNAs and 
RNA-binding proteins. The first was identified between FUS and two miRNAs—miR-141/200a-
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3p (Dini Modigliani et al., 2014). Beyond TDP-43 and FUS, other ALS-related RNA-binding 
proteins have been implicated in the miRNA biogenesis pathway including TAF15, EWSR1, 
hnRNPA1, hnRNPA2B1, MATR3, TIA-1 and ATXN2 (Alarcon et al., 2015; Ballarino et al., 
2013; Guil and Caceres, 2007; Kapeli et al., 2016; Kooshapur et al., 2018; Ouyang et al., 2017; 
Sanchez-Jimenez et al., 2013; Weiss et al., 2019). Therefore, several regulatory networks 
between miRNAs and RNA-binding proteins may be disrupted in ALS. Identification of these 
regulatory networks, how they are disrupted in ALS, there contribution to ALS pathogenesis, and 
how to restore these networks will assist in our understanding of ALS development and potential 
therapeutic targets.  
 Further, TDP-43 forms cytoplasmic aggregates in 97% of all cases regardless of genetic 
background (Ling et al., 2013). Therefore, identification for pathways that may explain the 
accumulation of TDP-43 in the cytoplasm has become critical. Loss of a negative feedback 
between TDP-43 and miRNA due to loss of nuclear localization, as shown in Chapter 5, may 
contribute to the formation of TDP-43 cytoplasmic aggregates in ALS. Therefore, if we are able 
to identify this negative feedback loop in motor neuron models, and further, show it is disrupted 
in ALS motor neuron models, it will be necessary to target this pathway to see if we can restore 
homeostatic levels of miR-27b-3p and miR-181c-5p to lower levels of TDP-43 to hopefully 
alleviate ALS-like phenotypes.      
6.2.4 Development of therapeutics targeting miRNA pathways 
 
 In this dissertation, I have identified 10 ALS-linked miRNAs that could contribute to 
intermediate filament and RNA-binding protein pathogenesis. This is likely an 
underrepresentation of the total amount of miRNAs that are involved in in the disease 
pathogenesis. This data highlights that there is not a single miRNA that will ameliorate the 
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dysfunctional physiology observed in ALS motor neurons, but rather a whole host of miRNAs, 
each individually contributing to the disease process. This is critical to understand if we are 
going to develop therapeutics that target miRNA pathways.  
 Targeting individual miRNAs in ALS likely will have minimal effects in terms of a 
therapeutic. Rather we need to focus on developing drugs that are able to reboot the miRNA 
biogenesis pathway. In chapter 5 of this thesis, I showed that reduced nuclear TDP-43, as seen in 
97% of all ALS cases, can inhibit efficient processing of miRNAs at multiple levels in the 
biogenesis pathway. Thus, rather than targeting specific miRNAs, developing therapeutics that 
increase the efficiency of DROSHA and DICER to process pri- and pre-miRNAs, respectively, 
may be a better approach. Enoxacin is a drug that can enhance miRNA biogenesis by interacting 
with TRBP to enhance DICER pre-miRNA processing (Shan et al., 2008). In ALS transgenic 
mouse models containing ALS-causing mutations in either SOD1 or TDP-43, enoxacin has been 
proven to delay motor deficiencies that are developed in these models, thus providing some 
evidence that enhancement of the miRNA biogenesis pathway could be an effective therapeutic 
approach (Emde et al., 2015). However, many of the RNA-binding proteins that are involved in 
ALS also interact with DROSHA to promote miRNA biogenesis. Thus, a better therapeutic may 
be one that improves the efficiency of both DROSHA and DICER processing.   
 Two acetylase inhibitors—trichostatin A and nicotinamide—have been shown to increase 
levels of DROSHA and enhance miRNA processing (Tang et al., 2013). In particular, 
nicotinamide is derivative form of vitamin B3 which has been implicated as potential therapeutic 
for several neurodegenerative diseases, including ALS (Fricker et al., 2018; Naia et al., 2017; 
Schondorf et al., 2018; Xie et al., 2019; Zhou et al., 2020). Nicotinamide is a critical metabolite 
involved in converting NADH to NAD+, an important process for the production of ATP 
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(Poddar et al., 2019). Low levels of NAD+ has been seen in animal models of Alzheimer’s 
Disease, Parkinson’s Disease, Huntingtion’s Disease and ALS, suggesting that oxidation of 
NADH may be a deficient process in neurodegeneration (Fricker et al., 2018; Zhou et al., 2020). 
Further, nicotinamide has been shown to prevent DNA damage, apoptosis, maintain cell 
membrane structure and reduce oxidative stress, all of which has been associated with several 
neurodegenerative diseases (Surjana et al., 2010; Turunc Bayrakdar et al., 2014). Recent work in 
ALS SOD1 mouse models has shown that nicotinamide may be a potential for therapeutic for 
ALS patients who contain SOD1 mutations (Zhou et al., 2020). Therefore, while nicotinamide is 
already being considered for an ALS therapeutic, understanding whether these beneficial affects 
occur in part by restoring miRNA homeostasis will be essential to understand its therapeutic 
effect and whether it can be used for non-mtSOD1 ALS patients.      
 While further work in iPSC-derived motor neuronal cell lines and in vivo models still 
need to be done, restoring miRNA production may be a potential therapeutic avenue by 
combining nicotinamide and enoxacin to increase both DROSHA and DICER activity, 
respectively, and in turn, overall miRNA processing. 
 
6.3 Caveats 
 
 The data presented in this dissertation has identified critical ALS-linked miRNAs 
responsible for regulating intermediate filaments and RNA-binding proteins related to the 
disease, and a negative feedback network, that if lost, may contribute to driving the disease 
pathogenesis. Despite the significance of this work in developing our understanding of the 
biological networks that connect ALS-associated miRNAs, intermediate filaments and RNA-
binding proteins, there are some caveats that should be taken into consideration.  
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 First, the cell models in which these interactions were characterized limit our ability to 
determine how significant these interactions are to ALS. As previously mentioned, miRNA 
expression, regulation and function can be highly dependent on cell type, cell environment, and 
altered cell physiology (Berezikov, 2011; Hawley et al., 2017a). Therefore, if we really want to 
understand these networks of miRNAs that are associated with ALS, we need to study these 
interactions in motor neuron models. Research using human iPSC-derived motor neuron models 
has proven to be effective in understanding specific aspects of motor neuron biology that would 
otherwise be missed if looking in other cell models. For example, the regulation of TDP-43 on 
STMN2 expression and its significance to ALS was discovered only because researchers used 
human iPSC-derived motor neuron models. This would have not been identified looking in other 
non-neuronal models, as STMN2 has neuronal specific expression, and further, the addition of 
the cryptic exon, as seen in STMN2 when TDP-43 expression is suppressed, is a human specific 
affect (Klim et al., 2019; Melamed et al., 2019). All this indicates using the appropriate models 
are important when discussing disease. A major experiment in our work was the FISH analyses 
to ensure that the miRNAs we were studying in our models were also expressed in motor 
neurons, and hence, provide an increased likelihood that the biological pathways identified in our 
models also exist in motor neurons. However, while our models allowed us to find several 
pathways that are likely related to the disease, we need to move into more complex models, and 
start understanding the specific relationship between miRNAs, intermediate filaments and RNA-
binding proteins within motor neurons. 
 Second, while we have shown several miRNAs that likely contribute to the pathology of 
the disease, at this point we have no data to support that loss of miRNA expression can induce 
the formation of cytoplasmic aggregates similar to those seen in ALS motor neurons. Mutations 
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in the 3’UTR of FUS that disrupt miRNA binding and gene silencing can induce cytoplasmic 
aggregates of FUS protein (Dini Modigliani et al., 2014; Morlando et al., 2012). However, it is 
still unclear whether the resulting pathology from those mutations is caused from loss of miRNA 
regulation or other factors. Further, while several lines of work have shown loss of intermediate 
filament stoichiometry induces the formation of intermediate filament aggregates (Robertson et 
al., 2002), does loss of miRNA regulators that alter the stoichiometry enough to induce 
intermediate filament pathology is still in question. 
 Finally, our assays where miRNA expression was either overexpressed or inhibited could 
have technical experimental issues. This is because when you transfect a miRNA mimic, the 
amount of miRNA that is present within the cellular system could easily out compete other 
trans-acting molecules that would normally regulate your gene of interest, even if your miRNA 
candidate does not regulate it normally. Further, ablating miRNA function in a cell via an 
inhibitor does not necessarily represent the changes seen in ALS spinal cord where we generally 
see reduced levels and not complete loss of the miRNA. Thus, we need to determine the 
threshold in which the change of expression in our miRNA candidates results in a change in the 
expression of our genes of interest, and determine if that is representative of what is seen in ALS 
spinal cord and motor neurons.  
Studying how reduced expression of specific ALS-related miRNAs using in vitro and in 
vivo motor neuron models will be necessary to understand the contribution of miRNAs to disease 
pathology and whether loss of miRNA regulation alone can drive ALS-like proteinopathies and 
motor neuron death. These are critical caveats to consider when interpreting the data, and further 
experiments will need to be done in motor neuron models to more accurately understand 
MotomiR biology and how loss of these miRNAs may contribute to the pathology of the disease.     
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6.4 Future Directions 
 
 As mentioned in the previous section, a major future direction for this work is to 
determine whether the loss of miRNA function can induce intermediate filament and/or RNA-
binding protein ALS-like proteinopathies. For example, does reduction or loss of miR-105-5p or 
miR-9-5p—two miRNAs know to regulate NEFL, PRPH and INA mRNA expression—result in 
intermediate filament aggregation? Does loss of miR-b2122 lead to cytoplasmic aggregates of 
TDP-43, FUS and RGNEF? The answer to these questions will be necessary to understand the 
contribution these miRNAs have in the progression of the disease. Some evidence has shown 
that knocking out Dicer in mouse motor neurons can recapitulate loss of intermediate filament 
stoichiometry and induce motor neuron death (Haramati et al., 2010). However, knockout of 
Dicer would cause a global downregulation of miRNAs in motor neurons and does not provide 
any information on specific miRNAs. Therefore, further analyzing the miRNAs identified in this 
dissertation and whether loss of these miRNAs via knockdown or knockout models could 
contribute to both intermediate filament and RNA-binding protein dysregulation, ALS-like 
pathologies and motor neuron death will help us to understand their contribution to disease 
pathogenesis.  
 Another important factor to consider is that miRNAs are promiscuous molecules where 
one miRNA can have many targets, as seen in the work presented in this dissertation. While I 
focused on the affect miRNA candidates would have on RNA-binding proteins and intermediate 
filaments, there could be other pathways affected due to the loss of the miRNAs I studied. For 
example, miR-105-5p and miR-9-5p, two miRNAs shown to regulate intermediate filament 
expression in this dissertation (Hawley et al., 2019), have also been shown to suppress the 
expression of several cell-cycle genes to promote cell-cycle arrest (Zhang et al., 2017; Zhang et 
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al., 2019). One theory in ALS is that many of these cell-cycle genes that are normally suppressed 
in post-mitotic motor neurons are activated in ALS motor neurons, putting cells in a S phase 
rather than a G0 phase (Ranganathan and Bowser, 2003; Ranganathan and Bowser, 2010; Sharma 
et al., 2017). The re-entry of post-mitotic neurons into the cell-cycle has been shown to lead to 
activation of apoptotic pathways and subsequent neuron death (Sharma et al., 2017). Thus, 
reduced levels of miR-105-5p and miR-9-5p, as seen in ALS, may contribute to the re-entry of 
ALS motor neurons into the cell-cycle, triggering apoptotic pathways, rather than disrupting 
intermediate filament stoichiometry, or the loss of these miRNAs could be contributing to both. 
Moving forward it will be necessary to determine all the pathways in which these miRNAs are 
contributing to in motor neurons to understand the full impact of the loss of these miRNAs in 
ALS.  
 In chapters 2 and 4, miRNAs that were predicted to regulate all our intermediate 
filaments or RNA-binding proteins of interest but were previously shown to have no change in 
expression in ALS spinal cord were not considered for our study (Fig. 2.1 & 4.1). This does not 
mean these miRNAs are not important. This is because if they are unchanged, they may become 
the dominant regulators of our genes of interest when the other miRNAs are reduced. Therefore, 
it will be crucial to not only determine how miRNAs that have altered levels in ALS affect the 
expression of our genes of interest, but as well as those miRNAs that are unchanging in ALS 
spinal cord and motor neurons.   
 Genetic association studies focusing on miRNA encoding regions could have a massive 
impact on our understanding of the relevance of miRNAs in ALS pathogenesis. As previously 
mentioned, mutations within the FUS 3’UTR located in two MREs—miR-141/200a-3p and miR-
b2122—cause overexpression and cytoplasmic aggregates of FUS protein, like the pathology 
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seen in ALS motor neurons (Dini Modigliani et al., 2014; Hawley et al., 2017b; Morlando et al., 
2012). This gives us an indication that loss of miRNA regulation on critical genes could 
contribute to the disease pathogenesis, giving significance to the mass downregulation of 
miRNAs seen in the spinal motor neurons of ALS patient groups. More recently, several rare 
mutations were identified in the miR-218 gene of patients with ALS (Reichenstein et al., 2019). 
These are the first genetic variants to date that have been identified in miRNA regions of the 
genome that are associated with ALS. Mutations in miR-218 reduced its processing by DICER, 
and further, less of this miRNA led to reduce motor neuron activity (Reichenstein et al., 2019). 
More genetic studies like these could identify miRNAs critical to motor neuron function and 
disease, better enabling us to find therapeutic targets. Historically, genetic studies have focused 
on coding regions of the genome with little work done outside those regions. However, now 
knowing non-coding regions of the genome contain critical genetic information to regulate cell 
physiology, expanding our efforts to look at miRNA genetic material may further drive our 
understanding of miRNAs role in disease pathogenesis and which miRNAs are the most critical 
to disease development.        
6.5 Conclusion 
 The research presented in this dissertation provided a foundational understanding of the 
potential consequence and cause of miRNA dysregulation in ALS. With the use of in vitro 
models, several miRNAs were identified to be critical for the regulation of RNA-binding protein 
expression and intermediate filament stoichiometry, and thus, loss of these miRNAs, as seen in 
ALS, may contribute to the pathogenesis of these two protein groups (Fig. 6.1). Finally, a novel 
negative feedback network between TDP-43 and miRNAs was identified in HEK293T cell 
models which could have major implications in our understanding of not only ALS development, 
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but other neurodegenerative diseases that have TDP-43 proteinopathies. Knowing that reduced 
miRNAs may play a major role in ALS pathogenesis, it is now time to move forward into in 
vitro and in vivo motor neuron models, which is a critical step if we are to develop potential 
therapeutics that target these miRNA regulatory networks.        
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Figure 6.1. Hypothesis of miRNA contribution to ALS pathogenesis. (A) Healthy motor 
neuron. TDP-43 contributes to miRNA biogenesis by assisting in pri- and pre-miRNA 
processing with DROSHA and DICER complexes, respectively. Further, we provided evidence 
that TDP-43 potentially assists in pre-miRNA export. FUS also assists in pri-miRNA processing. 
Certain miRNAs, as identified in this thesis, target RNA-binding protein transcripts to suppress 
and limit their expression. We showed this creates a negative feedback loop between TDP-43 
and miR-27b-3p/miR-181c-5p and suggests that these regulatory networks are essential in 
maintaining homeostatic levels of RNA-binding proteins and miRNAs. Further, we showed that 
certain ALS-linked miRNAs target neuronal intermediate filament transcripts to promote or 
suppress their expression, which is essential in maintaining stochiometric levels of intermediate 
filament proteins (NFL [L], NFM [M], NFH [H], PRPH [P], or INA [A]) . This allows for proper 
cytoskeleton formation, which is necessary to maintain axonal integrity, and in turn, overall 
neuronal transport and function. (B) Diseased motor neuron. Due to the loss of TDP-43 and FUS 
nuclear (purple) localization and their formation into cytoplasmic (yellow) inclusions, reduced 
miRNA processing is observed. Lower miRNA levels result in de-repression of ALS-linked 
RNA-binding proteins such as TDP-43, FUS and RGNEF. This rise in production of RNA-
binding proteins results in increased formation of toxic cytoplasmic inclusions through phase 
separation. Further, lower miRNA levels will cause loss of intermediate filament stoichiometry 
due to either degradation or overexpression of intermediate filament transcripts. This results in 
intermediate filament cytoplasmic inclusions and loss of cytoskeleton formation, and 
subsequentially, loss of axonal integrity. Overall, I hypothesize that reduced miRNAs levels, as 
seen in ALS, results in the increased formation of toxic cytoplasmic inclusions and a loss of 
proper cytoskeleton formation leading to motor neuron death.      
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Appendix A 
 
Tables indicating significant changes to small RNA expression following TDP-43 or FUS 
knockdown in HEK293T cells  
 
 
Data was collected using a microarray (GeneChip miRNA 4.0 Array) and analyzed using the 
Transcriptome Analysis Console. See Methods & Materials in Chapter 5 for further details. 
 
Table A.1. Small RNAs significantly altered following TDP-43 Knockdown. 
270 
 
ID Transcript ID(Array 
Design) 
P-val Fold Change siTDP Avg (log2) SCR Avg (log2) FDR P-
val 
Chromosome 
20518879 hsa-miR-4485 0.000000134 3.74 8.81 6.9 0.0009 chr11 
20524036 hsa-miR-6126 0.0000171 1.92 8.24 7.29 0.0531 chr16 
20525395 hsa-miR-6723-5p 0.000024 4.26 5.97 3.88 0.0531 chr1 
20518834 hsa-miR-4454 0.0000491 -3.55 6.53 8.36 0.0795 chr4 
20535460 hsa-mir-1298 0.0000697 -1.4 1.58 2.07 0.0795 chrX 
20528733 hsa-miR-7704 0.000072 1.77 9.78 8.96 0.0795 chr2 
20534812 hsa-mir-29c 0.0001 1.42 1.88 1.37 0.1139 chr1 
20537518 hsa-mir-6775 0.0001 -2.69 1.4 2.83 0.107 chr16 
20509224 hsa-miR-1908-5p 0.0002 1.64 6.74 6.03 0.1518 chr11 
20518933 hsa-miR-4532 0.0004 1.98 7.02 6.04 0.2686 chr20 
20536775 hsa-mir-4500 0.0004 -1.84 1.21 2.09 0.2627 chr13 
20518892 hsa-miR-4497 0.0005 1.52 9.21 8.61 0.2724 chr12 
20532932 ENSG00000202449 0.0005 1.43 1.33 0.81 0.2724 chr4 
20504413 hsa-miR-663a 0.0006 1.84 6.84 5.96 0.2741 chr20 
20518431 hsa-miR-3910 0.0006 1.66 1.72 0.99 0.2741 chr9 
20504433 hsa-miR-421 0.0007 -1.73 5.99 6.78 0.2805 chrX 
20517942 hsa-miR-3682-5p 0.0007 1.59 1.66 0.99 0.2805 chr2 
20533897 ENSG00000252190 0.0008 1.5 1.89 1.31 0.2995 chr1 
20536814 hsa-mir-4534 0.001 1.39 1.82 1.35 0.3166 chr22 
20536889 hsa-mir-4664 0.001 -1.58 1.4 2.06 0.3166 chr8 
20537456 hsa-mir-6715b 0.001 1.43 2.23 1.72 0.3166 chr10 
20504408 hsa-miR-652-3p 0.0011 -1.35 6.84 7.27 0.3166 chrX 
20507742 hsa-miR-1469 0.0011 1.63 7.05 6.34 0.3166 chr15 
20501197 hsa-miR-361-5p 0.0012 -1.47 8.8 9.36 0.3166 chrX 
20538223 U68 0.0012 1.24 6.54 6.24 0.3166 chr19 
20538181 U43 0.0015 1.29 10.23 9.87 0.3694 chr22 
20536568 hsa-mir-3664 0.0016 1.63 1.75 1.05 0.3694 chr11 
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ID Transcript ID(Array 
Design) 
P-val Fold Change siTDP Avg (log2) SCR Avg (log2) FDR P-
val 
Chromosome 
20537538 hsa-mir-6795 0.0016 1.59 1.78 1.11 0.3694 chr19 
20525526 hsa-miR-6782-3p 0.0017 -1.42 1.21 1.71 0.3779 chr17 
20533168 ENSG00000221633 0.0019 1.63 1.91 1.21 0.4082 chr3 
20533189 ENSG00000223027 0.0019 -1.5 1.23 1.82 0.4082 chr10 
20518816 hsa-miR-4441 0.0021 -1.3 1.08 1.46 0.4174 chr2 
20533677 ENSG00000239033 0.0021 -1.32 0.91 1.31 0.4174 chr12 
20534818 hsa-mir-219a-2 0.0021 -1.45 1.35 1.89 0.4174 chr9 
20500170 hsa-miR-92a-1-5p 0.0023 2.69 3.1 1.67 0.4247 chr13 
20536757 hsa-mir-4485 0.0023 1.4 3.54 3.05 0.4247 chr11 
20538180 U43 0.0028 1.2 10.63 10.37 0.5084 chr22 
20536760 hsa-mir-4487 0.0029 1.74 2.08 1.28 0.5135 chr11 
20500489 hsa-miR-224-5p 0.0036 1.39 1.57 1.09 0.5519 chrX 
20515595 hsa-miR-3170 0.0036 -1.29 1.08 1.45 0.5519 chr13 
20500742 hsa-miR-137 0.0037 1.3 1.08 0.7 0.5519 chr1 
20518878 hsa-miR-4484 0.0039 1.42 8.13 7.63 0.5519 chr10 
20533980 ENSG00000252526 0.0039 -1.38 1.34 1.81 0.5519 chr16 
20538048 hsa-mir-8088 0.0039 -1.45 1.33 1.87 0.5519 chrX 
20525416 hsa-miR-6727-5p 0.004 1.38 7.92 7.45 0.5519 chr1 
20519441 hsa-miR-4656 0.0041 2.37 3.53 2.29 0.5519 chr7 
20515551 hsa-miR-3142 0.0042 1.23 1.35 1.05 0.5519 chr5 
20500137 hsa-miR-19b-3p 0.0044 -5.02 3.6 5.93 0.5519 chr13 
20525554 hsa-miR-6796-3p 0.0045 1.5 2.08 1.49 0.5519 chr19 
20500721 hsa-miR-23b-3p 0.0046 -1.13 9.32 9.49 0.5519 chr9 
20504552 hsa-miR-671-5p 0.0047 -1.44 5.07 5.59 0.5519 chr7 
20500148 hsa-miR-24-3p 0.0048 -1.51 7.33 7.92 0.5519 chr19 
20500465 hsa-miR-210-3p 0.0048 -2.36 3.71 4.95 0.5519 chr11 
20536929 hsa-mir-4698 0.0048 2.08 2.53 1.48 0.5519 chr12 
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ID Transcript ID(Array 
Design) 
P-val Fold Change siTDP Avg (log2) SCR Avg (log2) FDR P-
val 
Chromosome 
20506005 hsa-miR-936 0.005 -1.53 1.33 1.94 0.5519 chr10 
20519570 hsa-miR-4728-5p 0.005 2.38 4.65 3.4 0.5519 chr17 
20525633 hsa-miR-6780b-5p 0.005 1.79 6.13 5.29 0.5519 chr6 
20534879 hsa-mir-151a 0.005 -1.75 1.47 2.27 0.5519 chr8 
20536902 hsa-mir-4676 0.005 1.38 1.93 1.47 0.5519 chr10 
20504342 hsa-miR-602 0.0051 -1.6 2.03 2.7 0.5519 chr9 
20525668 hsa-miR-6853-3p 0.0051 1.39 1.63 1.15 0.5519 chr9 
20533715 ENSG00000239084 0.0053 1.36 1.42 0.98 0.5674 chr5 
20506878 hsa-miR-548p 0.0054 1.47 1.58 1.02 0.5674 chr5 
20501293 hsa-miR-331-3p 0.0057 -2.17 3.74 4.86 0.5674 chr12 
20536769 hsa-mir-4495 0.0057 1.24 1.5 1.19 0.5674 chr12 
20523019 hsa-miR-6087 0.0058 1.37 10.47 10.02 0.5674 chrX 
20532926 ENSG00000202374 0.0059 -1.59 1.44 2.1 0.5674 chr4 
20536497 hsa-mir-4277 0.0059 -1.71 1.85 2.63 0.5674 chr5 
20536870 hsa-mir-4650-1 0.006 1.34 1.65 1.23 0.5674 chr7 
20536871 hsa-mir-4650-2 0.006 1.34 1.65 1.23 0.5674 chr7 
20533228 ENSG00000238339 0.0065 1.31 1.98 1.59 0.6054 chr2 
20532651 ACA32 0.0066 1.63 2.66 1.95 0.6104 chr11 
20505608 hsa-miR-675-5p 0.0069 1.51 2.05 1.46 0.6264 chr11 
20533161 ENSG00000221398 0.007 -1.58 1.39 2.05 0.6264 chr21 
20525421 hsa-miR-6729-3p 0.0072 1.32 1.4 1 0.6264 chr1 
20532748 ENSG00000199666 0.0072 -1.48 1.24 1.8 0.6264 chr1 
20515591 hsa-miR-1260b 0.0073 -2.96 3.74 5.31 0.6264 chr11 
20501280 hsa-miR-342-3p 0.0075 -1.18 8.62 8.86 0.6379 chr14 
20536560 hsa-mir-3656 0.008 -2.07 1.66 2.71 0.6726 chr11 
20533973 ENSG00000252495 0.0083 1.25 1.64 1.31 0.6775 chr1 
20537204 hsa-mir-5692c-2 0.0083 1.43 1.79 1.27 0.6775 chr7 
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ID Transcript ID(Array 
Design) 
P-val Fold Change siTDP Avg (log2) SCR Avg (log2) FDR P-
val 
Chromosome 
20536728 hsa-mir-4468 0.0084 -1.5 1.34 1.92 0.6775 chr7 
20500448 hsa-miR-181c-5p 0.0091 -1.46 1.42 1.97 0.7253 chr19 
20500456 hsa-miR-196a-3p 0.0094 -1.52 1.56 2.16 0.7344 chr12 
20522039 hsa-miR-5703 0.0094 -1.88 1.22 2.13 0.7344 chr2 
20506898 hsa-miR-1306-5p 0.0097 -1.55 1.21 1.85 0.7474 chr22 
20537467 hsa-mir-892c 0.0099 1.86 2.22 1.33 0.7528 chrX 
20500191 hsa-miR-103a-3p 0.0102 -1.31 10.45 10.83 0.7542 chr20 
20533078 ENSG00000212391 0.0102 1.41 2.2 1.7 0.7542 chr2 
20533463 ENSG00000238696 0.0103 1.24 1.36 1.05 0.7542 chr2 
20533676 ENSG00000239033 0.0105 -1.26 0.94 1.28 0.7542 chr12 
20536313 hsa-mir-3194 0.0105 -1.33 1.39 1.8 0.7542 chr20 
20504582 hsa-miR-766-5p 0.0106 -1.75 1.6 2.4 0.7576 chrX 
20534302 HBII-85-11 0.0111 1.2 1.58 1.32 0.7791 chr15 
20500791 hsa-miR-188-5p 0.0112 -2.19 1.71 2.85 0.7791 chrX 
20512262 hsa-miR-2277-3p 0.0113 1.76 2.42 1.61 0.7791 chr5 
20504583 hsa-miR-766-3p 0.0116 -1.41 3.5 4 0.7791 chrX 
20537158 hsa-mir-5583-2 0.0116 -1.38 1.43 1.89 0.7791 chr18 
20534534 hsa-mir-217 0.0118 1.27 1.59 1.25 0.7791 chr2 
20533843 ENSG00000251974 0.012 1.15 1.07 0.87 0.7791 chr2 
20500194 hsa-miR-106a-5p 0.0121 -1.67 10.35 11.09 0.7791 chrX 
20501176 hsa-miR-99b-5p 0.0122 -1.26 7.57 7.9 0.7791 chr19 
20501312 hsa-miR-345-5p 0.0122 -1.88 4.28 5.18 0.7791 chr14 
20534858 hsa-mir-380 0.0122 -1.37 1.33 1.78 0.7791 chr14 
20537157 hsa-mir-5583-2 0.0128 -1.36 1.44 1.89 0.7791 chr18 
20505746 hsa-miR-874-3p 0.0129 -1.95 2.62 3.59 0.7791 chr5 
20518627 hsa-miR-548y 0.0131 -1.28 0.98 1.34 0.7791 chr14 
20500144 hsa-miR-22-3p 0.0132 -2.31 1.68 2.89 0.7791 chr17 
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20518852 hsa-miR-4467 0.0133 1.51 4.79 4.2 0.7791 chr7 
20500196 hsa-miR-107 0.0136 -1.26 10.08 10.42 0.7791 chr10 
20517834 hsa-miR-3620-3p 0.0136 1.65 3.04 2.32 0.7791 chr1 
20519670 hsa-miR-4783-3p 0.0137 -1.61 1.32 2.01 0.7791 chr2 
20515607 hsa-miR-3178 0.0138 1.37 7.99 7.53 0.7791 chr16 
20534830 hsa-mir-361 0.0138 -1.22 7.2 7.5 0.7791 chrX 
20535688 hsa-mir-937 0.014 -1.61 1.57 2.26 0.7791 chr8 
20538244 U73a 0.0141 1.39 8.76 8.29 0.7791 chr4 
20500419 hsa-miR-129-1-3p 0.0142 1.36 1.31 0.87 0.7791 chr7 
20504310 hsa-miR-582-3p 0.0142 -1.17 1.09 1.32 0.7791 chr5 
20534042 ENSG00000252787 0.0142 -1.31 1.69 2.08 0.7791 chr3 
20500162 hsa-miR-30a-5p 0.0143 -2.17 1.99 3.11 0.7791 chr6 
20504374 hsa-miR-626 0.0143 -1.44 0.79 1.31 0.7791 chr15 
20535102 hsa-mir-450a-1 0.0143 1.58 1.54 0.89 0.7791 chrX 
20500454 hsa-miR-187-5p 0.0145 -1.46 2.03 2.57 0.7803 chr18 
20525731 hsa-miR-6885-5p 0.0146 -2.28 1.68 2.87 0.7803 chr19 
20534315 HBII-85-22 0.0149 -1.28 1.13 1.49 0.7857 chr15 
20533699 ENSG00000239063 0.0153 -1.24 1.08 1.39 0.7857 chr1 
20500182 hsa-miR-99a-3p 0.0154 1.36 1.52 1.08 0.7857 chr21 
20522031 hsa-miR-5696 0.0154 -1.5 1.12 1.7 0.7857 chr2 
20506886 hsa-miR-1288-3p 0.0156 -1.81 1.3 2.15 0.7857 chr17 
20537429 hsa-mir-548ay 0.0157 -1.34 1.2 1.62 0.7857 chr3 
20525479 hsa-miR-6759-5p 0.0158 -1.24 1.24 1.56 0.7857 chr12 
20503808 hsa-miR-193b-3p 0.016 -1.48 7.5 8.07 0.7857 chr16 
20533957 ENSG00000252433 0.0163 1.16 1.18 0.96 0.7857 chr1 
20529782 hsa-miR-8072 0.0165 1.47 7.11 6.56 0.7857 chr12 
20533570 ENSG00000238863 0.0165 1.21 1.16 0.88 0.7857 chr18 
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20519468 hsa-miR-4670-5p 0.0168 1.22 1.75 1.46 0.7857 chr9 
20535131 hsa-mir-376b 0.0168 -1.61 0.85 1.54 0.7857 chr14 
20536884 hsa-mir-4662a 0.0168 1.46 1.66 1.12 0.7857 chr8 
20519591 hsa-miR-4740-3p 0.0169 -1.92 1.55 2.49 0.7857 chr17 
20535101 hsa-mir-450a-1 0.0169 1.21 1.18 0.91 0.7857 chrX 
20535879 hsa-mir-1263 0.017 -1.78 2.08 2.91 0.7857 chr3 
20532658 ACA35 0.0172 -1.23 1.38 1.68 0.7857 chr1 
20500723 hsa-miR-27b-3p 0.0173 -2 4.11 5.12 0.7857 chr9 
20532645 ACA2b 0.0174 1.43 1.31 0.79 0.7857 chr12 
20534091 ENSG00000253013 0.0175 -1.45 1.78 2.31 0.7857 chr4 
20537086 hsa-mir-5094 0.0176 1.47 2.5 1.94 0.7857 chr15 
20533733 ENSG00000239123 0.0177 -1.45 1.57 2.11 0.7857 chr7 
20506844 hsa-miR-1251-5p 0.0178 1.37 1.52 1.07 0.7857 chr12 
20519459 hsa-miR-4666a-5p 0.0178 -1.21 1.56 1.83 0.7857 chr1 
20534234 HBII-240 0.0178 1.28 1.31 0.96 0.7857 chr5 
20533793 ENSG00000251775 0.018 1.19 1.53 1.27 0.7863 chr2 
20536614 hsa-mir-3915 0.0182 -1.25 1.09 1.41 0.7863 chrX 
20501772 hsa-miR-196b-3p 0.0183 -2.06 2.98 4.02 0.7863 chr7 
20535671 hsa-mir-873 0.0183 1.53 1.65 1.04 0.7863 chr9 
20522537 hsa-miR-5787 0.0184 1.38 7.77 7.3 0.7863 chr3 
20518782 hsa-miR-1268b 0.0186 1.44 5.82 5.3 0.7921 chr17 
20533113 ENSG00000212558 0.0189 1.57 1.86 1.21 0.7967 chr2 
20500163 hsa-miR-30a-3p 0.0191 -1.86 2.64 3.53 0.8027 chr6 
20537639 hsa-mir-6893 0.0196 -1.49 1.63 2.21 0.8148 chr8 
20520195 hsa-miR-4999-3p 0.0199 -1.45 1 1.54 0.8148 chr19 
20533553 ENSG00000238841 0.0199 1.48 1.76 1.2 0.8148 chr7 
20536792 hsa-mir-4514 0.02 -1.28 1.29 1.65 0.8148 chr15 
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20500130 hsa-miR-17-5p 0.0202 -1.62 10.53 11.23 0.8148 chr13 
20509227 hsa-miR-1909-3p 0.0204 2.06 3.17 2.12 0.8148 chr19 
20533041 ENSG00000212211 0.0204 1.39 1.67 1.2 0.8148 chr3 
20534125 ENSG00000262620 0.0204 1.39 1.67 1.2 0.8148 chrHG1091_PATCH 
20506837 hsa-miR-1246 0.0205 2.18 7.14 6.01 0.8157 chr2 
20500132 hsa-miR-18a-5p 0.0207 -1.81 7.22 8.07 0.8181 chr13 
20500779 hsa-miR-146a-3p 0.021 -1.3 1.44 1.82 0.8181 chr5 
20535199 hsa-mir-516a-1 0.0211 1.29 1.36 1 0.8181 chr19 
20535200 hsa-mir-516a-2 0.0211 1.29 1.36 1 0.8181 chr19 
20525423 hsa-miR-6730-3p 0.0215 -1.17 1.59 1.81 0.8235 chr1 
20535457 hsa-mir-762 0.0217 1.52 2.08 1.47 0.8235 chr16 
20538108 SNORA84 0.0218 -1.13 1.76 1.94 0.8235 chr9 
20537161 hsa-mir-5586 0.0219 -1.15 1.05 1.26 0.8235 chr14 
20536218 hsa-mir-3132 0.022 -1.33 1.48 1.88 0.8235 chr2 
20536616 hsa-mir-3914-2 0.022 1.42 1.47 0.96 0.8235 chr7 
20538300 mgh28S-2411 0.0221 1.13 8.7 8.52 0.8235 chr11 
20533286 ENSG00000238436 0.023 1.75 2.13 1.32 0.8278 chr12 
20500787 hsa-miR-185-5p 0.0233 -1.78 6.52 7.36 0.8278 chr22 
20537253 hsa-mir-6080 0.0234 -1.67 1.68 2.42 0.8278 chr17 
20535146 hsa-mir-493 0.0235 -1.84 1.57 2.45 0.8278 chr14 
20525515 hsa-miR-6777-5p 0.0236 1.62 3.26 2.56 0.8278 chr17 
20500142 hsa-miR-21-3p 0.0237 -1.19 1.5 1.75 0.8278 chr17 
20500446 hsa-miR-181b-5p 0.0239 -1.31 5.88 6.27 0.8278 chr1 
20515644 hsa-miR-3200-5p 0.0239 -1.57 1.17 1.82 0.8278 chr22 
20532737 ENSG00000199411 0.0239 -1.24 1.52 1.83 0.8278 chr9 
20517917 hsa-miR-3664-5p 0.024 1.13 1.35 1.17 0.8278 chr11 
20506787 hsa-miR-1237-5p 0.0243 1.4 7.38 6.89 0.8278 chr11 
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20533253 ENSG00000238375 0.0243 -1.18 1.4 1.63 0.8278 chr6 
20538319 hsa-mir-4466 0.0243 1.38 2.67 2.2 0.8278 chr6 
20517909 hsa-miR-3658 0.0244 1.16 0.96 0.75 0.8278 chr1 
20533389 ENSG00000238581 0.0244 -1.69 2.48 3.23 0.8278 chr21 
20536546 hsa-mir-3620 0.0244 -1.79 1.37 2.21 0.8278 chr1 
20538019 hsa-mir-8061 0.0248 -1.53 1.16 1.77 0.8278 chr19 
20529568 hsa-miR-7977 0.0249 1.44 5.78 5.25 0.8278 chr3 
20536885 hsa-mir-4659b 0.0249 1.53 1.6 0.99 0.8278 chr8 
20534270 HBII-52-26 0.025 1.13 1.32 1.13 0.8278 chr15 
20535432 hsa-mir-758 0.0251 -1.52 1.71 2.31 0.8278 chr14 
20536865 hsa-mir-4645 0.0251 -1.51 1.5 2.09 0.8278 chr6 
20517955 hsa-miR-3691-3p 0.0252 -1.62 1.66 2.36 0.8278 chr6 
20519604 hsa-miR-4747-5p 0.0255 -1.4 1.24 1.73 0.8278 chr19 
20532859 ENSG00000201410 0.0255 -1.51 1.09 1.68 0.8278 chr3 
20536493 hsa-mir-4276 0.0256 -1.49 1.28 1.85 0.8278 chr4 
20518897 hsa-miR-4501 0.0257 -1.52 1.02 1.63 0.8278 chr13 
20515523 hsa-miR-3125 0.0262 -1.15 0.98 1.18 0.8278 chr2 
20537984 hsa-mir-4433b 0.0262 -1.11 1.14 1.29 0.8278 chr2 
20533462 ENSG00000238696 0.0265 1.37 1.45 0.99 0.8278 chr2 
20535899 hsa-mir-1277 0.0265 -1.19 0.93 1.17 0.8278 chrX 
20533115 ENSG00000212565 0.0266 1.23 1.25 0.95 0.8278 chr17 
20536766 hsa-mir-4492 0.0266 -1.46 1.67 2.22 0.8278 chr11 
20533756 ENSG00000239153 0.0268 1.42 1.92 1.42 0.8278 chr11 
20533606 ENSG00000238922 0.027 -1.8 1.09 1.94 0.8278 chr7 
20505747 hsa-miR-890 0.0272 -1.42 0.98 1.49 0.8278 chrX 
20517821 hsa-miR-3613-3p 0.0273 1.56 6.92 6.27 0.8278 chr13 
20518843 hsa-miR-3135b 0.0273 1.57 5.43 4.79 0.8278 chr6 
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20534622 hsa-mir-138-1 0.0274 -1.19 1.59 1.84 0.8278 chr3 
20533190 ENSG00000223111 0.0275 -1.4 1.33 1.82 0.8278 chr10 
20533191 ENSG00000223182 0.0275 -1.4 1.33 1.82 0.8278 chr10 
20534172 ENSG00000265733 0.0275 -1.4 1.33 1.82 0.8278 chrHG1211_PATCH 
20535888 hsa-mir-1272 0.0276 1.61 1.68 1 0.8278 chr15 
20519517 hsa-miR-4701-5p 0.0279 1.56 2.26 1.62 0.8284 chr12 
20534238 HBII-295 0.0281 -1.39 1.52 1.99 0.8284 chr9 
20538489 gi:555853 0.0281 -1.14 13.45 13.63 0.8284 
 
20525026 hsa-miR-6512-3p 0.0283 -1.29 1.2 1.57 0.8284 chr2 
20538262 U85 0.0284 -1.92 1.38 2.32 0.8284 chr12 
20536900 hsa-mir-4674 0.0286 1.58 2.37 1.71 0.8284 chr9 
20533047 ENSG00000212229 0.0289 -1.15 1.41 1.62 0.8284 chr6 
20536970 hsa-mir-4734 0.0289 1.4 2.43 1.94 0.8284 chr17 
20521782 hsa-miR-4524b-3p 0.029 -1.27 1.22 1.56 0.8284 chr17 
20525453 hsa-miR-6746-5p 0.029 1.94 3.47 2.51 0.8284 chr11 
20525706 hsa-miR-6872-3p 0.029 -1.87 1.82 2.72 0.8284 chr3 
20501233 hsa-miR-373-5p 0.0291 -1.22 1.06 1.34 0.8284 chr19 
20535918 hsa-mir-1255b-2 0.0294 -1.41 1 1.5 0.8324 chr1 
20506788 hsa-miR-1237-3p 0.0297 -1.64 1.51 2.23 0.8331 chr11 
20535387 hsa-mir-638 0.0297 1.12 1.86 1.69 0.8331 chr19 
20536635 hsa-mir-676 0.0298 -1.35 1.28 1.71 0.8331 chrX 
20519611 hsa-miR-4751 0.0299 1.35 1.76 1.33 0.8331 chr19 
20521839 hsa-miR-5590-3p 0.0301 -1.22 0.89 1.18 0.8338 chr2 
20533114 ENSG00000212558 0.0302 1.52 1.87 1.27 0.8353 chr2 
20536437 hsa-mir-4293 0.0306 -1.86 1.49 2.39 0.8415 chr10 
20533384 ENSG00000238575 0.0307 -1.09 1.19 1.32 0.8415 chr18 
20538016 hsa-mir-8058 0.0309 1.49 1.9 1.32 0.8427 chr16 
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20500751 hsa-miR-143-5p 0.0314 -1.55 1.83 2.46 0.8492 chr5 
20535453 hsa-mir-766 0.0315 1.33 1.7 1.28 0.8492 chrX 
20518803 hsa-miR-548ad 0.0316 -1.29 0.89 1.26 0.8492 chr2 
20533729 ENSG00000239111 0.0316 -1.26 1.42 1.75 0.8492 chr1 
20537586 hsa-mir-6841 0.0318 1.21 1.43 1.15 0.85 chr8 
20536796 hsa-mir-4518 0.0321 -1.29 1.68 2.05 0.8541 chr16 
20506869 hsa-miR-1273a 0.0324 -1.56 1.33 1.98 0.855 chr8 
20519679 hsa-miR-4787-5p 0.0324 1.29 9.22 8.85 0.855 chr3 
20502122 hsa-miR-422a 0.0326 -1.22 6.64 6.93 0.855 chr15 
20536615 hsa-mir-3914-2 0.0326 1.46 1.52 0.97 0.855 chr7 
20533707 ENSG00000239072 0.0332 1.43 1.95 1.44 0.8557 chr2 
20534829 hsa-mir-26a-2 0.0333 -1.25 1.38 1.7 0.8557 chr12 
20532669 ACA40 0.0334 -1.72 2.02 2.8 0.8557 chr11 
20532862 ENSG00000201465 0.0334 -1.19 1.17 1.42 0.8557 chr7 
20500469 hsa-miR-212-3p 0.0335 1.84 3.6 2.72 0.8557 chr17 
20535218 hsa-mir-509-1 0.0337 -1.43 1.15 1.67 0.8557 chrX 
20535638 hsa-mir-509-2 0.0337 -1.43 1.15 1.67 0.8557 chrX 
20535683 hsa-mir-509-3 0.0337 -1.43 1.15 1.67 0.8557 chrX 
20533559 ENSG00000238852 0.0339 -1.22 1.45 1.74 0.8573 chr2 
20536652 hsa-mir-374c 0.0343 1.13 1.74 1.56 0.8636 chrX 
20538460 spike_in-control-17 0.035 1.2 1.68 1.42 0.8659 
 
20533092 ENSG00000212445 0.0354 -1.56 1.59 2.23 0.8659 chr16 
20515564 hsa-miR-3150a-5p 0.0356 -1.45 1.58 2.12 0.8659 chr8 
20532765 ENSG00000199934 0.0358 -1.34 0.94 1.36 0.8659 chr1 
20534526 hsa-mir-210 0.0359 -1.59 1.82 2.5 0.8659 chr11 
20518882 hsa-miR-4488 0.0364 1.27 7.51 7.16 0.8659 chr11 
20506012 hsa-miR-941 0.0365 -1.61 4.5 5.2 0.8659 chr20 
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20518628 hsa-miR-3939 0.0367 -1.31 1.42 1.81 0.8659 chr6 
20538044 hsa-mir-8084 0.0367 1.23 1.28 0.98 0.8659 chr8 
20517712 hsa-miR-4254 0.0369 1.79 2.44 1.6 0.8659 chr1 
20536805 hsa-mir-4525 0.037 -2.04 1.46 2.49 0.8659 chr17 
20536907 hsa-mir-4679-1 0.037 1.17 1.1 0.87 0.8659 chr10 
20532994 ENSG00000207130 0.0371 1.21 1.7 1.42 0.8659 chr3 
20536318 hsa-mir-3198-1 0.0374 -1.66 1.58 2.31 0.8659 chr22 
20536933 hsa-mir-3198-2 0.0374 -1.66 1.58 2.31 0.8659 chr12 
20500450 hsa-miR-182-5p 0.0375 -1.55 7.51 8.14 0.8659 chr7 
20500728 hsa-miR-124-5p 0.0375 1.33 2.22 1.81 0.8659 chr20 
20525690 hsa-miR-6864-3p 0.0376 1.22 1.48 1.2 0.8659 chr17 
20529133 hsa-miR-1273h-3p 0.0377 1.23 1.88 1.59 0.8659 chr16 
20538303 snR38C 0.0379 1.3 8.43 8.05 0.8659 chr17 
20533280 ENSG00000238428 0.0383 -2.4 1.17 2.43 0.8659 chr2 
20535144 hsa-mir-202 0.0383 1.33 1.61 1.2 0.8659 chr10 
20535822 hsa-mir-1285-2 0.0384 -1.18 1.14 1.37 0.8659 chr2 
20537608 hsa-mir-6862-1 0.0385 -1.53 1.27 1.89 0.8659 chr16 
20538092 hsa-mir-6862-2 0.0385 -1.53 1.27 1.89 0.8659 chr16 
20525466 hsa-miR-6752-3p 0.039 -1.4 0.86 1.35 0.8659 chr11 
20533988 ENSG00000252557 0.0394 1.11 1.17 1.02 0.8659 chr7 
20537594 hsa-mir-6849 0.0398 1.63 2.18 1.48 0.8659 chr8 
20535143 hsa-mir-146b 0.0399 -1.4 1.38 1.86 0.8659 chr10 
20504553 hsa-miR-671-3p 0.04 -1.57 2.19 2.84 0.8659 chr7 
20518856 hsa-miR-4471 0.04 1.21 1.46 1.18 0.8659 chr8 
20534845 hsa-mir-376c 0.0403 1.32 1.52 1.11 0.8659 chr14 
20533749 ENSG00000239141 0.0404 1.22 1.42 1.14 0.8659 chr3 
20536576 hsa-mir-3672 0.0404 -1.19 1.21 1.46 0.8659 chrX 
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20536718 hsa-mir-4461 0.0404 1.41 1.96 1.47 0.8659 chr5 
20537236 hsa-mir-5739 0.0404 -1.13 1.14 1.31 0.8659 chr22 
20504328 hsa-miR-591 0.0405 -1.19 0.98 1.23 0.8659 chr7 
20518000 hsa-miR-3714 0.0407 -2.06 1.26 2.31 0.8659 chr3 
20536641 hsa-mir-3936 0.0408 1.47 1.89 1.34 0.8659 chr5 
20532585 14qII-17 0.0409 1.16 1.3 1.09 0.8659 chr14 
20533179 ENSG00000222185 0.0409 1.28 1.23 0.87 0.8659 chr14 
20536873 hsa-mir-4652 0.041 -1.34 1.16 1.59 0.8659 chr7 
20536028 hsa-mir-2116 0.0411 -1.25 1.39 1.71 0.8659 chr15 
20534577 hsa-mir-124-1 0.0414 1.27 1.31 0.97 0.8659 chr8 
20501155 hsa-miR-194-3p 0.0418 -1.89 1.32 2.23 0.8659 chr11 
20538236 U71a 0.0418 -1.22 2.21 2.5 0.8659 chr20 
20533593 ENSG00000238899 0.042 -1.53 1.15 1.76 0.8659 chr5 
20537563 hsa-mir-6819 0.042 1.43 2.46 1.95 0.8659 chr22 
20536695 hsa-mir-4441 0.0421 -1.37 1.3 1.75 0.8659 chr2 
20506004 hsa-miR-935 0.0422 -1.37 6.38 6.84 0.8659 chr19 
20515638 hsa-miR-3196 0.0422 1.79 9.31 8.47 0.8659 chr20 
20536509 hsa-mir-4289 0.0424 -1.24 1.61 1.92 0.8659 chr9 
20534362 hsa-mir-22 0.0426 -1.17 1.5 1.73 0.8659 chr17 
20519409 hsa-miR-4634 0.043 1.61 1.98 1.3 0.8659 chr5 
20533323 ENSG00000238494 0.0431 1.27 1.68 1.33 0.8659 chr15 
20533349 ENSG00000238535 0.0431 1.27 1.68 1.33 0.8659 chr15 
20500486 hsa-miR-222-3p 0.0432 -1.26 11.72 12.04 0.8659 chrX 
20533061 ENSG00000212309 0.0433 1.24 1.47 1.16 0.8659 chr2 
20519473 hsa-miR-4673 0.0434 -1.56 1.91 2.55 0.8659 chr9 
20500780 hsa-miR-149-5p 0.0435 -1.23 5.69 5.98 0.8659 chr2 
20506873 hsa-miR-1276 0.0435 1.39 1.3 0.82 0.8659 chr15 
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20537227 hsa-mir-5704 0.0437 1.23 1.53 1.23 0.8659 chr3 
20525544 hsa-miR-6791-3p 0.0441 1.35 1.75 1.31 0.8659 chr19 
20532879 ENSG00000201701 0.0441 1.47 1.51 0.96 0.8659 chr3 
20533390 ENSG00000238582 0.0441 -1.4 1.14 1.63 0.8659 chr2 
20517938 hsa-miR-3680-5p 0.0442 1.51 1.79 1.19 0.8659 chr16 
20538307 ENSG00000199552 0.0443 -1.4 1.35 1.84 0.8659 chr5 
20536557 hsa-mir-3653 0.0444 -1.41 1.96 2.46 0.8659 chr22 
20538115 SNORD125 0.0444 -1.41 1.96 2.46 0.8659 chr22 
20537439 hsa-mir-6508 0.0445 1.49 1.77 1.19 0.8659 chr21 
20500399 hsa-miR-199a-5p 0.0447 -1.3 1.59 1.97 0.8659 chr1 
20532847 ENSG00000201316 0.0449 1.2 1.69 1.43 0.8659 chr8 
20534374 hsa-mir-28 0.0449 -1.12 1.6 1.77 0.8659 chr3 
20536552 hsa-mir-3648 0.0449 1.64 3 2.29 0.8659 chr21 
20507744 hsa-miR-1471 0.045 -1.52 1.37 1.97 0.8659 chr2 
20501157 hsa-miR-106b-5p 0.0451 -1.77 7.43 8.25 0.8659 chr7 
20536555 hsa-mir-3651 0.0451 1.24 3.15 2.84 0.8659 chr9 
20538106 SNORA84 0.0451 1.24 3.15 2.84 0.8659 chr9 
20537597 hsa-mir-6852 0.0452 1.53 2.05 1.44 0.8659 chr9 
20502452 hsa-miR-452-3p 0.0453 1.37 1.54 1.08 0.8659 chrX 
20519587 hsa-miR-4738-5p 0.046 1.22 1.55 1.26 0.8659 chr17 
20501201 hsa-miR-362-5p 0.0461 -2.41 3.84 5.11 0.8659 chrX 
20536268 hsa-mir-3161 0.0462 1.33 1.4 0.98 0.8659 chr11 
20536464 hsa-mir-4323 0.0464 -1.32 2.4 2.8 0.8659 chr19 
20533219 ENSG00000238328 0.0466 1.2 1.31 1.05 0.8659 chr2 
20535414 hsa-mir-656 0.0467 -1.12 1.34 1.51 0.8659 chr14 
20520197 hsa-miR-5000-3p 0.0469 1.4 1.43 0.95 0.8659 chr2 
20535306 hsa-mir-568 0.0469 1.24 1.37 1.06 0.8659 chr3 
 
Table A.1. Small RNAs significantly altered following TDP-43 Knockdown. 
283 
 
ID Transcript ID(Array 
Design) 
P-val Fold Change siTDP Avg (log2) SCR Avg (log2) FDR P-
val 
Chromosome 
20538000 hsa-mir-548ba 0.047 1.25 1.21 0.89 0.8659 chr2 
20536435 hsa-mir-4297 0.0473 -1.47 2.57 3.13 0.8659 chr10 
20533067 ENSG00000212347 0.0474 1.35 1.2 0.77 0.8659 chrX 
20534199 ENSG00000268513 0.0474 1.35 1.2 0.77 0.8659 chrHG1435_PATCH 
20525420 hsa-miR-6729-5p 0.0475 1.23 8.67 8.38 0.8659 chr1 
20535180 hsa-mir-517a 0.0479 -1.18 1.13 1.37 0.8659 chr19 
20506811 hsa-miR-548j-3p 0.048 -1.54 1.16 1.78 0.8659 chr22 
20525525 hsa-miR-6782-5p 0.048 2.12 3.13 2.05 0.8659 chr17 
20533794 ENSG00000251778 0.048 -1.51 1.25 1.85 0.8659 chr21 
20533967 ENSG00000252458 0.048 -1.14 1.36 1.55 0.8659 chr5 
20537632 hsa-mir-6886 0.0481 -1.43 2.8 3.32 0.8659 chr19 
20538270 U90 0.0482 -1.35 1.85 2.28 0.8659 chr3 
20519410 hsa-miR-4635 0.0485 -1.44 3.96 4.48 0.8659 chr5 
20502130 hsa-miR-425-3p 0.0488 -2.24 2.64 3.8 0.8659 chr3 
20518790 hsa-miR-4421 0.0488 1.36 1.55 1.11 0.8659 chr1 
20536504 hsa-mir-4284 0.0488 1.27 1.91 1.56 0.8659 chr7 
20536541 hsa-mir-3616 0.0488 1.32 2.1 1.69 0.8659 chr20 
20538045 hsa-mir-8085 0.0492 -1.49 1.54 2.12 0.8659 chr19 
20533700 ENSG00000239063 0.0496 -1.35 1.21 1.65 0.8659 chr1 
20500152 hsa-miR-26a-5p 0.0497 -1.43 8.25 8.77 0.8659 chr12 
20502237 hsa-miR-20b-5p 0.0498 -1.59 6.18 6.85 0.8659 chrX 
20504550 hsa-miR-758-3p 0.0498 -1.59 1.18 1.84 0.8659 chr14 
20500139 hsa-miR-20a-5p 0.0499 -1.55 9.45 10.08 0.8659 chr13 
20536578 hsa-mir-3674 0.05 -1.19 1.07 1.32 0.8659 chr8 
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Chromosome 
20537518 hsa-mir-6775 0.0002 -2.34 1.61 2.83 0.8811 chr16 
20534818 hsa-mir-219a-2 0.0003 -1.49 1.31 1.89 0.8811 chr9 
20518818 hsa-miR-4443 0.0005 -1.46 6.5 7.04 0.8811 chr3 
20535460 hsa-mir-1298 0.0005 -1.3 1.68 2.07 0.8811 chrX 
20537592 hsa-mir-6847 0.0009 1.66 2.24 1.51 0.9953 chr8 
20536775 hsa-mir-4500 0.001 -1.69 1.33 2.09 0.9953 chr13 
20506005 hsa-miR-936 0.0011 -1.56 1.29 1.94 0.9953 chr10 
20535879 hsa-mir-1263 0.0017 -2.15 1.81 2.91 0.9953 chr3 
20522017 hsa-miR-548ax 0.0023 -1.63 0.95 1.66 0.9953 chrX 
20520348 hsa-miR-5095 0.0025 -1.49 1.31 1.88 0.9953 chr1 
20517909 hsa-miR-3658 0.0028 1.29 1.11 0.75 0.9953 chr1 
20529568 hsa-miR-7977 0.0029 1.9 6.18 5.25 0.9953 chr3 
20536752 hsa-mir-4480 0.003 -1.3 1.23 1.6 0.9953 chr10 
20533957 ENSG00000252433 0.003 1.29 1.33 0.96 0.9953 chr1 
20537586 hsa-mir-6841 0.0031 1.3 1.53 1.15 0.9953 chr8 
20532591 14qII-20 0.0032 1.28 1.53 1.18 0.9953 chr14 
20525669 hsa-miR-6854-5p 0.0033 1.5 1.58 1 0.9953 chr9 
20504582 hsa-miR-766-5p 0.0033 -1.91 1.47 2.4 0.9953 chrX 
20525546 hsa-miR-6792-3p 0.0039 1.51 1.59 0.99 0.9953 chr19 
20536018 hsa-mir-1976 0.0039 -1.9 1.51 2.44 0.9953 chr1 
20534091 ENSG00000253013 0.004 -1.82 1.44 2.31 0.9953 chr4 
20537456 hsa-mir-6715b 0.0041 1.36 2.16 1.72 0.9953 chr10 
20517821 hsa-miR-3613-3p 0.0052 1.81 7.13 6.27 0.9953 chr13 
20532932 ENSG00000202449 0.0053 1.32 1.22 0.81 0.9953 chr4 
20525569 hsa-miR-6804-5p 0.0054 -1.85 1.25 2.14 0.9953 chr19 
20518879 hsa-miR-4485 0.0054 1.5 7.49 6.9 0.9953 chr11 
20536268 hsa-mir-3161 0.0054 1.6 1.66 0.98 0.9953 chr11 
20535402 hsa-mir-652 0.0055 -1.48 1.49 2.06 0.9953 chrX 
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Chromosome 
20533069 ENSG00000212363 0.0057 1.3 1.3 0.91 0.9953 chr5 
20536889 hsa-mir-4664 0.0059 -1.51 1.47 2.06 0.9953 chr8 
20518816 hsa-miR-4441 0.0071 -1.23 1.17 1.46 0.9953 chr2 
20537988 hsa-mir-7845 0.0073 -1.88 1.54 2.45 0.9953 chr2 
20536920 hsa-mir-4689 0.0075 -1.85 1.68 2.57 0.9953 chr1 
20536297 hsa-mir-3181 0.0076 1.48 1.88 1.31 0.9953 chr16 
20536025 hsa-mir-2110 0.0076 1.27 1.93 1.58 0.9953 chr10 
20525027 hsa-miR-6513-5p 0.0078 -1.59 1.41 2.08 0.9953 chr2 
20536800 hsa-mir-4521 0.0078 1.57 2.25 1.6 0.9953 chr17 
20500741 hsa-miR-135a-3p 0.008 -1.64 1.15 1.86 0.9953 chr3 
20532570 14qI-5 0.0082 1.4 1.46 0.97 0.9953 chr14 
20520197 hsa-miR-5000-3p 0.0083 1.53 1.56 0.95 0.9953 chr2 
20533763 ENSG00000239159 0.0084 -1.33 0.99 1.41 0.9953 chr5 
20537563 hsa-mir-6819 0.0085 1.57 2.6 1.95 0.9953 chr22 
20519451 hsa-miR-4659b-5p 0.0086 1.3 1.18 0.8 0.9953 chr8 
20518929 hsa-miR-4529-5p 0.0087 1.5 1.78 1.2 0.9953 chr18 
20534238 HBII-295 0.0088 -1.48 1.42 1.99 0.9953 chr9 
20535842 hsa-mir-1302-5 0.0092 -1.38 0.91 1.38 0.9953 chr20 
20500462 hsa-miR-205-5p 0.0094 1.44 1.57 1.04 0.9953 chr1 
20535432 hsa-mir-758 0.0094 -1.6 1.63 2.31 0.9953 chr14 
20536497 hsa-mir-4277 0.0106 -1.86 1.73 2.63 0.9953 chr5 
20537026 hsa-mir-4776-1 0.0107 1.59 2.13 1.46 0.9953 chr2 
20533253 ENSG00000238375 0.011 -1.27 1.29 1.63 0.9953 chr6 
20518834 hsa-miR-4454 0.0111 -1.51 7.76 8.36 0.9953 chr4 
20533431 ENSG00000238656 0.0112 1.11 1.02 0.87 0.9953 chr8 
20525731 hsa-miR-6885-5p 0.0114 -2.33 1.65 2.87 0.9953 chr19 
20535446 hsa-mir-1271 0.0114 1.4 2.05 1.57 0.9953 chr5 
20521804 hsa-miR-548ar-5p 0.0116 1.37 1.55 1.1 0.9953 chr13 
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Chromosome 
20510800 hsa-miR-1973 0.0121 -2.27 1.89 3.07 0.9953 chr4 
20536628 hsa-mir-3910-2 0.0122 1.52 1.99 1.39 0.9953 chr9 
20532626 ACA16 0.0125 1.68 2.58 1.83 0.9953 chr1 
20537565 hsa-mir-6821 0.0126 1.47 1.83 1.27 0.9953 chr22 
20533128 ENSG00000212604 0.0126 -1.61 1.17 1.86 0.9953 chr15 
20520565 hsa-miR-5187-5p 0.013 -1.63 0.92 1.62 0.9953 chr1 
20506771 hsa-miR-1227-5p 0.013 -1.77 2.91 3.74 0.9953 chr19 
20518893 hsa-miR-4498 0.0131 -1.31 2.24 2.63 0.9953 chr12 
20532926 ENSG00000202374 0.0132 -1.61 1.42 2.1 0.9953 chr4 
20522039 hsa-miR-5703 0.0133 -1.91 1.2 2.13 0.9953 chr2 
20537868 hsa-mir-7152 0.0133 1.53 2.13 1.52 0.9953 chr10 
20533760 ENSG00000239157 0.0134 -1.23 1.38 1.68 0.9953 chr20 
20519075 hsa-miR-3973 0.0137 -1.27 1.64 1.99 0.9953 chr11 
20533280 ENSG00000238428 0.014 -2.15 1.33 2.43 0.9953 chr2 
20538115 SNORD125 0.0142 -1.49 1.88 2.46 0.9953 chr22 
20536560 hsa-mir-3656 0.0142 -1.7 1.94 2.71 0.9953 chr11 
20536557 hsa-mir-3653 0.0142 -1.49 1.88 2.46 0.9953 chr22 
20536963 hsa-mir-4727 0.0145 -1.5 1.42 2.01 0.9953 chr17 
20537143 hsa-mir-3680-2 0.0148 1.53 1.83 1.21 0.9953 chr16 
20536583 hsa-mir-3680-1 0.0148 1.53 1.83 1.21 0.9953 chr16 
20533583 ENSG00000238888 0.0149 1.39 1.39 0.92 0.9953 chr2 
20520568 hsa-miR-5189-5p 0.015 -1.93 2.32 3.27 0.9953 chr16 
20500448 hsa-miR-181c-5p 0.0152 -1.37 1.51 1.97 0.9953 chr19 
20533980 ENSG00000252526 0.0153 -1.36 1.36 1.81 0.9953 chr16 
20519408 hsa-miR-4633-3p 0.0157 -1.56 1.26 1.9 0.9953 chr5 
20504553 hsa-miR-671-3p 0.0158 -1.74 2.04 2.84 0.9953 chr7 
20533810 ENSG00000251836 0.0158 1.55 1.92 1.29 0.9953 chr10 
20501274 hsa-miR-340-3p 0.0159 1.25 2.03 1.71 0.9953 chr5 
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Chromosome 
20500454 hsa-miR-187-5p 0.016 -1.53 1.96 2.57 0.9953 chr18 
20518943 hsa-miR-548an 0.0161 1.32 1.48 1.08 0.9953 chrX 
20506708 hsa-miR-1178-5p 0.0163 -1.26 1.06 1.39 0.9953 chr12 
20538215 U61 0.0165 1.28 3.24 2.88 0.9953 chrX 
20536605 hsa-mir-3909 0.0165 1.57 1.97 1.31 0.9953 chr22 
20537011 hsa-mir-4769 0.0166 -1.38 1 1.46 0.9953 chrX 
20538270 U90 0.0168 -1.45 1.74 2.28 0.9953 chr3 
20533654 ENSG00000238996 0.0168 1.46 1.65 1.1 0.9953 chr9 
20533156 ENSG00000221300 0.0169 1.31 1.36 0.97 0.9953 chr2 
20537517 hsa-mir-6774 0.017 -1.6 1.67 2.35 0.9953 chr16 
20537221 hsa-mir-5699 0.017 1.33 2.01 1.6 0.9953 chr10 
20533047 ENSG00000212229 0.017 -1.22 1.33 1.62 0.9953 chr6 
20537519 hsa-mir-6776 0.0171 1.47 4.53 3.97 0.9953 chr17 
20533594 ENSG00000238900 0.0171 1.26 1.31 0.98 0.9953 chr10 
20517819 hsa-miR-3612 0.0173 -1.25 0.89 1.21 0.9953 chr12 
20515608 hsa-miR-3179 0.0174 -1.41 1.15 1.65 0.9953 chr16 
20506789 hsa-miR-1238-5p 0.0175 -1.6 1.33 2.01 0.9953 chr19 
20535246 hsa-mir-545 0.0175 1.34 1.72 1.3 0.9953 chrX 
20524051 hsa-miR-6130 0.0177 -1.11 0.98 1.13 0.9953 chr21 
20521782 hsa-miR-4524b-3p 0.0184 -1.3 1.18 1.56 0.9953 chr17 
20534194 ENSG00000268145 0.0185 1.41 1.78 1.29 0.9953 chrHG1462_PATCH 
20533963 ENSG00000252441 0.0185 1.41 1.78 1.29 0.9953 chrX 
20519695 hsa-miR-4797-5p 0.0187 1.42 2 1.49 0.9953 chr3 
20533808 ENSG00000251830 0.0187 -1.38 1.42 1.89 0.9953 chr6 
20536580 hsa-mir-3677 0.0189 1.21 2.16 1.89 0.9953 chr16 
20533952 ENSG00000252405 0.0189 1.26 1.32 0.99 0.9953 chr16 
20525732 hsa-miR-6885-3p 0.0193 1.66 1.74 1.01 0.9953 chr19 
20518785 hsa-miR-4417 0.02 -2.11 1.94 3.01 0.9953 chr1 
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20534360 hsa-mir-20a 0.02 1.21 1.47 1.2 0.9953 chr13 
20537226 hsa-mir-5692b 0.0204 1.36 1.4 0.95 0.9953 chr21 
20504374 hsa-miR-626 0.0209 -1.26 0.98 1.31 0.9953 chr15 
20505755 hsa-miR-889-3p 0.0211 1.16 1.18 0.97 0.9953 chr14 
20537538 hsa-mir-6795 0.0211 1.4 1.59 1.11 0.9953 chr19 
20536759 hsa-mir-4487 0.0212 -1.74 1.29 2.09 0.9953 chr11 
20532571 14qI-6 0.0214 1.17 1.53 1.3 0.9953 chr14 
20506008 hsa-miR-938 0.0216 1.35 1.41 0.97 0.9953 chr10 
20520217 hsa-miR-5009-3p 0.0218 1.29 1.26 0.89 0.9953 chr15 
20535360 hsa-mir-613 0.0218 1.21 1.76 1.48 0.9953 chr12 
20534083 ENSG00000252985 0.022 -1.25 1.46 1.78 0.9953 chr9 
20535393 hsa-mir-643 0.0225 1.48 1.49 0.93 0.9953 chr19 
20511549 hsa-miR-2110 0.0228 -2.23 3.11 4.26 0.9953 chr10 
20519564 hsa-miR-4725-5p 0.023 -1.52 1.35 1.96 0.9953 chr17 
20536853 hsa-mir-4633 0.023 1.89 2.45 1.53 0.9953 chr5 
20519432 hsa-miR-4650-3p 0.0231 -1.22 1.17 1.46 0.9953 chr7 
20535838 hsa-mir-1302-1 0.0232 1.18 1.21 0.98 0.9953 chr12 
20518928 hsa-miR-4528 0.0237 1.29 1.24 0.87 0.9953 chr18 
20535673 hsa-mir-374b 0.0242 -1.53 1.49 2.11 0.9953 chrX 
20538236 U71a 0.0244 -1.29 2.13 2.5 0.9953 chr20 
20536966 hsa-mir-4730 0.0247 -1.36 2.09 2.54 0.9953 chr17 
20518919 hsa-miR-4521 0.0248 2.76 5.28 3.81 0.9953 chr17 
20537229 hsa-mir-5706 0.0248 -1.36 1.18 1.62 0.9953 chr5 
20504421 hsa-miR-654-3p 0.0249 1.55 2.01 1.38 0.9953 chr14 
20506710 hsa-miR-1179 0.0251 1.42 1.18 0.67 0.9953 chr15 
20532880 ENSG00000201710 0.0251 -1.16 1.08 1.29 0.9953 chr14 
20517721 hsa-miR-4267 0.0257 1.12 1.51 1.34 0.9953 chr2 
20519587 hsa-miR-4738-5p 0.0258 1.42 1.77 1.26 0.9953 chr17 
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Chromosome 
20536602 hsa-mir-3689b 0.0258 -2.26 1.55 2.72 0.9953 chr9 
20532737 ENSG00000199411 0.026 -1.32 1.43 1.83 0.9953 chr9 
20536873 hsa-mir-4652 0.0261 -1.41 1.09 1.59 0.9953 chr7 
20535353 hsa-mir-606 0.0261 1.49 1.74 1.16 0.9953 chr10 
20533768 ENSG00000239172 0.0261 -1.19 1.32 1.57 0.9953 chr16 
20533626 ENSG00000238954 0.0261 -1.19 1.32 1.57 0.9953 chr16 
20533471 ENSG00000238712 0.0261 -1.19 1.32 1.57 0.9953 chr16 
20525747 hsa-miR-6893-5p 0.0262 -1.6 1.94 2.62 0.9953 chr8 
20535926 hsa-mir-1322 0.0262 1.39 1.44 0.97 0.9953 chr8 
20536327 hsa-mir-3201 0.0263 1.24 1.36 1.05 0.9953 chr22 
20537167 hsa-mir-5590 0.0264 -1.18 0.82 1.05 0.9953 chr2 
20505746 hsa-miR-874-3p 0.0265 -1.54 2.96 3.59 0.9953 chr5 
20501178 hsa-miR-296-5p 0.0265 -1.21 1 1.27 0.9953 chr20 
20534006 ENSG00000252646 0.0265 1.32 1.71 1.31 0.9953 chr1 
20501278 hsa-miR-328-3p 0.0266 -2.5 2.34 3.66 0.9953 chr16 
20501163 hsa-miR-200a-3p 0.0268 -1.13 1.17 1.35 0.9953 chr1 
20534534 hsa-mir-217 0.0268 1.19 1.5 1.25 0.9953 chr2 
20533092 ENSG00000212445 0.0268 -1.64 1.51 2.23 0.9953 chr16 
20504283 hsa-miR-562 0.0269 1.22 1.25 0.96 0.9953 chr2 
20538016 hsa-mir-8058 0.0269 1.6 2.01 1.32 0.9953 chr16 
20533869 ENSG00000252083 0.0269 1.49 1.9 1.32 0.9953 chr5 
20533068 ENSG00000212363 0.0269 1.28 1.24 0.89 0.9953 chr5 
20502446 hsa-miR-451a 0.027 -1.44 1.49 2.02 0.9953 chr17 
20519694 hsa-miR-4796-3p 0.0273 1.47 1.55 0.99 0.9953 chr3 
20506886 hsa-miR-1288-3p 0.0277 -1.62 1.46 2.15 0.9953 chr17 
20534829 hsa-mir-26a-2 0.0278 -1.33 1.28 1.7 0.9953 chr12 
20500794 hsa-miR-190a-3p 0.0282 -1.49 1.03 1.6 0.9953 chr15 
20533596 ENSG00000238902 0.0284 1.28 1.45 1.09 0.9953 chr3 
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20525421 hsa-miR-6729-3p 0.0286 1.19 1.25 1 0.9953 chr1 
20525706 hsa-miR-6872-3p 0.0297 -1.73 1.93 2.72 0.9953 chr3 
20537984 hsa-mir-4433b 0.0302 -1.09 1.18 1.29 0.9953 chr2 
20532729 ENSG00000199282 0.0302 -1.32 1.17 1.57 0.9953 chr13 
20533761 ENSG00000239157 0.0306 -1.46 1.16 1.71 0.9953 chr20 
20504313 hsa-miR-584-3p 0.0307 1.48 2.05 1.48 0.9953 chr5 
20535198 hsa-mir-527 0.0308 -1.25 1.28 1.6 0.9953 chr19 
20504429 hsa-miR-659-5p 0.031 -1.62 0.96 1.65 0.9953 chr22 
20535071 hsa-mir-196b 0.031 1.36 1.91 1.47 0.9953 chr7 
20532625 ACA16 0.031 1.37 2.68 2.22 0.9953 chr1 
20525605 hsa-miR-6822-5p 0.0311 -1.29 1.31 1.68 0.9953 chr3 
20529565 hsa-miR-7974 0.0312 -1.43 1.35 1.87 0.9953 chr19 
20506873 hsa-miR-1276 0.0316 1.41 1.31 0.82 0.9953 chr15 
20500779 hsa-miR-146a-3p 0.0317 -1.33 1.4 1.82 0.9953 chr5 
20536648 hsa-mir-3942 0.0319 1.63 1.97 1.26 0.9953 chr15 
20537228 hsa-mir-5705 0.0321 1.38 1.77 1.3 0.9953 chr4 
20519707 hsa-miR-4804-5p 0.0324 -1.15 1.15 1.34 0.9953 chr5 
20537444 hsa-mir-6513 0.0326 1.53 2.03 1.42 0.9953 chr2 
20536480 hsa-mir-4265 0.0326 1.29 1.64 1.28 0.9953 chr2 
20532963 ENSG00000206901 0.0328 1.33 1.82 1.41 0.9953 chr2 
20537464 hsa-mir-6722 0.033 1.17 5.32 5.08 0.9953 chr9 
20537446 hsa-mir-6515 0.033 1.34 1.81 1.39 0.9953 chr19 
20535324 hsa-mir-584 0.0332 -1.18 1.46 1.7 0.9953 chr5 
20501233 hsa-miR-373-5p 0.0334 1.24 1.65 1.34 0.9953 chr19 
20537219 hsa-mir-5697 0.0336 1.33 1.68 1.27 0.9953 chr1 
20536865 hsa-mir-4645 0.0336 -1.37 1.64 2.09 0.9953 chr6 
20524053 hsa-miR-6132 0.0337 -1.11 2.22 2.37 0.9953 chr7 
20537030 hsa-mir-4777 0.0337 -1.2 1 1.26 0.9953 chr2 
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20534582 hsa-mir-125b-1 0.0339 1.28 1.81 1.45 0.9953 chr11 
20537575 hsa-mir-6831 0.034 1.26 1.85 1.52 0.9953 chr5 
20537524 hsa-mir-6781 0.034 1.39 2.06 1.59 0.9953 chr17 
20525685 hsa-miR-6861-3p 0.0341 1.52 1.84 1.24 0.9953 chr12 
20519602 hsa-miR-4746-5p 0.0344 1.66 2.26 1.53 0.9953 chr19 
20533477 ENSG00000238722 0.0345 -1.32 1.38 1.79 0.9953 chr2 
20537213 hsa-mir-5692a-2 0.0347 -1.09 1.42 1.55 0.9953 chr8 
20537212 hsa-mir-5692a-1 0.0347 -1.09 1.42 1.55 0.9953 chr7 
20533729 ENSG00000239111 0.0359 -1.2 1.49 1.75 0.9953 chr1 
20500748 hsa-miR-141-3p 0.036 -1.21 1.1 1.37 0.9953 chr12 
20505788 hsa-miR-744-3p 0.0364 1.79 2.25 1.41 0.9953 chr17 
20533412 ENSG00000238620 0.0365 -1.41 1.15 1.64 0.9953 chr10 
20535310 hsa-mir-570 0.0369 1.55 1.56 0.93 0.9953 chr3 
20533821 ENSG00000251866 0.0369 -1.31 1.7 2.09 0.9953 chr1 
20500764 hsa-miR-9-3p 0.037 1.09 1.13 1.01 0.9953 chr1 
20535101 hsa-mir-450a-1 0.037 1.21 1.19 0.91 0.9953 chrX 
20533677 ENSG00000239033 0.037 -1.07 1.2 1.31 0.9953 chr12 
20533330 ENSG00000238506 0.0371 -1.39 1.23 1.7 0.9953 chr7 
20536506 hsa-mir-4287 0.038 1.31 1.74 1.36 0.9953 chr8 
20533179 ENSG00000222185 0.0381 1.27 1.22 0.87 0.9953 chr14 
20532897 ENSG00000201853 0.0381 1.24 1.53 1.21 0.9953 chr2 
20537083 hsa-mir-5091 0.0383 1.54 2.09 1.47 0.9953 chr4 
20521817 hsa-miR-548at-3p 0.0386 -1.23 1.27 1.57 0.9953 chr17 
20532798 ENSG00000200422 0.0387 -1.36 1.04 1.49 0.9953 chrX 
20504190 hsa-miR-544a 0.0391 1.17 1.11 0.88 0.9953 chr14 
20535684 hsa-mir-933 0.0392 -1.48 1.72 2.29 0.9953 chr2 
20536616 hsa-mir-3914-2 0.0393 1.34 1.39 0.96 0.9953 chr7 
20532598 14qII-26 0.0397 -1.11 1.24 1.39 0.9953 chr14 
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ID Transcript ID(Array 
Design) 
P-val Fold Change siFUS Avg (log2) SCR Avg (log2) FDR P-
val 
Chromosome 
20515610 hsa-miR-3180-3p 0.0398 -1.35 2.67 3.1 0.9953 chr16 
20535453 hsa-mir-766 0.0404 1.27 1.63 1.28 0.9953 chrX 
20532748 ENSG00000199666 0.0406 -1.31 1.42 1.8 0.9953 chr1 
20505798 hsa-miR-543 0.0407 1.3 1.52 1.14 0.9953 chr14 
20519481 hsa-miR-4679 0.0409 1.25 1.41 1.09 0.9953 chr10 
20533532 ENSG00000238806 0.041 1.19 1.36 1.11 0.9953 chr17 
20535826 hsa-mir-1289-2 0.0411 -1.34 1.24 1.66 0.9953 chr5 
20529147 hsa-miR-7855-5p 0.0413 1.17 1.65 1.43 0.9953 chr14 
20500489 hsa-miR-224-5p 0.0413 1.29 1.46 1.09 0.9953 chrX 
20538460 spike_in-control-17 0.0414 1.21 1.7 1.42 0.9953 
 
20502455 hsa-miR-409-5p 0.0415 1.43 1.86 1.34 0.9953 chr14 
20534617 hsa-mir-126 0.0415 1.11 2.2 2.06 0.9953 chr9 
20518872 hsa-miR-548ak 0.0417 1.16 1.15 0.93 0.9953 chr10 
20501294 hsa-miR-324-5p 0.0417 -2.62 2.55 3.94 0.9953 chr17 
20535873 hsa-mir-1260a 0.0418 -1.4 1.54 2.02 0.9953 chr14 
20533695 ENSG00000239058 0.0418 1.19 1.29 1.05 0.9953 chrX 
20536748 hsa-mir-4479 0.0419 -1.65 1.18 1.9 0.9953 chr9 
20534005 ENSG00000252646 0.0419 1.42 1.64 1.14 0.9953 chr1 
20537591 hsa-mir-6846 0.0424 -1.41 1.37 1.86 0.9953 chr8 
20536702 hsa-mir-4449 0.0424 -1.36 4.46 4.91 0.9953 chr4 
20520580 hsa-miR-5197-3p 0.0425 1.14 1.08 0.89 0.9953 chr5 
20520219 hsa-miR-5010-3p 0.0426 -1.27 1.51 1.86 0.9953 chr17 
20537580 hsa-mir-6780b 0.0428 1.67 2.15 1.42 0.9953 chr6 
20506857 hsa-miR-1263 0.043 -2.57 2.45 3.81 0.9953 chr3 
20532771 ENSG00000200026 0.0431 -1.34 2.23 2.66 0.9953 chr9 
20535683 hsa-mir-509-3 0.0433 -1.37 1.22 1.67 0.9953 chrX 
20535638 hsa-mir-509-2 0.0433 -1.37 1.22 1.67 0.9953 chrX 
20535218 hsa-mir-509-1 0.0433 -1.37 1.22 1.67 0.9953 chrX 
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Chromosome 
20536576 hsa-mir-3672 0.0435 -1.23 1.17 1.46 0.9953 chrX 
20538233 U70G 0.0438 1.33 1.55 1.14 0.9953 chr12 
20533088 ENSG00000212428 0.044 1.21 1.36 1.08 0.9953 chr15 
20533022 ENSG00000212144 0.0443 -1.18 1.12 1.35 0.9953 chr1 
20504296 hsa-miR-573 0.0444 1.39 1.57 1.1 0.9953 chr4 
20536893 hsa-mir-4668 0.0444 1.38 1.32 0.85 0.9953 chr9 
20519441 hsa-miR-4656 0.0446 1.98 3.27 2.29 0.9953 chr7 
20525673 hsa-miR-6856-5p 0.0447 -1.57 1 1.65 0.9953 chr9 
20504310 hsa-miR-582-3p 0.0447 -1.1 1.18 1.32 0.9953 chr5 
20520215 hsa-miR-5008-3p 0.0448 -2.41 2.29 3.55 0.9953 chr1 
20501240 hsa-miR-377-5p 0.0448 -1.52 1.22 1.83 0.9953 chr14 
20536757 hsa-mir-4485 0.0448 1.07 3.14 3.05 0.9953 chr11 
20537488 hsa-mir-6745 0.0452 1.56 1.99 1.35 0.9953 chr11 
20533534 ENSG00000238807 0.0452 1.33 2.01 1.6 0.9953 chr17 
20533007 ENSG00000207299 0.0452 1.33 1.61 1.19 0.9953 chr11 
20535131 hsa-mir-376b 0.0454 -1.4 1.05 1.54 0.9953 chr14 
20535350 hsa-mir-603 0.0455 -1.4 1.04 1.52 0.9953 chr10 
20533849 ENSG00000252000 0.0457 1.42 1.94 1.44 0.9953 chr2 
20536615 hsa-mir-3914-2 0.0459 1.3 1.35 0.97 0.9953 chr7 
20533958 ENSG00000252433 0.0459 1.36 1.41 0.96 0.9953 chr1 
20525492 hsa-miR-6765-3p 0.046 1.32 1.86 1.46 0.9953 chr14 
20520564 hsa-miR-5186 0.046 1.27 1.11 0.77 0.9953 chr3 
20515515 hsa-miR-3120-3p 0.0466 1.3 1.47 1.09 0.9953 chr1 
20515645 hsa-miR-3200-3p 0.0467 -1.48 2.23 2.8 0.9953 chr22 
20506833 hsa-miR-548f-5p 0.0467 1.21 1.44 1.16 0.9953 chr10 
20538031 hsa-mir-8072 0.0467 -1.05 1.94 2.01 0.9953 chr12 
20532576 14qII-10 0.0467 1.37 1.25 0.8 0.9953 chr14 
20533384 ENSG00000238575 0.0468 -1.09 1.19 1.32 0.9953 chr18 
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val 
Chromosome 
20532731 ENSG00000199321 0.0468 1.32 1.39 0.99 0.9953 chr10 
20533853 ENSG00000252016 0.0474 1.5 1.97 1.38 0.9953 chrX 
20536982 hsa-mir-4744 0.0478 -1.23 1.17 1.46 0.9953 chr18 
20537064 hsa-mir-5000 0.0479 -1.29 1.33 1.7 0.9953 chr2 
20532819 ENSG00000200891 0.0479 -1.41 1.39 1.89 0.9953 chr10 
20524999 hsa-miR-6500-5p 0.048 1.14 1.78 1.6 0.9953 chr1 
20535810 hsa-mir-1204 0.0481 1.23 1.93 1.63 0.9953 chr8 
20504551 hsa-miR-1264 0.0483 1.22 1.41 1.13 0.9953 chrX 
20536287 hsa-mir-3176 0.0483 -1.57 1.78 2.44 0.9953 chr16 
20500445 hsa-miR-181a-2-3p 0.0484 -2.11 1.72 2.8 0.9953 chr9 
20538234 U70G 0.0487 1.29 1.54 1.17 0.9953 chr12 
20500135 hsa-miR-19a-3p 0.0488 1.29 1.25 0.88 0.9953 chr13 
20532744 ENSG00000199566 0.0494 1.22 1.98 1.69 0.9953 chr12 
20537597 hsa-mir-6852 0.0495 1.58 2.1 1.44 0.9953 chr9 
20504356 hsa-miR-615-5p 0.0496 -1.28 2 2.35 0.9953 chr12 
20533762 ENSG00000239159 0.0498 -1.24 1.06 1.37 0.9953 chr5 
20533966 ENSG00000252448 0.0499 1.13 1.38 1.21 0.9953 chr1 
20533892 ENSG00000252170 0.0499 -1.2 1.53 1.79 0.9953 chr3 
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Amyotrophic lateral sclerosis (ALS) is a debilitating 
neurodegenerative disease that is defined by the progressive 
loss of motor function due to degeneration of upper and 
lower motor neurons in the brain and spinal cord tissue, 
respectively, with an average life-expectancy of 2–5 years 
post-diagnosis (1). Riluzole and edaravone are currently the 
only two FDA approved drugs for patients with ALS, but 
these drugs have minimal effect, extending life only for a 
matter of months (2).  
In 1993, the first causative mutations of ALS were 
identified in the SOD1 gene (3). Today, mutations in SOD1 is 
the second most common cause of genetic ALS (~5–6% of all 
ALS cases), only falling behind the hexanucleotide repeat 
expansions observed in C9ORF72 (~12–14% of all ALS 
cases). However, the vast majority of ALS cases (~80%) 
have no known genetic background giving no clear 
indication on the causative factor that results in the disease 
development (1). In the last decade, miRNAs have been 
increasingly implicated in the pathogenesis of ALS due to 
the mass dysregulation of these molecules observed in ALS 
spinal cord and motor neurons (4-8). 
MiRNAs are small RNA molecules (~22–25 nucleotides) 
that are primarily responsible for post-transcriptional gene-
silencing generally through interactions with the 3’  
 
  
^Michael J. Strong ORCID: 0000-0003-1988-6262. 
untranslated region (UTR) of messenger RNA (mRNA) (9). 
Their interactions are highly dependent on environmental 
cues. Therefore, cell development, cell type, cell stress, and 
aging all have an impact on mRNA post-transcriptional 
regulation via miRNAs. This is an especially true for 
neurons which have spatiotemporal needs within the cell 
where post-transcriptional regulation via miRNAs differs 
depending on soma, dendritic and axonal needs (9,10). 
Further, miRNAs are also regulated by other non-coding 
RNAs (i.e., long non-coding RNAs, circular RNAs, etc.) 
which work together to control the degree of expression of a 
gene (11), highlighting the sophistication of these noncoding 
RNA networks (Figure 1). Not surprisingly, because of 
miRNAs dynamic nature in these RNA networks, it has 
become increasingly of interest to determine the 
contribution of miRNAs in disease. 
As mentioned, miRNAs have become increasingly 
implicated in ALS pathogenesis. This has mainly stemmed 
from observations that in sporadic ALS (sALS) spinal cord 
and motor neurons there are pools of miRNAs that are 
reduced (4-6). In contrast, mutant SOD1 (mtSOD1) ALS 
cases and rodent models have observed that miRNAs are 
generally upregulated, suggesting inhibition of these 
miRNAs may have therapeutic effects (7,12,13). In 
particular, high levels of miR-155 in mtSOD1 rodent models 
has been reported to promote neuroinflammation. 
Interestingly, inhibition of this miRNA via antisense 
oligonucleotides (ASOs) has been shown to decrease  
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Figure 1 MiRNA biogenesis and regulation. The canonical biogenesis pathway (represented by bold arrows): MiRNAs are transcribed from 
the genome via RNA polymerase (RNA pol.) II/III producing a primary miRNA (pri-miRNA). Interestingly, both circular and long non-
coding RNAs (circRNAs and lncRNAs, respectively) are known to assist in RNA pol. II transcription indicating these class of non-coding 
RNAs may assist in miRNA transcription. Further, these pri-miRNAs can be transcribed into small nucleolar RNA (snoRNA) and transfer 
RNA (tRNA) transcripts. Once produced, pri-miRNAs are processed by the DROSHA/DCGR8 complex into a pre-miRNA which is shuttled 
from the nucleus to the cytoplasm via XPO5 and RAN-GTP. Both DROSHA processing and pre-miRNA nuclear export have been shown to 
be inhibited by lncRNAs. Cytoplasmic pre-miRNAs are then processed by DICER/TRBP/PACT complex to produce a miRNA duplex which 
is unwound via AGO1-4 creating a mature miRNA. Non-canonical biogenesis pathway: There are 3 major non-canonical pathways – I) pre-
miRNAs are produced directly from the spliceosome after pre-mRNA processing skipping DROSHA/DCGR8 processing; II) cytoplasmic 
pre-miRNAs need to get mono-uridylated by TUT2/4/7 proteins before being processed by DICER/TRBP/PACT; or III) cytoplasmic pre-
miRNAs get processed by AGO1-4/PARN rather than DICER/TRBP/PACT to produce the miRNA duplex. MiRNA regulation: Once 
produced miRNA are: (I) incorporated into the RNA-induced silencing complex (RISC) and generally target the 3’UTR of mRNA to suppress 
translation OR induce mRNA degradation. This represents the primary function of miRNAs; (II) bind to the 3’UTR of mRNA to promote 
translation and mRNA stability usually with proteins not associated with the RISC complex (non-RISC). However, this is far less common 
than gene silencing; (III) targeted by circRNAs and lncRNAs that act as sponges to prevent miRNAs from reaching their mRNA targets; 
(IV) MiRNAs can be incorporated into the AGO complex and transported back into the nucleus via IPO8 and XPO1 to either promote or 
suppress transcription by binding to promoter/enhancer regions of the genome. While presumed that GTP converts to GDP via IPO8 to 
allow entry of the miRNA in the nucleus, this has yet to be shown in the literature. This figure highlights this highly sophisticated RNA 
network between circRNAs/lncRNAs/snoRNAs/ mRNAs that are responsible for regulating miRNA biogenesis and function ensuring gene 
expression is tightly controlled.  
neuroinflammation and alleviate ALS-like phenotypes in 
rodent models (7). Others have used miRNAs to reduce 
SOD1 expression, and in turn reduce mtSOD1s toxic effects, 
by intrathecally delivering artificial miRNAs that were 
cloned into an Adeno-associated virus (AAV) and target the 
SOD1 transcript. Use of SOD1 targeting artificial miRNAs 
has been shown to have therapeutic effects in both rodent 
and macaque models (14,15). However, the effectiveness of 
theses therapeutics in humans is still unknown. This 
previous research provides evidence of the utility of 
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miRNAs as potential therapeutic targets, and further, 
highlights the use of either ASOs or AAV-miRNAs as ways 
to develop therapeutics that will potentially treat 
neurodegeneration. 
Recent work published by Loffreda et al., 2020 in 
Progress in Neurobiology highlights miR-129-5p as another 
upregulated miRNA in rodent models of mtSOD1 ALS 
which, if inhibited using an ASO, could have therapeutic 
effects for patients with ALS (16). The research group 
looked at mtSOD1 (SOD1 G93A) in vitro neuronal cell 
models in addition to in vivo mouse models and determined 
that mtSOD1 causes an increase in miR-129-5p levels. 
Further, they observed increased levels of miR-129-5p in 
peripheral blood mononuclear cell (PMBC) samples of 
sALS patients, suggesting that this phenomenon may be 
related to ALS more broadly rather than just those who 
contain mutations in SOD1. These researchers reported that 
increased levels of miR-129-5p in both their in vitro and in 
vivo models correlates with decreased levels of ELAVL4, 
otherwise known as HuD—a protein critical for neuronal 
cell identity, maturation, axogenesis, dendrite growth, 
plasticity and survival (17). Through robust experimental 
analyses, the authors were able to show that increased levels 
of miR-129-5p were directly responsible for the reduced 
levels of HuD, identifying the biological mechanism by 
which high levels of miR-129-5p may contribute to 
neurodegeneration. Having made this observation, the 
authors then examined the ability of an ASO targeting 
miR129-5p to reduce its levels in mtSOD1 rodent models. 
Administration of the ASO via intracerebroventricular 
injection at an early symptomatic stage (post-natal 80 days) 
led to increased survival, improved motor capabilities, and 
increased neuromuscular junction connections. However, it 
only had a mild effect on preventing motor neuron 
degeneration which was not statistically significant. The 
authors concluded that while reducing levels of miR-1295p 
may have some therapeutic effects, the most optimal 
approach may be to pair their ASO with another 
miRNAbased therapeutic currently in development—an 
ASO targeting miR-155 (7,18).   
ASO-based therapeutics have become popular as an 
approach to treat neurodegenerative diseases due to the 
success in treating Spinal Muscular Atrophy (SMA)—a 
juvenile neurodegenerative disease caused by loss of lower 
motor neurons —using an ASO targeting SMN2 (19). 
Several modifications to the nucleotide backbone of an ASO 
can be done to increase its affinity to its target and make it 
resistant to nucleases. For example, morpholino 
modifications were used to develop the SMN2 ASO and the 
miR-129-5p ASO (16,19). Morpholino modifications alter 
the sugar-phosphate backbone by changing the sugar ring 
from a five-membered to a six-membered ring and the sugar 
rings are linked to phosphoramidates groups rather than 
phosphate groups. These modifications have been proven to 
be beneficial to develop ASOs that either knockdown 
expression of a specific gene, as seen in Loffreda et al., 2020, 
or alter mRNA splicing as seen for the ASO that targets 
SMN2 (16,19). Moreover, the ASO produced in Loffreda et 
al., 2020 is called an antagomir—an ASO that targets a 
miRNA—and they have been increasingly shown to be 
effective therapeutics. For example, the drug miravirsen, 
which has completed phase II clinical trials, is an antagomir 
targeting miR-122 and has been shown to prevent 
propagation of hepatitis C virus (HCV) RNA in the liver 
highlighting the potential use of antagomirs in clinical 
practice (20). Despite these developments, ASOs still have 
their limitations which include their potential off-target 
affects, their expense to develop, and their inability to cross 
the blood-brain barrier; making them difficult to administer 
for neurological diseases (21). However, the current success 
of ASO treatments thus far has sparked more innovative 
research to determine whether further modifications to 
these oligos will allow us to overcome these limitations, 
offering new opportunities for therapeutic development.   
Loffreda et al., 2020 provides clear evidence that 
increased levels of miR-129-5p is caused by mtSOD1 and 
that lowering its levels in mtSOD1 mice has some 
therapeutic effects; however, it is unclear whether reduction 
of miR-129-5p would be a good ALS therapeutic more 
broadly (16). The authors identified increased levels of miR-
129-5p in sALS patient PBMCs, but not in human spinal 
cord or motor neurons (16). As mentioned previously, the 
environmental context matters when discussing miRNA 
regulation (9). Further, in the several studies that have 
examined miRNA expression in the spinal cord and motor 
neurons of sALS cases, upregulation of miR-129-5p has not 
been observed (4-6). Thus, it is unclear whether this 
observation of increased levels of miR-129-5p in PBMCs is 
relevant to the dysfunction of motor neurons, or more 
broadly, the central nervous system of the sALS patient 
group within their study.  
Further, the use of an ASO to suppress miR-129-5p 
expression should be approached with caution. In the 
central nervous system, miR-129-5p has been shown to 
suppress apoptosis and alleviate neuroinflammation (22). 
Low levels of miR-129-5p have been reported in the 
degenerating brain of patients with Alzheimer’s Disease, 
and lack of this miRNA creates an inflammatory response 
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that can be neurotoxic (23). Thus, too much or too little of 
miR129-5p could be damaging to the central nervous 
system. This is likely because miRNAs can target several 
transcripts to regulate a network of genes, which can make 
cells sensitive to fluctuations in miRNA expression. In this 
case, the authors showed that miR-129-5p regulates HuD 
levels, but miR-129-5p has also been shown to regulate 
critical neuronal genes involved in synaptic plasticity 
(FMR1) and neuroinflammation (HMGB1) (22,24). All this 
suggests that further work needs to be done to ensure 
reduction of this miRNA will not have long-term effects that 
may be more damaging than therapeutic. 
Loffreda et al., 2020 proposed that while their ASO had 
some beneficial effects in their mtSOD1 models, matching it 
with an ASO that inhibits miR-155 may have the greatest 
overall therapeutic effect (16). This points to the idea that 
simply targeting one miRNA may not be enough to 
ameliorate ALS. In fact, as mentioned previously, several 
miRNAs have been shown to be upregulated in mtSOD1 
models (7,12,13). Further, the article provides data 
indicating that mtSOD1 increased the levels of DICER, a 
critical protein in miRNA biogenesis, which may explain 
why miRNAs are upregulated in mtSOD1 models (16). 
Therefore, there seems to be a systemic issue with miRNA 
production in the presence mtSOD1. Thus, lowering levels 
of DICER might seem to be a better target to slow the 
production and reduce the toxicity of these upregulated 
miRNAs in mtSOD1 ALS cases. However, knockout of 
DICER in mouse motor neurons has been shown to lead to 
motor neuron degeneration, and thus, reducing levels of 
DICER should be approached with caution as well (25).  
Overall, while this latest work by Loffreda et al., 2020 
provides another interesting avenue for miRNAbased 
therapeutics for ALS, this work still has far to go before we 
can think about administering it to patients. Large-scale 
preclinical studies still need to be done to determine if 
inhibition of miR-129-5p prevents motor 
neurodegeneration, helps alleviate ALS-like phenotypes in 
several models of ALS or just SOD1-related models, and 
finally, determine whether downregulation of this miRNA 
has any potential negative long-term outcomes (i.e., chronic 
neuroinflammation). Further, we still do not know whether 
miR-129-5p is upregulated within the spinal cord or motor 
neurons of mtSOD1 ALS cases, which will be necessary to 
address to ensure development of this ASO as a therapeutic 
is not in vain. All this taken together, miR129-5p could be a 
potential therapeutic for ALS, but in agreeance with the 
authors, it is unlikely that targeting this miRNA alone will 
be enough to completely halt the disease progression (16). 
However, the mere identification of this miRNA, its 
biological network and its potential relevance to disease will 
be incredibly important to our understanding of 
mechanisms associated with ALS progression, opening more 
avenues for potential therapeutics.  
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